sartorius stedim biotech group reference document order intake sale revenue underlying ebitda ebita million million order intake ebitda sale revenue ebita key figure figure given million according ifrs unless otherwise specified oder intake sale revenue earnings order intake sale revenue underlying ebitda underlying ebitda sale revenue underlying ebita underlying ebita sale revenue ebit ebit sale revenue net profit noncontrolling interest group net profit noncontrolling interest research development cost financial data per share earnings per share earnings per share dividend per share balance sheet balance sheet total equity equity ratio gearing ratio financials capital expenditure excluding financial asset goodwill sale revenue depreciation amortization net cash flow operating activity net debt ratio net debt underlying ebitda total number employee december adjusted extraordinary item restated see note financial statement pp information ebitda ebita net profit underlying presentation please refer group business development chapter glossary excluding amortization linked business combination excluding fair value adjustment hedging instrument amount suggested board director conseil dadministration subject approval annual general shareholder meeting excluding tap biosystems sustainable growth financial target fully achieved sartorius stedim biotech ssb posted double sale revenue earnings digit growth order intake well sale reve nue third consecutive year business fueled singleuse product equipment biomanufacturing regional perspective asia led growth sale revenue increased ssb boosted earnings proportionately mainly driven economy scale underlying ebitda margin surged sale revenue earnings reached upper end guidance provided beginning fiscal ebitda margin acquisition partnership growth addition product development sartorius stedim biotech focus alliance bolton acquisition extend offering ssb acquired tap biosystems group plc added bioreactors early phase process development portfolio addition cell culture medium business taken ssb end fully inte ml ml l l l grated performed strongly first year new roof tap biosystems sartorius stedim biotech highly dedicated employee employee worked sartorius stedim biotech good five year ago compared previous year alone number employee increased across ssb group new job created region first global employee engagement survey mirrored company success active people management response rate result clearly industry bench mark production capacity expanded sartorius stedim biotech constantly expands capacity accompany growth company significantly extended manufacturing area injection molding goettingen investment made headquarters aubagne yauco puerto rico increase production singleuse bag chinese site beijing cleanroom installed pre pare manufacture fluid management product market shanghai ssb opened new sale headquarters group asia stock moved sbf index ssbs profitable growth also reflected development share price around outperformed french stock market result increased liquid sartorius stedim biotech share ity free float market capitalization ssb stock moved june sbf index sbf composed active share paris stock exchange mission sartorius stedim biotech leading provider cuttingedge equipment service development quality assurance production process biopharmaceutical industry integrated solution covering fermentation filtration purification fluid management lab technology supporting biopharmaceutical industry around world develop produce drug safely timely economically nextgeneration process sartorius stedim biotech focus singleuse technology addedvalue service meet rapidly changing technology requirement industry serf strongly rooted scientific community closely allied customer technology partner company dedicated philosophy turning science solution reference document present original french document de référence section document included translated reference document filed interest investor covered autorité de marchés financier another part reference document february accordance article règlement général may used copy present reference document connection offering security obtained following supplemented prospectus note dopération autorité de marchés financier issued sartorius stedim biotech sa endorsement reference document zi le paluds avenue de jouques made issuer engages responsibility c aubagne cedex signatory group website wwwsartoriusstedimcom autorité de marchés financier website reference document incorporates reference wwwamffranceorg preceding reference document filed march filed march following information included reference present reference document year consolidated financial statement sartorius stedim biotech prepared using international accounting standard report statutory auditor relating statement group management report appearing page respectively reference document filed autorité de marchés financier march number year consolidated financial statement sartorius stedim biotech prepared using international accounting standard report statutory auditor relating statement group management report appearing page respectively reference document filed autorité de marchés financier march number shareholder chairman message executive committee sartorius stedim biotech share management report sartorius stedim biotech macroeconomic environment condition sector group business development sustainability report statutory auditor report review environmental social societal information net worth financial position risk opportunity report forecast report financial statement parent company sartorius stedim biotech sa reference document contains statement concerning future performance sartorius stedim biotech sa statement based assumption estimate although convinced forwardlooking statement realistic cannot guarantee actually apply assumption harbor risk uncertainty could lead actual result diverging substantially expected one planned update forwardlooking statement translation original frenchlanguage reference document document de référence sartorius shall assume liability correctness translation original french reference document legally binding version furthermore sartorius stedim biotech sa reserve right responsible topicality correctness completeness quality information provided liability claim regarding damage caused use information provided including kind information incomplete incorrect therefore rejected throughout reference document difference may apparent result rounding addition content corporate governance nnual financial statement sartorius stedim biotech sa note board director committee executive committee annual financial statement hairmans report pursuant article c statutory auditor report financial statement l french commercial code r emuneration executive nonexecutive member board tatutory auditor report prepared supplementary information accordance article l information legal nature independent auditor fee pecial report statutory auditor related party agreement commitment c onsolidated financial esolutions submitted annual combined r shareholder meeting april statement note information reference document annual financial report statement profit loss glossary comprehensive income address statement financial position product highlight statement cash flow statement change equity note financial statement note statement profit loss note individual balance sheet item disclosure tatutory auditor report consolidated financial statement shareholder chairman message dear shareholder pleased report marked another year positive development also reflected progress sartorius stedim biotech group development share price soared sale operational profit outperformed french stock market margin reached upper end result increased liquidity free float market guidance provided january capitalization ssb stock moved june third year succession posted doubledigit sbf index composed topline growth even slightly higher active share paris stock exchange expectation market rate also satisfied profit development however success company past five year able add one financial perspective also percentage point underlying ebitda margin operational viewpoint key element total year year whole see u well track solution provider strategy continuously add new achieve strategic plan defined two offering portfolio customer year ago product development alliance bolton acquisition satisfied cell culture medium geographic perspective asia led growth business started integrate share sale asian market first quarter performed strongly first meanwhile surpassed mark see u fully year ssbs roof moreover yearend participating growth opportunity afforded able move forward acquisition region key u biotech market also tap biosystems group plc tap bringing steadily becoming stronger even though sale promising product line smallscale singleuse figure show moderate expansion bioreactors early phase process mainly due high comparables previous development concentrate year extraordinary performance finally europe extending global reach innovative still generate almost sale technology regard partnership entered grew solid rate alliance several company example field process analytical tool strong growth sale also resulted significant increase underlying earnings per year keep u busy share based continue execute regional growth initiative positive result board director strive outpace market north submit proposal annual general shareholder america leverage market growth asia obviously meeting raise dividend per integration tap agenda well share unlock synergy cell culture medium complementary product portfolio ensure properly structured keep achieved show potential growth also continue invest global behind company employee would like infrastructure capability decided initiate thank worldwide team outstanding multiyear investment program goettingen commitment accomplishment equally appreciate site involves expanding production capacity continued trust valued customer partner well demonstration application laboratory shareholder placed u active people development also remain priority company happy global building attractive business model track employee engagement survey showed aboveaverage record strength team cordially invite result category positive feedback inspires continue u road success u become even better employer example promoting crossfunctional cross regional career path enable staff fully develop potential sincerely financial standpoint set ambitious target aim increase sale revenue around operational profit margin also medium long term see excellent prospect business global pharma market continuing grow biotech remain innovation engine joachim kreuzburg pharma industry furthermore singleuse production chairman board ceo device made inroad major biomanufacturing step penetrating market high momentum strong advantage regard production cost flexibility driving change still considerable challenge remain jointly solved supplier user full scalability increased standardization single use device required innovation ssb one pioneer singleuse technology fully committed forefront deliver new solution executive committee joachim kreuzburg chairman board chief executive officer head finance human resource compliance legal affair corporate communication hold doctorate economics university degree mechanical engineering joachim kreuzburg also ceo ssbs parent corporation sartorius ag chairman sartorius group executive committee oscarwerner reif executive vice president research development manages group global research development unit hold doctorate chemical engineering studied chemistry molecular biology germany usa oscarwerner reif also member sartorius group executive committee volker niebel executive vice president operation responsible production supply chain management business process management information tech nology hold university degree business administration economics volker niebel also belongs sartorius group executive committee reinhard vogt executive vice president marketing sale service charge marketing sale service hold vocational diploma industrial business administration reinhard vogt also member executive board sartorius ag member sartorius group executive committee shareholder sartorius stedim biotech share sartorius stedim biotech share fact share isin fr liquidity provider gilbert dupont stock exchange euronext paris market segment local security compartment large cap index sbf sbf cac mid cac share cac mid small cac small cac health care number shares thereof sartorius ag thereof free float thereof treasury share number share outstanding thereof sartorius ag thereof free float voting rights voting right outstanding december number issued share minus number treasury share number voting right minus number voting right connected treasury share stock market significantly strong share price development stock market around world developed strongly sartorius stedim biotech share price slow start year contributing performed better french stock market factor included historically low interest rate well whole close end expectation european economy share price rose end particular would increasingly return even keel sbf example rose significantly share hit lowest closing price year course year reach alltime high january rising sharply point november ended year next month highest closing price point represents overall gain registered august buoyed favourable business development improved overall forecast year ssb included sbf index june sartorius stedim biotech included sbf index euronext paris sbf index composed active stock paris stock exchange ie component cac index plus stock quoted continuously euronext paris criterion admission index liquidity free float market capitalization shareholder sartorius stedim biotech share sartorius stedim biotech share january december jan feb march april may june july aug sept oct nov dec sartorius stedim biotech share sartorius stedim biotech share comparison sbf cac mid small nasdaq biotechnology index indexed january december jan feb march april may june july aug sept oct nov dec sartorius stedim biotech share sbf cac mid small nasdaq biotechnology index shareholder sartorius stedim biotech share market capitalization trading volume analyst reflecting increase sartorius stedim biotech recommendation financial analyst serve share price market capitalization surged important foundation decision private course reporting year billion institutional investor investing share december billion december currently following institution regularly prepare report update sartorius stedim biotech average number sartorius stedim biotech share share traded daily paris bourse reporting period thus substantially research coverage ahead previous year level total institute date recommendation trading volume euronext stock exchange portzamparc january add however increased million société générale january hold million oddo midcap january buy investor relation activity gilbert dupont january add investor relation work focus maintaining ongoing open dialog shareholder potential financial calendar investor financial analyst ensure highest possible level transparency provide share financial calendar holder interested general public alike agm april equal timely access information relevant mo april share price reporting together provide regular hy july detailed insight strategy latest development mo october business prospect provided regular information current business development via press release halfyear annual report addition quarterly telephone webcast conference stepped contact capital market including large number oneonone meeting plus confe rences road show main european financial center london paris frankfurt main zurich also new york elsewhere investor relation communication activity reporting year made particular point explaining current business performance corporate strategy well change portfolio ie acquisition area cell culture medium smallvolume singleuse bioreactors information publication relating company share may found internet page wwwsartoriusstedimcom sartorius stedim biotech investor relation team available private institutional investor well financial analyst wishing contact directly question relating group sartorius stedim biotech shareholder sartorius stedim biotech share key figure sartorius stedim biotech share share price reporting date high low dividends total dividend paid million payout ratio dividend yield market capitalization million average daily trading number share trading volume share million cac mid small million sbf million daily closing price amount suggested board director subject approval annual general shareholder meeting based underlying net result excluding amortization dividend relation corresponding closing price year source euronext bloomberg dividend sartorius stedim biotech group applies dividend based underlying net profit policy intended ensure shareholder adequately information underlying net profit please refer rewarded company sustained success glossary dividend payout ratio would dividend accordingly determined basis compared previous year underlying net profit year definition see would result dividend yield relation p xx sartorius stedim biotech endeavor principle closing price share december distribute underlying previous year net profit dividend fiscal well board director plan enable shareholder participate adequately company success therefore annual general shareholder meeting april board director submit proposal pay dividend per share net profit million reported sartorius stedim biotech sa would represent gain previous year figure therefore total profit distributed would increase million year ago million amount suggested board director subject approval annual general shareholder meeting shareholder sartorius stedim biotech share shareholder structure sartorius stedim biotech sa issued capital amounted million reporting date divided share calculated par value share convey double voting right result total voting right reporting date completion share buyback program sartorius stedim biotech sa hold share reporting date furthermore sartorius ag hold share approxi mately outstanding voting right around share outstanding voting right free float outstanding share treasury share deducted sartorius ag owns free float account remaining shareholding structure share capital sartorius ag treasury share free float shareholding structure voting right sartorius ag free float management report management report sartorius stedim biotech sartorius stedim biotech strategy sartorius stedim biotech provides integrated solution global leader field process core process step biopharmaceutical production filtration fermentation fluid management technology total solution provider strategy extensive membrane chromatography cell culture range technology product service help offer range conventional lab product customer manufacture medication vaccine biopharmaceutical laboratory safely efficiently using biological method integrated product service along customer process chain management report sartorius stedim biotech extensive singleuse portfolio sector expanding product portfolio specialize providing singleuse product besides realizing organic growth potential biopharmaceutical production process singleuse intend expand position sartorius stedim product account around three quarter biotech group also strategic alliance sale revenue provide biopharmaceutical customer acquisition acquisition cell culture medium innovative alternative conventional reusable business swiss life science group lonza stainless steel system cost timesavings december added another important element offer particularly attractive also reduce product portfolio risk contamination dispose extensive portfolio singleuse technology also completed acquisition british company sector also able offer integrated singleuse tap biosystems group plc december system variety process step service move enhances fermentation range tailor specifically requirement especially early phase process development individual application comprehensive technical consulting give u additional edge competition organization sartorius stedim biotech group organized total solution provider strategy strictly function worldwide company offer great potential accordingly controlled core operating function marketing sale distribution service sartorius stedim biotech continuing execute research development operation finance etc solution provider strategy proven successful responsibility various function higher past decade focus biopharma tier management assigned global level ceutical market regard highly attractive hence span site country stable betterthanaverage growth potential global functional organization creates aim capitalize strong position effective platform central strategic control already enjoy core technology target fast efficient collaboration within group achieve continued significant organic growth also make easier company realize future regionally prioritize north america total solution provider strategy position world leading biopharmaceutical market effectively respect global customer rapidly expanding pharmaceutical market asia management report macroeconomic environment condition sector macroeconomic environment condition sector macroeconomic environment forecast indicate slight improvement french economy expected grown global economy expanded period growth previous previous year according international year economic activity france suffered result monetary fund imf slightly less significant fall corporate investment rate still forecast middle year imf suggests effect gradual recovery southern eurozone country remained economic activity industrialized country recession second year succession partially offset weakening impetus growth rate previous year italy emerging country thirdlargest economy eurozone spain previous year confirming another period recession global development gdp gross domestic product eu source international monetary fund germany france spain italy nether economic output industrialized country rose land overall reporting year according imf figure previous year performance source international monetary fund varying enormously country country rate growth u economy likely economic growth asia china india indonesia reached well short figure malaysia philippine thailand vietnam reporting year due declining export impacted weak start year especially significantly reduced government spending china eventually reached almost level result country automatic budget cut previous year however still short midyear forecast economic activity eurozone whole declined slightly growth rate previous imf put likely rate growth economic year german economy eurozones output japan around largest continued expand rate growth previous year growth fueled largely slowed previous year private government expansionary fiscal policy consumption public consumption investment prompted rising consumer spending corporate building equipment provided momentum investment economic stimulus program effect offset weak start year upturn export following devaluation yen negative net export figure also helped management report macroeconomic environment condition sector gross domestic product region interest rate trend average global interest rate fell historic low reporting year ecb example cut base rate twice reporting year record low month euribor rate rate interest fixedterm deposit denominated euro interbank business still low level december previous year source international monetary fund world economic outlook october vwd ecb deeuriborrateseu global eurozone u japan asia sector condition sartorius stedim biotech serf customer mainly asia china india asean indonesia malaysia biopharmaceutical industry make philippine thailand vietnam business particularly sensitive development source international monetary fund industry exchange rate trend stable growth pharmaceutical market important currency sartorius group besides international market research institute ims health euro include especially u dollar well expects global pharmaceutical market grow currency like chinese yuan indien follows growth rupee previous year eurous dollar exchange rate slipped low principal factor influencing global year u dollar end march pharmaceutical industry remained unchanged result uncertainty surrounding economic reporting year demographic change development europe euro strengthened improved access healthcare especially u dollar finish year emerging market featuring among key u dollar december driver growth availability new drug remained high approval u market world largest reporting development eur u dollar january december period positive factor countered effect austerity measure notably healthcare system industrialized nation expiration patent source bloomberg management report macroeconomic environment condition sector growth regional pharma market monoclonal antibody undergoing clinical deve lopment phase iiii represents significant increase previous year pronounced move singleuse system biopharmaceutical production biotech production method much complex traditional method far also proved costintensive manufacturer supplier consequently engaged intensive effort develop efficient production technology europe north asia japan latin singleuse product require significantly less america africa america capital expenditure reduce cleaning validation australia cost minimize downtime crucial role play singleuse product deliver greater flexibility help bring development source ims health market faster thanks particular cost efficiency singleuse product become well established large number process step according ims growth strongest region asia africa australia latin america amongst others expansion budget consolidation affect statefunded healthcare provision higher public research sector consumer spending medicine fueled market growth proportion demand laboratory product come publicsector research research budget many country unchanged slightly biotechnology market growth average compared previous year knock effect economic crisis reporting year global market pharmaceutical manufactured consequently brought slight yearonyear fall using biotech method grew around demand public research sector according reporting year outperforming global data frost sullivan pharmaceutical market whole attributable particular launch many new biopharmaceutical drug last year competition expanded indication existing medicine proportion sale revenue accounted primary mean company medication manufactured using biotech method biotechnology market differentiate doubled ten year stand competitor innovative prowess quality around therapeutic protein play performance product biotechnology important role treatment condition including sector constantly discovering new area diabetes chronic anemia still make largest application expects supplier equally fast category active ingredient produced using biotech moving creative developing new equipment method importance monoclonal antibody manufacture biotech product new supplier used application including particular seek exploit opportunity inherent treatment cancer hiv autoimmune disease environment gain foothold market multiple sclerosis rheumatoid arthritis carefully targeted niche product also continues grow according study established supplier meanwhile expanding boston consulting group product range continuously management report macroeconomic environment condition sector generate round sale revenue validated process replacing product production cycle expensive receive high proportion followup repeat business particular strength sartorius stedim biotech lie integrated process solution investigation development substance lab production end product offer broadest range industry strategic focus singleuse product give u another edge competition sartorius stedim biotech occupies strong position market worldwide field bioprocess filtration fermentation fluid management membrane chromatography competitor multinationals based usa merck millipore pall general electric healthcare among main rival process area thermo fisher merck millipore key player laboratory field also face competition smaller company applikon atmi individual segment source boston consulting group medizinische biotechnologie deutschland medical biotechnology germany ims health market prognosis june evaluate pharma world preview june frost sullivan annual forecast analysis global market laboratory product icis market outlook management report group business development group business development order intake sale revenue period customer required time transition contribution sale revenue approx sartorius stedim biotech group adopted pct point slightly forecast however slight change reporting structure result earnings business consolidated fiscal change relate amortization full year please refer page tax since shown functional sale revenue region expense change cost allocation impact group net profit ensure europe comparability business figure restated see consolidated financial statement north america note moreover underlying ebitda used key performance indicator since beginning instead underlying ebita however profit figure continue reported asia pacific order intake sale revenue million market acc customer location group strong performance supported region europe region generated highest revenue accounted around business posted gain cc driven particularly strong demand singleuse product north america earned around total sale revenue whereas sale revenue order intake significant doubledigit rate previous year sale revenue growth moderate cc reporting period given high yearearlier base sartorius stedim biotech group reported strong asia pacific region accounted growth order intake reporting year around total sale revenue developed million order intake constant dynamically yet region recorded currency cc compared yearearlier figure gain sale revenue cc growth million considerable increase fueled strong demand singleuse driven high demand singleuse product well product equipment special growth impulse form large equipment order sale revenue grew cc million million thus reached upper end growth guidance cc provided outset year organic sale revenue growth cc ahead expectation cell culture medium business acquired december showed strong operating performance reporting management report group business development sale revenue region fiscal earnings sartorius stedim million unless otherwise specified biotech group developed better expected beginning year given excellent sale revenue growth thus underlying ebitda increased proportionately million respective margin improved compared initial forecast inclusion full earnings cell culture medium business corresponding sale revenue recognized pro rata contributed increase margin turn currency fluctuation slightly negative impact underlying ebita rose million corresponding margin increased europe north asia america pacific market underlying ebitda ebita million sales growth growth million group europe north america asia pacific market acc customer location currencyadjusted ebitda earnings ebita sartorius stedim biotech group earnings interest tax depreciation amortization ebitda used key profitability measure addition report ebita profit figure context amortization refers exclusively purchase price allocation ppa intangible asset acquired specified ifrs provide complete transparent presentation group profitability report earnings adjusted extraordinary item underlying ebitda underlying ebita information definition please refer glossary page underlying presentation reconciled ebitda key indicator see glossary following page management report group business development underlying ebitda ebita margin underlying earnings per share excluding amortization ebitda excluding amortization excluding fair value adjustment ebita hedging instrument adjusted extraordinary item restated see note consolidated financial statement page reconciliation underlying presentation ebitda key indicator extraordinary item amounted million million previous year million essentially cover underlying ebitda onetime expense various corporate project including extraordinary item amortization depreciation group ebit see glossary rose million underlying ebita million respective margin increased amortization extraordinary effect relevant underlying net profit group surged ebit million year ago million fiscal extraordinary effect profit figure calculated adjusting amortization ifrs extraordinary item eliminating noncash financial result amortization million previous year valuation hedging instrument million fair value adjustment hedging income tax instrument well corresponding tax effect underlying net result item corresponding earnings noncontrolling interest per share year earlier underlying net result excluding amortization ifrs non controlling interest underlying earnings per share restated see consolidated financial statement note page see glossary definition total listed management report group business development appropriation profit research development board director submit proposal sartorius stedim biotech group stepped annual general shareholder meeting april research development activity reporting payment dividend per share fiscal year increasing spending area previous year total million previous year million profit distributed would accordingly increase respective ratio rd cost sale revenue also million year earlier million higher year earlier relation closing price share december would result dividend research development cost yield previous year million restated see note consolidated financial statement page research development ratio sale revenue restated see note consolidated financial statement page protect knowhow pursue targeted intellectual industrial property right policy systematically monitor compliance right review cost benefit viewpoint whether necessary continue maintain individual right management report group business development number application intellectual control unit order implement new operating industrial property right filed amounted concept standard bioreactors technical compared previous year result upgrade give user option operating application submitted past year issued bioreactor either reusable disposable system patent trademark previous year balance sheet date total patent sartorius stedim biotech developed new package trademark portfolio previous year process analytics software continuous control fermentation process software allows additional sensor linked capture number patent trademark considerably process data previous option application paving way particularly efficient cell culture registered patent trademark process customer development new cell culture medium lonza brandnew membrane virus removal prefiltration worked development new cell culture medium suitable cultivating cell line rd priority reporting year included used manufacture vaccine moreover development new filter membrane already optimized initial group culture design size round existing product line medium specific customer enhanced medium one highlight new virosart hf hollowfiber provide optimal growth condition cell ensure membrane used purification process high yield target biological active ingredient biopharmaceutical medium developed virus removal collaboration one partner product performance data set new benchmark market also successfully completed development new prefilter cartridge extended line sartopore platinum sterilizinggrade filter membrane adding new version biostat str bioreactor liter version novel plastic film singleuse bag project develop liter model successful biostat str range singleuse bioreactors completed successfully reporting year rounding range enabling u offer customer attractive alternative conventional stainless steel bioreactors productionscale process singleuse bag new bioreactor designed largescale cell cultivation first feature novel polyethylene film developed collaboration one partner notably robust film particularly wellsuited application involving cell culture microbial fermentation application use wide range new product fermentation fluid management new controller standard bioreactors innovative process analytics software reporting year developed brandnew software solution continued extend system management report group business development marketing sale distribution service strong demand validation maintenance service beyond supplying product existing production process sartorius stedim biotech make particular provide comprehensive range service priority working customer starting right designed around often complex manufacturing earliest phase process development process customer biopharmaceutical company accordingly market product directly industry result offering clearly set u apart field sale representative key competition validation service account additionally supported global key consulting expertise enjoyed strong demand account management organization collaborates reporting year particularly customer asia closely direct sale team sartorius stedim business maintenance service also made biotech activity focus particular new project excellent progress ensure keep pace solution deployed feature burgeoning demand sophisticated service large proportion singleuse product offer future well conducted training program large number service employee sale initiative europe china new sale marketing headquarters asia acquisition tap biosystems alliance forged launched sale initiative usa still world largest pharmaceutical market continued extend leading market reorganize strengthen sale position fermentation technology acquiring tap activity extended initiative region biosystems british company specializes southern central europe china developing multiparallel bioreactors smallscale reporting year objective initiative cell culture volume marketleading mini achieve international harmonization sale bioreactor system called ambr provide marketing analyzing optimizing activity biopharma industry equipment solution also spurred continued growth china early phase process development asian country established new sale marketing headquarters shanghai also stepped sartorius stedim biotech entered global sale marketing sale distribution activity partnership german gas measurement specialist latin america another attractive growth region bluesens expand portfolio area sartorius process analytics addition company forged sale development alliance welsh company aber instrument highly specialized cell culture medium join product portfolio supplier sensor technology acquisition cell culture medium business swiss life science group lonza december added important component sartorius product portfolio like bioreactors singleuse bag container cell culture medium key cell cultivation process making ideal complementary product range assumed global marketing sale distribution activity cell culture medium reporting period therefore offer customer fully integrated product solution single source moreover integrated former lonza employee team application specialist management report group business development product another product equipped new single use sensor additional accessory sartorius stedim biotech range product includes univessel su singleuse bioreactor designed process large number singleuse product development optimization task manufacture active pharmaceutical ingredient operated different controller pre upstream downstream application company sterilized readytouse singleuse system offer extensive lineup singleuse filter flexible alternative conventional glass bioreactors membrane plus singleuse reusable bioreactors singleuse bag tubing connector container cell culture medium range also includes filtration enhanced process efficiency safety reliability system filter integrity testing equipment sophisticated service reporting year added introduced special sensor offgas analysis complementary product many product line facilitate continuous control unveiled series new equipment generation monitoring fermentation process readily integratable bioreactors size sensor allows bioprocesses monitored real time new filtration product key parameter determined helping make process significantly efficient product launch included introduction increasing yield result secondgeneration crossflow filtration system purifying vaccine monoclonal antibody new sartocheck plus bag test system enables recombinant protein designed efficient purification customer check integrity singleuse bag small batch compact modular system installed bioreactor ability used development process smallscale detect even slightest damage bag help production operation filtration system feature make process safer reliable new control unit large selection filter element provide even greater flexibility reporting year saw unveiling new expanded fluid management portfolio virosart hc filter membrane designed specifically purification proteinrich medium year review sartorius stedim biotech blood plasma virosart hc used remove viral expanded array singleuse bag plastic contaminant also added new filter element tubing connector equipment fluid sartopore xlm sartobran filter membrane management application example introduced product line new product cultibag line singleuse bag cell cultivation launched new generation mobile mixing system biopharmaceutical medium bioreactors additional feature extended capability system sterile disconnection plastic tubing cell cultivation included additional feature biostat cplus bioreactor used microbial well cell culture application result specifically customconfigured according user special need management report group business development production supply chain management sartorius stedim biotech operates well developed global production network largest site plant goettingen germany aubagne france followed production facility bangalore india yauco puerto rico guxhagen germany advanced production facility support efficient manufacturing process short lead order processing time need maintain competitive edge around world completed number significant capacity expansion project goettingen guxhagen yauco previous year implemented series small mediumscale project reporting year extend manufacturing capacity goettingen site april opened new building manufacturing plastic part use product like singleuse filter bag substantially expanded production area provides ample space installation additional injection molding machine first commissioned reporting year also hired employee expand production capacity significantly new plant puerto rico response persistently high demand singleuse bag pharmaceutical industry elsewhere acquired building directly adjacent aubagne facility order increase space available site producing singleuse bag plan move additional machinery mid moreover chinese site beijing installed cleanroom intend manufacture fluid management product local market initial preparatory step taken installation casting machine goettingen site provide greater capacity flexibility filter membrane manufacturing operation work install machine scheduled commence management report sustainability report sustainability report sustainability one core value firmly following report provides overview embedded sartorius stedim biotech corporate key indicator activity project culture ever since company established three area sustainable corporate management sustainable development company ecological sustainability contributing society major objective primary business responsibility offer methodological note attractive product solution customer innovation well strategic operational personnel indicator regarding health excellence key meeting objective u safety reported refer entire group sustainability context mean pursuing indicator referenced range business objective take longterm broadly global scope scope consolidation indicated based view also specifically includes social separately environmental indicator refer ecological interest take responsibility sartorius stedim biotech production site toward various stakeholder seriously believe located aubagne lourdes mhamdia goettingen longterm relation deliver benefit guxhagen stonehouse tagelswangen yauco party involved accordingly regard active bangalore represent group total management social ecological task workforce compensation business activity rather one success factor line approach regard essential comply legal ethical standard manufacture ecological responsibility keep en vironmental impact mind developing product innovation likewise hr policy aimed preserving right interest employee actively using developing potential global workforce company site around world employer contractor take active part developing regional environment increasing attractiveness supporting cultural social project since sartorius stedim biotech reporting key personnel environmental indicator metric compliance french grenelle ii environmental law indicator oriented towards general standard thus permit comparison company internally figure provide basis defining reviewing controlling environmental personnel target enhanced groupwide recording reporting environmental personnel data sartorius stedim biotech base recording greenhouse gas emission greenhouse gas protocol also introduced number new performance indicator including general absence rate total amount carbon total consumption chemical example addition international environment health occupational safety steering group established harmonize continuously improve process three area worldwide management report sustainability report sustainable corporate management organization ilo united nation global compact furthermore reject form detailed information economic dimension compulsory labor child labor respect sustainability sartorius stedim biotech provided special need protect young employee sartorius page explain stedim biotech employee required adopt strategy measure use achieve profitable taskoriented open friendly fair approach growth interacting colleague employee third party thereby helping create atmosphere respectful cooperation tolerate employee compliance legal ethical standard discriminated disadvantaged harassed excluded based gender ethnic origin life activity based corporate value philosophy race religion age disability appearance sustainability openness enjoyment value sexual preference identity origin political govern treat customer business partner position uphold freedom association investor well work together within right individual fairly represented labor company time corporate value organization choosing pursuant local law guide u direction intend develop company future code conduct help ensure operate highest level integrity binding sartorius stedim biotech conduct business employee anticorruption guideline accordance legal regulation individual measure intended help employee act country globally accepted ethical standard ethically accordance law daily action follow principle responsible work employee around globe required corporate governance control focused complete training course u fictitious sustainable value added includes compliance example train deal ethically legally legal groupinternal regulation consideration problematic situation whistleblower portal stakeholder interest transparent corporate telephone hotline enable employee supplier communication appropriate risk management customer partner report dubious conduct proper accounting auditing sartorius stedim biotech complies rule recommendation remuneration paid sartorius stedim biotech afepmedef corporate governance code regular working hour overtime compensation information provided chairman report hour worked excess contract regular work chapter starting page reference schedule either meet case exceeds document industry standard legal minimum wage depending particular country germany instance compliance system intended ensure compensation paid according pay rate set member executive body manager employee trade union ig metall stand industrial comply legal regulation code internal union metalworker guideline designed preemptive nature aim prevent misconduct prevent financial loss many employee covered remuneration damage company image important pillar system include variable well fixed compliance system based code compensation component level variable conduct anticorruption code code component linked progress comprise minimum standard legally compliant company attainment personal target ethical behavior defined employee respective manager annual target agreement adhere set principle defined code conduct sartorius stedim biotech support business partner adhere highest respect principle human right defined standard business ethic compliance respect united nation universal declaration human supplier subcontractor partner right convention international labor request respect human right management report sustainability report complying code conduct applicable employee function december human right law regulation also ensuring compliance throughout production supply chain marketing sale service employee number employee reported following research development include staff member except vocational trainee intern employee extended leaf administration absence participating early retirement plan number recorded head count ie employee counted regardless whether work full part time december sartorius stedim biotech number employee function show group employed total people figure production area directly linked production yet include approximately employee accounted largest share people british company tap biosystems sartorius company total workforce reporting year stedim biotech acquired end reporting previous year active recruitment response year compared workforce sustained strong demand singleuse product reporting date year earlier equates accounted yearonyear increase increase total people quarter company total workforce work marketing sale distribution service function previous employee region year number people employed december research development unit increased europe previous year head count administrative function include finance north america human resource little changed previous year figure include additional administrative function performed asia pacific sartorius corporate administration gmbh part sartorius stedim biotech group market employee age head count region sartorius stedim biotech employed twothirds total workforce people europe december previous year represents increase compared end reported head count rose sartorius stedim biotech employed woman north america men december therefore woman asia pacific region make total workforce men largest group employee age category people average employee age across entire workforce virtually unchanged reporting period year previous year year management report sustainability report new hire attrition rate average seniority represented second management level absenteeism vice president intend continue striving international lineup management level medium term new hire another priority diversity strategy ensure redundancies na woman adequately represented management attrition rate position succeeded increasing proportion average seniority year woman total head count slightly year year trend redundancy companydriven dismissal layoff first reporting year recorded mirrored management level number group whole post held woman two tier management express number people leaving company immediately executive board rising year percentage average head count year december previous year includes terminated contract retirement reason employee leaving company reporting period sartorius stedim biotech attrition rate express number employed people registered disabled people leaving company percentage work france germany average head count fell group represents yearonyear increase whole reporting year previous year attrition rate generally subject regional variation therefore also applies sartorius stedim biotech developing potential rate reporting year europe employee worldwide north american region asia pacific region adjusted figure grow successfully dynamic market environment excluding resignation employee terminated need competent qualified employee contract amount group whole therefore endeavor continuously enhance attrition rate previous appeal employer internally year site germany employ externally providing employee good people previous year opportunity continuing personal development france central effort sartorius stedim biotech provided total hour training absence rate express proportion planned site france tunisia puerto rico working time lost due general absence corresponds average hour training rate stood group whole average training cost per employee reporting year average period missed due illness amounted day per employee employee annual performance review day include time lost due structure assessment criterion longterm health condition statutory maternity standardized cover development opportunity entitlement day missed result workrelated well target performance ultimate accident objective expand human resource program cover whole global operation appropriate expedient harmonize applying different perspective throughout group multicultural company diversity sartorius stedim biotech fill management vacancy market business region customer also largely within rank accordingly reflected workforce setting team develops promotes employee management therefore ensure different perspective potential international level conduct background combined productively also special program help junior manager develop filling management vacancy aim achieve mix refine management skill specific culture gender age group manager project directly related company business germany france usa india example sartorius stedim biotech also provides separate management report sustainability report development program experienced management leonardo da vinci scheme international staff designed reference management vocational education connection many guideline program promotes establishment year support intern number way common management culture example enabling take part training initiative thanks alliance kedge structured expert career path program business school marseille france intern introduced throughout group reporting aubagne site instance able attend year run alongside existing management master business administration course offered program new addition enables sartorius stedim biotech provide specific development opportunity scientist engineer rd function sartorius bioscience scholarship program raise profile expert within meanwhile supporting talented student outside company graduate scientific technical field financially also technically personally managing change process successfully issue provision mentor within everincreasing importance company sartorius organization reporting year selected stedim biotech operates strategic change manage first group participant india ment system help employee implement change scholarship program successfully sustainably managementlevel staff worldwide received training area sartorius stedim biotech continued develop reporting year international link research institution university highlight area included sartorius college offer wide range training alliance école nationale supérieure de continuing personal development opportunity technologie de biomolécules de bordeaux number language employee help granted scholarship first time improve language methodological skill reporting year value selling course example teach field sale representative application specialist worldwide strategic skill necessary provide freedom flexibility work firstclass customer advisory service added new elearning platform technical training program sartorius stedim biotech set employee demanding provides interactive way employee task delegate responsibility early stage marketing sale service function leaf freedom arrange daily work prepare individually subsequent facetoface importance enabling flexible work practice training session widely recognized across company number parttime employee equates train production staff cleanroom working total head count accordance uniform standard method working time model give employee german special training program offered ssb site option scheduling working hour aubagne yauco focus building developing flexibly instance flextime parttime work technical skill total employee teleworking received hour training program aubagne site example encouraging social dialog finding developing talented young staff sartorius stedim biotech place great importance communication employee interoffice memo sartorius stedim biotech offer young people newsletter employee magazine inform opportunity work within company order staff example change within company enhance professional knowledge skill goal economic situation first global experience company making use employee survey took place achieved corresponding european union funding program participation rate question posed covered including marie curie scheme young scientist company respondent personal working management report sustainability report condition result particularly good recorded workrelated accident site plan repeat employee survey regular around world reporting period previous interval future enable u identify change year great majority minor nature time investigate significance number day lost due work accident consequently considerably lower france well germany sartorius stedim previous year compared biotech staff represented three employee accident largest production site council employee council hold regular staff goettingen germany reporting year meeting eight collective agreement previous year seven occurred signed french site eight german company premise rather employee location cover particular pay level travel home work review working time integration young employee effectiveness accident prevention measure retention elderly employee deployment regularly reference accident analysis industrial camera production personnel development signed one collective agreement environment health safety issue ehs statistic accident work germany occupational integration management employee returning work relatively long number work accident illness france agreement concluded number day lost due work accident area harmonization health insurance frequency rate severity rate employee health safety measured calendar day represents number accident per theoretical sartorius stedim biotech corporate health working hour theoretical working hour management policy covering physical represents number day lost accident per psychosocial element health order enhance theoretical working hour employee performance motivation reduce cost associated illness sartorius stedim biotech also promotes awareness personal health among ecological sustainability employee special action day individual site offer vice president sustainable production ecological product germany annual medical checkup selected innovation important basis longterm partner clinic financial success sartorius stedim biotech design manufacturing process conserve sartorius stedim biotech strive improve resource offer customer product technical organizational working condition efficient safe also provide ecological continuously order bring benefit planning operation look reduction jobrelated medical condition risk beyond immediate use resource health potential cause industrial accident understand entire lifecycle product well providing regular training employee including customer process supplier area occupational health safety also required meet specification green environmental protection site germany approach growth coupled underproportionate provided hour total training ehs issue use natural resource goal sartorius continuously adapt job safety work stedim biotech implement various level organization condition line applicable information environmental protection adopted law regulation connection sartorius stedim biotech employee described responsive concern employee page aubagne site example operate special program preventing potential health hazard implement specific improvement suggested employee management report sustainability report high standard quality environmental improved emission monitoring protection taking greenhouse gas protocol ghg global sartorius stedim biotech certified according standard recording greenhouse gas internationally recognized standard quality emission guide sartorius stedim biotech iso environment iso two expanded reach greenhouse gas emission management system ensure comply recording reporting year significantly quality requirement manufacture increased level detail captured emission product prudent use resource categorized three broad scope scope record minimize environmental risk manufacturing co emission caused directly production site site certified compliance iso scope determines indirect emission arise series international standard apart tagels course power generation external energy wangen switzerland employ around staff supplier scope considers co emission member environmental management system associated factor manufacture pre already certified compliance iso cursor product distribution operation sartorius sartorius stedim india sartorius stedim already report scope scope emission biotech gmbh goettingen latter intends gradually integrate scope emission sartorius stedim biotech plastic goettingen co accounting right along value chain site guxhagen additionally introduced energy management system specified application ghg accounting method mean iso intend energy manage beginning consider report ment system certified two environmental co equivalent coeq emission co standard today set benchmark inter gas relevance climate change national site respective company data previous year converted organizational unit ensure law accordingly order make yearonyear com regulation relating environmental protection parisons meaningful observed technical possibility reducing environmental risk identified strive continuously improve existing management system working toward gradual rollout production site appropriate expedient overall environmental risk identified require company make specific provision annual financial statement sartorius stedim biotech supply product directly end consumer rather manufacturer pharmaceutical food chemical also research development laboratory ensure product satisfy stringent quality requirement employ rigorous quality check advanced manufacturing method process cleanroom technology manufacturing method process subject constant review continuous improvement process moreover refined appropriately requirement evolve successful completion host annual audit customer accreditation iso iso together document high standard quality achieved sartorius stedim biotech product process respond rapidly product defect minimize adverse consequence sartorius stedim biotech established traceability system enables u recall entire product batch immediately necessary management report sustainability report greenhouse gas emission sartorius stedim introduced energy management system two biotech sa developed follows goettingen site nearby guxhagen site enables u identify strategic opportunity reduce energy consumption intend energy consumption greenhouse gas certified energy management system specified iso overall energy consumption goettingen site increased much slower total energy consumption mwh rate sale revenue last year electricity adoption modern technology including energy natural gas efficient combined heat power chp plant fuels compressed air center controlling production energy source machine brought reduction annual carbon total greenhouse gas emission dioxide emission around metric ton use coeq intelligent control system enabled u realize scope additional energy saving mwh scope reporting year sartorius stedim biotech key indicator commissioning second combined heat power coeq emission per employee plant goettingen site early coeq emission per sale revenue tmio international site well sartorius stedim figure corrected ex post biotech continuously develops manufacturing inconsistency process enhances building facility data range cover diesel consumption electricity conserve resource particularly new building generator increasing proportion renewable energy emission coeq calculated university source energy mix plant yauco applied science art goettingen using emission factor listed professional software called gabi cover estimated energy consumption scope excluding fuel consumption car fleet requirement site solar energy furthermore guxhagen factory germany source part energy need local photovoltaic plant scope emission consumption electricity make use geothermal energy account almost three quarter company total emission represent main source whole strategy supplying local emission sartorius stedim biotech market far possible directly local quarter attributed largely combustion production facility help shorten transportation fossil fuel scope route thus lower carbon dioxide emission total amount carbon released solvent emission occur principally filter production reducing climate change goettingen yauco site stood metric ton reporting year share since sartorius stedim biotech figure relevance term greenhouse gas measuring scope well scope scope emission taken account calculating co emission main production site singleuse equivalent figure bag aubagne using bilan carbone method also measure total emission carbon dioxide greenhouse gas process efficient use energy upstream downstream production operation analysis found business sartorius stedim biotech strives adapt workrelated travel employee account consequence climate change lower around environmental footprint greenhouse gas emission finding way improve source co include raw material obtained company energy efficiency one main sartorius stedim biotech supplier approach reducing carbon dioxide largest freight transport packaging group site goettingen account approximately threefourths energy consumption newly management report sustainability report drawn plan action make cut amount waste site co emission based finding example set employee working site aubagne moving plan encourage total amount waste carpooling public transportation waste recycling waste disposal nonhazardous waste sustainable use water hazardous waste waste per employee water sartorius stedim biotech recycling rate consumes used rinsing process proportion hazardous waste manufacture filter membrane according precipitation bath method advanced casting machine regarding waste indicator india group implemented working group order improve reliability data help ensure efficient use water site reported goettingen germany bangalore india company operates water treatment system thus contributing sustainable use raw organic solvent sartorius stedim biotech material according estimate yauco need manufacturing membrane filter sartorius stedim biotech reduces usage drinking cartridge recovered recycled goettingen water approximately compared facility account solvent use conventional plant based low water solvent reprocessing plant site strategy implemented inside new building solvent used recovered fed back plant india achieve reduction production operation without ever leaving measure including intelligent solution premise way maintain closed material making use rain water cycle minimize transport requirement reduce quantity water used volume waste water produced conducting research water consumption development also achieved overall reduction amount solvent required membrane manufacture order reduce water consumption cbm consumption polyethylene packaging sartorius water consumption per employee cbm stedim biotech switched delivery polypropylene waste water sack silo manufacture injectionmolded biological oxygen demandbod component required singleuse product contaminated wastewater without sanitary wastewater return recyclable material sartorius stedim biotech strives reduce amount waste generated using waste sorting system contribute toward enabling reusable material recycled proportion waste stored landfill lowered moreover company safely disposes hazardous waste management report sustainability report supplier pharmaceutical industry sartorius building council leed initiative goettingen stedim biotech currently prohibited regulatory invested particular energyefficient air requirement using recycled plastic conditioning system ventilation equipment ground product safety yet consistently send use energysaving led lighting guxhagen site plastic waste recycling disposed substantially reduce consumption fossil fuel environmentally responsible way name using geothermal solar energy example approximately waste manufacturing plant mostly situated industrial produced french site aubagne lourdes area noise pollution resident relevant tunisian site mohamdia recycled issue company care biodiversity energyrich composite plastic waste resulting estimate impact biodiversity low bag manufacture used generate therefore consider action necessary energy incineration special power plant area time larger proportion polymer waste separated collected according type material polyamide polyethylene reused secondary sustainable product innovation material reporting year reduced paper consumption site mentioned effort optimize environmental performance returned waste paper recycling disposal product production method begin environmentally responsible manner research development stage wherever safety functionality permit increase proportion sartorius stedim biotech complies european renewable raw material used reduce packaging directive waste electrical electronic sartorius stedim biotech also work partner equipment weee site germany industry scientific community sustainable using electronic signature hazardous product solution efficient use raw material material caustic solution oil since instance explore possibility obtaining result document production hazardous polymer membrane capsule renewable waste provide digital proof proper recovery raw material recycled substance determine andor disposal ensuring waste fully green house gas emission released tracked end end manufacture filter cartridge environmentally friendly expansion use raw material according infrastructure legal regulation expanding infrastructure sartorius stedim sartorius stedim biotech established material biotech line local regulation practice management system test safety raw land use inside new building extended material use compliance environmental production facility integrate advanced ecological protection occupational safety regulation utility technology eg regarding energy europe include international rohs directive consumption preventing waste limiting noise pollution restriction use certain hazardous reducing scrap resulting manufacturing substance electrical electronic equipment process often exceed european reach regulation registration requirement imposed u local environmental evaluation authorisation chemical well protection regulation sartorius stedim biotech comparable international standard customer site yauco expanded serve informed safety data sheet product safety central manufacturing logistics site information warning alert operating north american market meet highest u instruction hazardous substance present standard green resourcesaving efficient product construction became first pharmaceutical industry supplier worldwide achieve platinumlevel certification u green management report sustainability report sartorius stedim biotech intends gradually integrated solution sartorius stedim introduce various new indicator raw material use biotech flexact product range example next year began reporting approach beyond ecological benefit year quantitative data chemical group generally offered singleuse technology flexact purchased metric ton worldwide solution reduce need stationary installation use manufacturing product equipment thus quantity material consumed versatile central control unit flexact instance used number different highperformance product improve customer biopharmaceutical process environmental footprint technical refinement membrane filter series singleuse product becoming increasingly enabled sartorius stedim biotech slash consumption widespread manufacture innovative effective ultrapure water wetting rinsing medication practical membrane around filter significantly economic aspect also provide ecological benefit lower adsorption lessens amount highvalue compared conventional equipment made steel protein solution lost result pharmaceutical glass singleuse product eliminate need manufacturer substantially reduce quantity resourceintensive cleaning process ultrapure resource use recovering higher yield water well subsequent wastewater processing study shown singleuse service unit assist customer adapting product made plastic far superior complex solution optimally requirement site reusable system consumption energy always analyze customer process whole water chemical product lifecycle identify potential financial ecological expert compared approach based primarily improvement way contribute making reusable material approach based process customer efficient predominantly singleuse material across various environmentally compatible scenario including typical industrial manufacturing process monoclonal antibody result clear sinclair lindsay l et al environmental impact cut manufacturer employing mostly singleuse disposable technology biopharm int november wwwbiopharmservicescomdocsenvironmentimpactdisposabl solution consume around less water espd rawlings b pora h environmental impact less energy addition expert found singleuse reusable bioprocess system bioprocess int deployment singleuse solution reduces size february production unit manufacturer said require less space thus also saving energy material research confirmed energy required sterilization cleaning material process based singleuse product around half conventional processes although singleuse product clear ecological benefit regarding energy water consumption use generates waste yet consistent reuse recycling could improve environmental performance well ultrapure plastic use manufacture various singleuse product contain around energy pure crude oil thus valuable secondary raw material high energy content polymer example mean reused fuel heat power generation management report sustainability report contributing society local subsidiary involved alongside representative political industrial social business activity many positive effect community initiative strengthen progress city community competitiveness respective region focus sartorius stedim biotech based many year area directly indirectly related instance often one largest local business activity infrastructure logistics private employer contractor area environmental protection education maintain main manufacturing site consequently play open constructive dialogue various significant role helping increase local growth local stakeholder inform promptly purchasing power together cooperation comprehensively activity partner sartorius stedim biotech actively help shape development affect concern economic social environment providing financial support project sphere standard function maintenance education culture social affair sport machine building plant security cafeteria contribute toward making region operation use service provided various operate attractive current future subcontractor local site contract sartorius stedim biotech employee alike service awarded according standardized transparent bidding procedure company social outreach activity targeting area beyond mostly locally based sustainability criterion play role home region concentrate field supplier assessment code conduct connection core business fostering research supplier subcontractor sartorius stedim education supporting event scientific biotech drew requires comply community remain chief priority recognized quality environmental standard supplier evaluation program currently preparation sartorius stedim biotech work contributing toward regional employment approximately subcontractor french site development provider recruitment training service site germany long relatively large production facility sartorius standing relationship subcontractor stedim biotech aubagne yauco goettingen among key industrial employer respective promoting sustainable development longterm region instance headquarters aubagne cooperation reliable partnership key tenet city inhabitant provide policy aubagne collaborated many attractive longterm job good people year local community goettingen member large french employer organization actively participate several initiative network medef sartorius stedim biotech collaborates closely including local climate protection initiative national local institute help improve reduce carbon dioxide emission sartorius stedim job market situation expanded yauco plant biotech help enhance education provides employment almost people directly granting scholarship assisting career sartorius stedim biotech another guidance fund charitable work non approximately people local service provider governmental organization example supplier sartorius stedim biotech one goettingen company operates industrial larger private employer university town partner several high school university goettingen local workforce people goettingen yauco cooperate several also major force local economy public school award scholarship rural region surrounding nearby guxhagen excellent student student low income family sartorius stedim biotech also support cultural event one group sponsor behind cultural program presented part marseille year european capital culture management report sustainability report supporting student graduate sartorius stedim biotech ensures gain young talent dedicated program alliance international bioscience scholarship provides financial technical personal support student graduate scientific technical discipline program intended attract appropriately qualified young people particularly global growth market company enhance international project activity sartorius stedim biotech group headquarters aubagne collaborate several school university including école dingénieurs marseille give recently qualified biotechnology engineer opportunity gain professional experience application engineer marketing entered new partnership école nationale supérieure de technologie de biomolécules providing scholarship student choice also extended collaboration école nationale supérieure de art métiers student opportunity attend company workshop reporting year helping young people lowincome family gain access scientific technical career another priority activity year review sartorius stedim biotech supported california nonprofit organization biotech partner organizes internship opportunity disadvantaged young people sponsoring event scientific community addition maintaining longterm alliance scientific institution sartorius stedim biotech regularly take part symposium convention annual conference example included number scientific event bioprocess industry covering subject development antibody vaccine sartorius also supported annual conference usbased parenteral drug association pda various pda convention including event singleuse system microbiological analysis management report statutory auditor report review environmental social societal information statutory auditor report review environmental social societal information statutory auditor report review environmental social societal information published management report free translation english original report paragraph article r french issued french provided solely convenience commercial code attestation completeness english speaking reader csr information year ended december express limited assurance fact taken whole csr information presented fairly attention shareholder material aspect accordance adopted reporting criterion reasoned opinion capacity statutory auditor sartorius fairness csr information stedim biotech designated independent thirdparty entity whose request accreditation work carried threeman team deemed admissible french national january february ie period accreditation body cofrac hereby present around two week assist u conducting work report social environmental referred corporate responsibility expert societal information presented management report prepared year ended december conducted following procedure accordance hereinafter csr information pursuant professional standard applicable france article l french commercial code order may determining methodology code du commerce according independent third party entity conduct assignment regard responsibility company fairness opinion isae international standard assurance engagement board director sartorius stedim biotech responsible preparing management report including csr information provided article attestation completeness csr r french commercial code information prepared accordance reporting criterion used sartorius stedim biotech reporting based interview management familiarized criterion presented throughout group sustainable development management report available request strategy regard social environmental company registered office impact company business societal commitment appropriate resulting independence quality control action programs independence defined regulatory text compared csr information presented profession code ethic well provision management report list set forth set forth article l french article r french commercial code commercial code furthermore set quality control system includes documented event omission certain consolidated policy procedure designed ensure compliance information verified explanation rule ethic professional standard provided accordance third paragraph applicable legal text regulation article r french commercial code responsibility statutory auditor order may determining methodology according independent third party entity conduct assignment based work responsibility isae assurance engagement audit attest required csr information review historical information presented management report event article omission explained pursuant third art r ii management report statutory auditor report review environmental social societal information verified csr information covered representative sample entities consolidated scope ie company selected according activity subsidiary within meaning article l contribution consolidated indicator french commercial code company location risk analysis held interview control within meaning article l verify correct application procedure french commercial code subject limit implemented substantive test sampling basis set forth methodological memo paragraph consisting verifying calculation performed presented management report reconciling data supporting evidence selected sample represented average based work considering aforementioned quantitative information limit attest completeness required csr information management report regarding consolidated csr information assessed consistency relation knowledge group reasoned opinion fairness csr information finally assessed relevance explanation relating necessary total nature scope procedure partial omission certain information held seven interview person responsible believe sampling method size preparing csr information sample used exercising professional department charge csr information judgment enable u express limited assurance collection process appropriate higher level assurance would required responsible internal control risk indepth verification due use sampling management procedure order technique limit inherent operation information internal control assess appropriateness reporting criterion system risk material anomaly identified respect relevance completeness csr information cannot totally eliminated reliability neutrality clarity taking consideration relevant sector best practice section nep art sartorius stedim fmt sa sartorius stedim biotech gmbh verify setup process collect compile process check csr information regard completeness consistency familiarize conclusion internal control risk management procedure relating compilation based work identify material csr information anomaly likely call question fact csr information presented fairly determined nature scope test material aspect accordance reporting control according nature significance criterion csr information regard company characteristic social environmental observation challenge activity sustainable development strategy sector best practice without qualifying conclusion draw attention following matter concerning csr information consider calculation waste indicator specified significant reporting criterion recovery recyclable material paragraph due consolidating entity consulted insufficient level internal control reliability documentary source held interview level reporting waste lower corroborate qualitative information indicator organization policy action implemented analytical procedure quantitative marseille february information verified using sampling technique calculation well data consolidation deloitte associés verified consistency christophe perrau information shown management report management report net worth financial position net worth financial position cash flow cash flow statement summary sartorius stedim biotech group substantially million increased net cash flow operating activity net cash flow million reporting period compared operating activity yearearlier figure million essentially net cash flow investing gain driven higher earnings moreover net activity acquisition operating cash flow fiscal impacted net cash flow financing activity nonperiodic tax payment cash cash equivalent gross debt owed bank net cash flow operating activity net debt owed bank million consolidated balance sheet balance sheet total sartorius stedim biotech group increased million million december reporting date december mainly due acquisition tap biosystems group expansion production capacity buildup working capital predominantly induced sale growth asset side noncurrent asset rose million million planned net cash flow investing activity primarily due previously mentioned acquisition taking account cash flow investment made production capacity acquisition disposal subsidiary million last year figure current asset grew million million however included several large million due buildup capacity expansion project investment mainly million working capital partly related several small mediumsize project related acquisition tap biosystems production including cash outflow related acquisition cell culture medium business tap biosystems group respectively net cash flow investing activity amounted million compared million thus group mainly financed investment acquisition operating cash flow management report net worth financial position key working capital figures balance sheet structure day asset equity liability rate turnover inventory inventory x sale revenue rate turnover receivables trade receivables x sale revenue rate turnover net working capital net working capital x sale revenue noncurrent asset equity better comparability pro forma sale revenue current asset noncurrent liability tap biosystems completely included current sum inventory trade receivables less trade payable liability equity million million sartorius stedim biotech ratio longterm capital fixed asset increased group equity ratio rose slightly december gearing ratio cal thus remained comfortable culated ratio net debt equity remained level strong level december noncurrent liability markedly million december compared gearing ratio million december current liability year year million million mainly related change maturity syndicated loan refinanced reporting year overall gross debt increased million december million december net debt reporting date stood million compared million year ago management report net worth financial position financing treasury consequence global sale distribution structure generate payment various foreign sartorius stedim biotech group financed currency essentially payment u dollar longterm welldiversified basis element japanese yen british pound financing syndicated credit facility affected currency fluctuation especially refinanced reporting year result exchange rate euro u dollar using sartorius stedim biotech group entered global manufacturing network production facility new syndicated loan agreement volume outside germany france north america million term september uk india compensate majority currency fluctuation natural hedging furthermore longterm loan agreement generally hedge twothirds remaining net volume currently million concluded currency exposure year ahead kreditanstalt für wiederaufbau kfw relating suitable currency transaction investment production capacity financing sartorius stedim biotech group another element financing structure factoring comprises instrument fixed variable program maximum volume million interest generally target hedge two moreover diverse bilateral credit line third bank loan taken far approximately million total variable interest rate increase general interest rate level ratio net debt underlying ebitda remained unchanged year ended december key financials interest coverage ratio ratio underlying ebitda interest payable stood december netdebttounderlying ebitda ratio hence key financials remained net debt excellent level underlying ebitda ratio net debt underlying ebitda interest coverage underlying ebitda interest expense gearing net debt equity information underlying ebitda please refer group business development chapter glossary management report risk opportunity report risk opportunity report every entrepreneurial act entail opportunity throughout group opportunity short risk opportunity risk term nature considered annual budget managed skill done go planning medium longerterm opportunity long way determining future prospect tracked systematically course strategic company sartorius aim management planning status opportunity management opportunity risk identify exploit business permanent fixture corporate management opportunity systematically recognize system mean also feature discussion evaluate risk early stage take measure decision process senior management counter possible unrealistic expect body risk management eliminate risk approach consciously accept certain measure risk key area opportunity presented entrepreneurial activity order able make appropriate reference made relevant section use opportunity successfully important group management report order avoid connection keep risk contained within repetition risk presented section acceptable limit control carefully specific risk could equally seen representing opportunity event develop opposite sartorius single unit charged managing direction opportunity accordingly discus opportunity risk prefers instead make section specific risk opportunity function integral element groupwide end part document planning control system described area opportunity managing opportunity pharmaceutical laboratory sector opportunity management center analysis sartorius draw customer combine strong growth target market sector environment appetite advanced technology assessment trend give strong significant opportunity generated various indication future business opportunity market technology trend described detail identification potential development sector condition outlook context one key role relevant sector section page manager initially take place local rather central level marketfacing function assessment rank company one strategic marketing product global market leader many subsegments management department individual division product area believe high quality play leading role respect central business product strong brand recognition development section assist department established customer relationship put u market monitoring data analysis good position continue building leading implementation strategic project market position corresponding strategy growth opportunity initiative based member group executive committee discussed section concerning strategy regularly discus short medium longterm begin page opportunity potential various business area manager operational responsibility also access opportunity realize business development department part improvement profitability strict strategy review subsequent step prioritizing management process cost key target area opportunity evaluating business respect include improvement administration perspective deriving strategic measure procurement chain ongoing effort optimize allocating resource proceed accordance production present page standardized decisionmaking process applies management report risk opportunity report opportunity discussed context urgent reporting procedure place presentation specific risk opportunity ensure new emerging significant risk beginning page net worth financial position profitability identified executive board receives necessary detail without delay risk management case opportunity management overall risk classification responsibility maintenance effective risk management system ensuring comprehensive first level risk management relates four consistent management material risk rest main risk category defined sartorius external risk board director responsibility coordinating operating risk financial risk corporate developing system rest internal governance risk control system compliance corporate department audit committee sartorius stedim biotech sa second level consists additional subcategories monitor effectiveness risk management within main category legal risk system production risk receivables risk organizational risk risk management system risk reporting process also includes allocation functional category example supply chain sale heart risk management system sits distribution human resource accordance sartorius group risk management handbook group structural organization applies throughout organization handbook includes definition framework categorize risk according scale structural organization process risk reporting implication also perform specific evaluation monitoring control effectiveness risk assigned value risk management system based maximum impact time risk analysis internationally recognized coso standard say record maximum risk without also number source contain considering probability occurrence stipulation handling risk including effect risk alleviation measure bylaw rule procedure group company internal guideline specific risk opportunity groupwide risk reporting system form cornerstone internal risk communication object make possible address risk structured general macroeconomic risk manner continuous basis document opportunity accordance relevant statutory regulatory requirement nature various business area mean sartorius whole insulated certain extent prescribed reporting process requires head full force wider cyclical effect central department managing director economic development prove positive various group company review risk expected turn stimulate stronger growth situation within area responsibility two division ongoing basis report finding every quarter process involves evaluating specific risk ability foresee mitigate direct probability occurrence scale potential indirect effect risk broader sense impact reporting case central risk example currency crisis natural disaster management function whenever defined threshold associated damage commercially significant breached critical infrastructure limited management report risk opportunity report supply chain risk opportunity production risk opportunity supply chain extends way manufacture large proportion product procurement production sale distribution belong core area technical expertise problem within sequence consequential involve high level vertical integration effect including delay delivery global supply example include bag filter chain management system introduced product reusable fermenters bioreactors throughout production process prevent manufactured collaboration supplier problem largely minimizes associated risk production risk transferred analyzing controlling operation external third party manufacture product involved strongly international alignment also bear associated risk capacity organization open whole series opportunity bottleneck overcapacity production downtime various risk opportunity encountered excessive reject rate high level tiedup within supply chain explained detail working capital contain reduce risk planning production capacity carefully using versatile machine semiautomated individual procurement risk opportunity workstation flextime work schedule continuously monitoring production process purchase wide range raw material moreover global manufacturing network enables component part service supplier u compensate capacity bottleneck consequently exposed risk unexpected shifting production regional plant delivery bottleneck price increase global supply chain management system reduces risk consider opportunity various enabling u monitor supervise procurement production facility able concentrate activity moreover conduct regular supplier specific production technology result review also use early warning system refine production operation greater continued increase number master efficiency international production network also agreement concluded safeguard supply make possible capitalize cost advantage supplier strategically important raw material offered individual site furthermore continuous fiscal always maintain reserve inventory improvement production simplifying strategic raw material work multiple process increasing level automation supplier possible created risk manager help drive efficiency even higher function purchasing within material group management system principal task function classify supplier sale distribution risk opportunity material purchased according risk factor derive implement necessary risk containment make use variety channel sell measure basis distribute product around world potential risk entailed unexpected change opportunity arise area procurement demand structure growing price pressure non growth enables u increase order compliance supply agreement concluded quantity thereby strengthen position customer employ targeted market analysis supplier increased globalization supplier identify emerging demand trend individual pool hold prospect purchasing segment early time respond favorable term moreover also appropriately technical innovation focus possibility expanded purchasing activity less pricesensitive sale market product international market leading u identify supplier validated production process special product technical expertise could biopharmaceutical industry reduce exposure eventually enhance competitive edge risk growing price pressure minimized risk exposure area logistics recent year setting using central warehouse optimize distribution logistics management report risk opportunity report opportunity arise area sale rd risk opportunity distribution increasing breadth product range put u position sell new devote considerable share resource product existing customer business research development potential risk area relationship built long may arise development result diverge term global presence present opportunity market need exceeding planned development moreover ongoing project strengthen deadline unintentional transfer knowhow direct sale also promise improve sale competitor advanced project management prospect intensive rd controlling early involvement customer development process substantially limit rd risk patent quality risk opportunity continuous tracking technology competitor relevant u secure technology customer use sartorius product wide range position critical production process including manufacture pharmaceutical research hand rd sphere also offer development laboratory main risk encountered kind potential opportunity firstly intensive area noncompliance agreed quality collaboration partner rank among criterion lead loss customer global market leader field open may made liable compensation opportunity u develop particularly highly claim employ rigorous quality check modern innovative product joint effort area production method process cleanroom membrane technology turn expertise technology ensure product satisfy specialist put u right forefront stringent quality requirement global research development present u manufacturing method process subject opportunity turn technical knowledge constant review continuous improvement potential sale stronger position market process moreover refined appropriately requirement evolve successful completion host annual audit customer customer risk opportunity accreditation iso iso together document high level quality achieved sartorius draw key customer sartorius product process irrespective pharmaceutical biotech industry public measure also maintain significant insurance sector research educational institution coverage product liability risk sartorius customer usually relatively large organization established traceability system enables u existence time recall entire production batch immediately strong credit rating business area necessary minimize adverse consequence highly diversified customer base group event defect discovered product whole dependent individual key account significant degree factoring program quality requirement growing introduced keep risk exposure regard stringent time least result trade receivables customer constant low regulatory pressure actually regard first level work continuously improve foremost risk opportunity receivables management explore new possibility market challenging quality demand represent considerable barrier entry potential new competitor moreover competitive risk opportunity provide stimulus technical innovation happy respond sartorius leading competitive position market competitor larger u share status global operator example include merck millipore pall substantial technological barrier market entry management report risk opportunity report fact serve large number customer specific risk associated group accounting highly regulated sector like pharmaceutical industry lead u assess risk new competitor specific risk concerning group accounting arise emerging low global presence help attenuate example arrangement unconventional implication regional risk significantly complex transaction cannot processed routine mean discretion granted change competitive environment example employee involved preparation consolidation market throw consolidated financial statement respect opportunity risk sector find recognition measurement asset liability ongoing process change sartorius outsourcing transfer task specific remains active participant made relevance accounting external service provider acquisition continuously recent year reinforce actuary management consultant may market position open new potential synergy also entail risk risk associated accounting stem derivative financial instrument explained note consolidated financial employee risk opportunity statement innovative technology group sartorius employ large number highly qualified people possible exchange rate risk opportunity scarcity necessary specialist represents opportunity well risk company prof generate good third consolidated sale particularly good training retaining revenue u dollar currency pegged staff counter threat demographic change u dollar smaller proportion foreign losing employee especially currency exchange rate fluctuation key position offering performancerelated consequently matter concern u especially remuneration model targeted continuing professional converting currency balance sheet development option interesting development income statement item time global opportunity continuous education training production network enables u offset lion rising star within organization range share sale revenue received foreign currency attractive employee benefit success within group cost likewise incurred measure apparent low attrition rate foreign currency example manufacture many recent year fact people tend product north american market locally average stay company long time therefore disadvantaged way employment contract certain case contain competition u rival continuously clause prohibiting move direct competitor monitor exchange rate net currency exposure proportion foreign currency sale revenue remains settled financial risk opportunity cost make use derivative financial instrument notably spot forward swap transaction global nature sartorius group operation basis current anticipated net currency mean business activity inevitably exposure foreign currency level hedge exposed financial risk significant exposure advance following aside specific risk associated group month hedging transaction set one accounting exchange rate risk interest rate risk group staff monitored another separate group liquidity risk described addressed detail note consolidated financial statement course interest rate risk opportunity financial risk notably exchange rate risk interest rate risk balanced opportunity concluded fixed interest agreement approximately equal magnitude portion outstanding loan eliminate risk posed variable interest payment however financial instrument outstanding reporting date subject interest based market rate almost two third line credit currently covered interest hedge interest rate risk opportunity apply remainder monitor interest rate trend interest rate exposure management report risk opportunity report constantly facility arrange additional environmental risk hedging transaction consider necessary economically advisable sartorius established environmental management system encompasses integrated division cover whole series liquidity risk opportunity environmental regulation order minimize environmental risk system certified sartorius stedim biotech group actively manages iso several larger production liquidity centrally order check minimize facility corresponding organizational unit liquidity risk optimize liquidity management site concerned ensure related law within organization regulation observed additional technical option limiting environmental risk identified group u various financial instrument ensure ongoing basis longterm liquidity supply sartorius stedim biotech group syndicated loan agreement place established factoring program risk opportunity continued total scope around million sartorius stedim biotech group exposed loan agreement sartorius stedim biotech potential risk realm addition group refinanced september volume risk already described result pronounced new facility end september dependence effective system whose smooth increased million previous functioning essential operation reduce figure million refinancing arrangement security risk continuously enhancing configured provide even greater implementing security guideline policy flexibility capital procurement future rule measure based requirement diversify lending base remaining term two iso standard german federal four half year respectively loan office information security bsi standard agreement mean sound longterm financing base company existing application system checked potential risk regular external employ various measure shortterm liquidity internal audit moreover appropriate measure procurement central management solvency taken minimize risk identified continuous throughout group credit line alignment strategy business strategy accessed repaid short notice agreed tracking new technical development use syndicated loan agreement individual advanced hardware software minimize risk group company also bilateral credit line inherent operation system place smaller scale amounting million environment new erp system commissioned cash pooling agreement selected group sartorius production site goettingen company primary tool used manage gradually rolled group site around liquidity within group agreement world paid particular attention gradually expanded throughout delivery project mastering accompanying risk least maintaining precautionary backup system intend continue regulatory risk vein implementation new system brings whole series opportunity role supplier biopharmaceutical especially relation efficiency gain industry health care provider mean standardization harmonization business sartorius also affected underlying process worldwide development area possibility regulatory authority fda emea adopting restrictive approach approval new medication remains principal source risk context move would reduce number new pharmaceutical product marketed would consequently downgrade future prospect sartorius medium term management report risk opportunity report process risk made allowance balance sheet pending legal dispute proceeding potential produce substantial negative impact group result insurance taken insurance policy cover wide range risk possible economically advisable insurance policy include coverage liability business interruption transport material pecuniary damage risk provide comprehensive coverage legal cost independent department working conjunction external insurance broker regularly review nature extent insurance protection make adjustment necessary assessment overall risk situation risk outlook expedient feasible adopted counter measure arranged balance sheet measure reporting year cover discernible risk within sartorius stedim biotech group potential damage net worth financial situation profitability judge probability occurrence risk presented low case occurrence could material significance sartorius stedim biotech group whole individual group company thorough analysis entire risk situation according current review discernible risk could jeopardize existence group similarly based current review discernible risk could jeopardize existence group future management report forecast report forecast report future macroeconomic environment forecast two southern country eurozone italy spain indicate return growth pace global economic growth likely two year recession gross domestic product increase noticeably according expected expand italy figure imf spain previous year information oecd point increasing growth export stabilization private domestic demand forecasted gdp growth rate imf forecast emerging country indicate growth prime driving force grouping asia china india indonesia malaysia philippine thailand vietnam rate growth economic output expected rise previous year chinese economy appears set grow make strong contribution region progress imf forecast japan suggests rate global u japan euro developing economic growth drop back somewhat zone emerging result main market anticipated gradual winding expansive source international monetary fund fiscal policy effect time coupled weaker private demand following percentage point increase sale tax planned april estimate industrialized country suggest growth year future exchange interest rate trend imf expects rate economic growth leading central bank expected keep interest u pick strongly reporting rate low indeed ecb made clear year decisive factor behind option reduction base rate forecast include higher government spending well entirely table continued recovery u real estate market forecast eurous dollar exchange rate germany expected see growth course range euro u forecast based primarily economic recovery dollar euro u dollar within eurozone particular germany important trading partner france source international monetary fund world economic outlook october scotiabank global forecast update november rate economic growth france predicted reuters forex poll december ecb oecd economic outlook improve reporting year volume issue november suggestion increased growth france reflects expected upturn business investment activity country management report forecast report pharmaceutical industry positive prospect expiry austerity measure make presence felt effect introduction state health demographic change steadily increasing access insurance usa yet become apparent healthcare emerging country general japanese government example planning rise lifestyle chronic disease look set remain less double use favorably priced primary factor driving expansion generic period pharmaceutical industry new medication especially targeting condition currently difficult treat also make significant contribution emerging country continue drive growth future growth expiry patent austerity measure cut healthcare spending particular growth pharmerging market contrast industrialized country nevertheless tend remain well average around per weigh future growth industry year period apart demographic trend rapid growth driven market researcher ims health forecasting notably rising level state investment overall growth global healthcare system increased private spending pharmaceutical industry period especially among fastexpanding middle class consequently share global pharmaceutical market accounted pharmerging market moderate growth industrialized nation increase around ten percentage point approximately next five year growth north american european japanese region expected remain moderate average period patent pronounced longterm trend drive average growth biopharmaceutical industry source ims global use medicine outlook evaluate pharma returning growth june bioplan th annual report april management report forecast report biotech sector outgrow market whole persistently strong research development pipeline given proportion new development based expert forecast suggest biopharma segment biological manufacturing process particularly pharmaceutical market enjoying high around total pharma pipeline particularly strong growth year continue outperform market whole going forward expiry patent expected proportion sale revenue accounted increasingly strong effect growth rate medication vaccine manufactured using biotech biotechnology sector future noting expiry method expected rise currently around whole series patent ims health forecast sale approximately period biosimilars biobetters likely swell less u billion today u billion continued overproportionate growth driven part biopharmaceuticals already market observer forecast biotechnology gained approval increasing market penetration market whole reach around u billion expanding range indication additional average rate growth period growth impetus expected segment expected biopharma growing market percentage worldwide rx otc pharmaceutical sale biotech v conventional technology biotech share within top product bn bn bn biotechnology conventional unclassified split biotech n avg bn conv n avg bn source evaluate pharma june management report forecast report squeeze publicsector research continue expert expect reduction overall public sector rd spending result widespread consolidation national budget handful emerging country large market china india investment science education likely rise government plan china example provide massive investment pharma ceuticals research pharmaceutical industry source global use medicine outlook evaluate pharma returning growth june bioplan th annual report april cefic tough condition lead eu chemical output contraction growth return june future business development outlook fiscal incorporates risk opportunity outlined report supply biopharmaceutical industry business development generally driven stable longterm trend therefore economic fluctuation play less role example decision regulatory agency regarding drug approval use medication assuming trend toward biomanufacturing pharmaceutical increasing utilization single use technology continue forecast sale revenue rise constant currency cell culture medium small scale fermentation business acquired projected contribute around six percentage point growth management expects underlying ebitda margin rise around without currency effect considered please refer definition operating earnings margin page glossary moreover plan invest sale revenue expansion production capacity among project regard financial position forecast end ratio net debt underlying ebitda edge slightly without taking potential portfolio change account management report financial statement parent company sartorius stedim biotech sa december financial statement parent company sartorius stedim biotech sa december financial statement parent company therefore considering company hold treasury share net dividend paid sartorius stedim biotech sa parent company every share par value group accordance decision extraordinary shareholder meeting held annual shareholder meeting acknowledges april sartorius stedim biotech sa informed new tax regulation transformed mixt holding company retroactively dividend according finance law january company therefore abolished right choose withholding tax managing investment group real submitting dividend estate french company distribution progressive scale tax income application allowance sale revenue generated sartorius stedim retained without modification accordance biotech sa k relative k article french general code important reduction connection wtih contribution partial asset sartorius stedim biotech dividend paid april sa sartorius stedim fmt sa operating profit versus k net financing income amount distributed january totaled versus k eligible tax rebate follows net profit k compared k income eligible tax rebate income appropriation net profit fiscal year ended dividend distributed dec annual general shareholder meeting agm dec suggest appropriate net profit dec reporting year director receive director meeting attendance fee whose amount allocation established board director consideration limit set agm sartorius stedim biotech sa share capital follows share capital december legal reserve total capital amount ten million three hundred balance resulting deduction legal reserve ninetyfive thousand eight hundred six euro sixtysix cent divided share worth sixtyone cent following amount added balance fully subscribed paid heading article yearearlier profit carried forward bylaw would yield distributable profit total amount dividend disbursed shareholder balance resulting disbursement remaining amount carried next year management report financial statement parent company sartorius stedim biotech sa december movement sartorius stedim biotech sa share capital increase share capital exclusively attributable exercise stock option number number share share capital share par share capital share new date nature transaction value increase premium share transaction transaction exercise share st half subscription option exercise share nd half subscription option exercise share st half subscription option exercise share nd half subscription option exercise share st half subscription option exercise share nd half subscription option exercise share nd half subscription option exercise share nd half subscription option exercise share st half subscription option exercise share st half subscription option exercise share year subscription option sartorius stedim biotech sa shareholding december situation sartorius stedim biotech sa shareholding shareholder share voting right sartorius ag sartorius ag less none none less none none management report financial statement parent company sartorius stedim biotech sa december past three year ownership sartorius stedim biotech share capital distributed follows december december december number share voting number share voting number share voting shareholder share capital right share capital right share capital right sartorius ag single voting right double voting right vl finance single voting right double voting right total sartorius group treasury share personnel shareholder general public single voting right double voting right total share belonging sartorius ag reverse merger sartorius stedim legal disclosure threshold crossed treasury share held sartorius stedim biotech sa legal disclosure threshold crossed registered company according resolution passed annual general shareholder meeting agm april share buyback program implemented control company december sartorius stedim biotech sa sartorius ag hold directly indirectly information following movement done share capital outstanding voting right movement registered since treasury share without voting right time number share bought staff shareholding average purchase price amount negotiation cost exception stock subscription plan stock number share held end year option plan company run employee value purchase price profitsharing scheme nominal value corresponding fraction share capital management report financial statement parent company sartorius stedim biotech sa december treasury share held company affected security representative theshare capital following goal none return share exchange payment within scope potential external project authority delegated annual general deliver share case exercise shareholder meeting board director right attached security giving access mean immediately certain future date annual general shareholder meeting capital company delegate authority board director increase capital board director decided propose resolution april ordinary annual shareholder meeting order modify security giving access share capital allocation treasury share knowing maximum purchase price paid company share shall exceed fortyfive euro per stock option share specified informative purpose share constitute share capital company maximum sum allocated share subscription plan share buyback plan amount seventysix million four hundred seventyfour thousand seven hundred stock option plan detailed table ten euro authority delegated board director setting new plan recently expired board director longer delegated unpaid capital authority set new plan none authorized unissued capital none management report financial statement parent company sartorius stedim biotech sa december number share total number subscribed number number date total option senior number option target number agm number granted executive initial subscrip jan granted performance beneficiary authorized option senior bene bene tion dec based valid plan board meeting granted executive ficiaries ficiaries price exercisable option option june aug june sept june oct june sept june feb june july june sept june nov total agm annual general shareholder meeting change number stock option january december outstanding share january allocated period cancelled period exercised period lapsed period outstanding december share capital dilution share subscription option granted ten top nonsenior executive beneficiary option december total number share exercised fiscal year capable issued basis performance based share subscription option potential none share fully diluted share capital option exercised fiscal year share subscription option granted senior reported year option exercised executive company option exercised ten significant accounted total fiscal option exercised none management report financial statement parent company sartorius stedim biotech sa december share subscription warrant dividend distribution policy sartorius stedim biotech sa issued share company dividend distribution policy based subscription warrant net profit generated group level relevant fiscal year well group foreseeable growth profitability pledging share april annual general shareholder sartorius stedim biotech sa share pledged meeting voted payment net dividend per share dividend available payment april pledging asset dividend interim dividend unclaimed five none year following payment date must paid state ie france article french civil code dividend per share fiscal year number share dividend corrected per share compared number share december senior executive membership committee director receives lumpsum amount per information sartorius stedim biotech sa senior full year membership addition executive list position hold attendance fee insofar hold held past five year included chair instead receive lumpsum corporate governance report amount per full year hold chairperson addition attendance fee remuneration activity committee director meeting attendance fee due together remuneration term previous subsection hereof director meeting attendance fee calculated annual basis method calculating fee valueadded tax reimbursed changed fiscal year corporation insofar member board entitled invoice corporation separately director receive director meeting attendance valueadded tax exercise right fee whose amount allocation established board director consideration limit resolution applied set agm director got executive top management activity group level context director receives fixed remuneration executive corporate officer receive per year paid annual remuneration membership financial statement adopted annual shareholder meeting fall due total paid director meeting payment annual shareholder meeting attendance fee chairman board receives twice amount furthermore member board receive attendance fee per meeting reimbursement expense addition annual remuneration management report financial statement parent company sartorius stedim biotech sa december compensation executive management team director meeting base fixed annual long term stock departure attendance salary incentive incentive option indemnity fee k k k k k k k total total joachim kreuzburg joachim kreuzburg reinhard vogt reinhard vogt volker niebel volker niebel oscarwerner reif oscarwerner reif dr joachim kreuzburg receives salary sartorius ag duty entire sartorius group remuneration determined annually supervisory board sartorius ag phantom stock plan used variable longterm incentive component incorporates risk remuneration component depends development sartorius ag share price period least four formerly three year payable price exceeds least formerly per year relative time phantom stock assigned share price outperformed tecdax comparative index amount paid capped maximum time share price time phantom stock assigned based case actual annual tranche concerned use component designed longterm incentive effect incorporates risk corresponds suggestion french german corporate governance code date payment made joachim kreuzburg reinhard vogt according phantom stock plan reinhard vogt receives salary sartorius ag duty entire sartorius group remuneration determined annually supervisory board sartorius ag volker niebel receives salary subsidiary sartorius stedim biotech gmbh work entire sartorius stedim biotech group remuneration determined annually shareholder sartorius stedim biotech gmbh oscarwerner reif receives salary subsidiary sartorius stedim biotech gmbh work entire sartorius stedim biotech group remuneration determined annually shareholder sartorius stedim biotech gmbh independent auditor current regulated agreement independent auditor sartorius stedim shareholder sartorius stedim biotech biotech sa group requested approve agreement covered article l french ernst young represented xavier senent commercial code duly authorized board alternate auditor auditex director form submitted deloitte associés represented christophe perrau alternate auditor beas payment term trade payable december balance trade payable totaled trade payable comprised following invoice paid day regarding invoice issue date management report financial statement parent company sartorius stedim biotech sa december invoice paid day regarding december balance trade payable invoice issue date totaled trade payable comprised following date cumulative overdue trade payable amounted invoice paid day regarding invoice issue date invoice paid day regarding invoice issue date date cumulative overdue trade payable amounted fiveyear financial result parent company sartorius stedim biotech sa k share capital end period share capital capital stock number share outstanding transaction financial performance sale revenue excl vat profit tax employee profit sharing plan amortization depreciation provision expense reversal income tax contribution employee profitsharing plan net profit dividend paid proposal dividend earnings per share eps tax employee profitsharing amortization depreciation provision expense eps tax employee profitsharing amortization depreciation provision expense dividend per share personnel workforce size personnel cost social security cost corporate governance corporate governance board director committee board director committee board director joachim kreuzburg board director composed eight member chairman chief executive officer two independent director date birth april appointed threeyear period nationality german composition board director appointed april december first appointment june mandate renewed april appointed date annual general shareholder meeting approve financial statement fiscal year ending december number sartorius stedim biotech share held current directorship position within group chairman executive board vorstand sartorius ag vice chairman supervisory board sartorius stedim biotech gmbh managing director sartorius lab holding gmbh member board director sartorius stedim north america inc member board director sartorius stedim filter inc member board director sartorius stedim japan kk member board director sartorius stedim lab ltd président vl finance sa member board director sartorius japan kk member board director denver instrument beijing co ltd member board director sartorius scientific instrument beijing co ltd member board director sartorius hong kong ltd member board director sartorius biohit liquid handling oy member board director sartorius north america inc président member comité exécutif sartorius stedim fmt sa member board director sartorius stedim biotech sarl member board director sartorius stedim integrated service sarl member board director sartorius stedim bioprocess sarl corporate governance board director committee past directorship held past five year volker niebel within group vice chairman supervisory board executive member sartorius weighing technology gmbh executive vice president operation managing director geschäftsführer date birth august sartorius corporate administration gmbh nationality german member board director sartorius stedim sus inc first appointment june member board director mandate renewed april sartorius stedim industry sarl appointed date annual general member board director shareholder meeting approve sartorius stedim sus sarl financial statement fiscal year ending december current directorship position number sartorius stedim biotech share held outside group current directorship position member advisory board regionalbeirat within group commerzbank ag germany managing director geschäftsführer member advisory board beirat sartorius stedim biotech gmbh hameln group gmbh germany member board director member advisory board beirat sartorius stedim north america inc otto bock holding gmbh co kg germany member board director member economic advisory board wirtschafts sartorius north america inc beirat norddeutsche landesbank germany member board sartorius stedim filter inc member board director educational professional background sartorius stedim india pvt ltd diplommaschinenbauingenieur dr rer pol member board director university degree mechanical engineering sartorius stedim lab ltd doctorate economics member board director sartorius stedim aseptics sa managing director member board research associate institute director sartorius stedim biotech sarl solar energy research hamelin managing director member board germany director sartorius stedim integrated service sarl research associate faculty managing director member board economics management director sartorius stedim bioprocess sarl university hanover germany directeur général member comité executif since sartorius ag goettingen germany sartorius stedim fmt sa may recent position promotion executive board past directorship held past five year vice president finance within group investor relation member board director since member executive board sartorius stedim sus inc nov sartorius ag goettingen germany managing director member board may spokesman sprecher executive director sartorius stedim sus sarl nov board sartorius ag goettingen managing director sartorius stedim dd sarl germany managing director member board since ceo executive board chairman director sartorius stedim industry sarl nov sartorius ag goettingen germany member board director currently responsible operation sartorius stedim system inc human resource legal affair compliance corporate communication corporate governance board director committee educational professional background sartorius stedim biotech gmbh diplombetriebswirt university degree business recent position vice president administration economics rd technology since managing director sartorius schmidt clemens lindlar stedim biotech gmbh goettingen germany sale manager petro germany chemical industry usa gambro ab lund sweden skanska ab malmö sweden reinhard vogt member executive management team poggenpohl executive member gmbh herford germany executive vice president marketing sale service sartorius ag goettingen germany date birth august recent position senior vice nationality german president operation biotechnology division first appointment june since managing director sartorius stedim mandate renewed april biotech gmbh goettingen germany appointed date annual general shareholder meeting approve financial statement fiscal year ending december oscarwerner reif number sartorius stedim biotech share held executive member executive vice president research development current directorship position within group date birth november member executive board sartorius ag nationality german managing director sartorius stedim biotech gmbh first appointment april managing director ofsartorius weighing technology gmbh appointed april managing director appointed date annual general sartorius lab holding gmbh shareholder meeting approve financial member board director statement fiscal year ending december sartorius stedim north america inc member board director number sartorius stedim biotech share held sartorius north america inc member board director current directorship position within group sartorius stedim india pvt ltd managing director sartorius stedim biotech gmbh member board director member board director sartorius stedim malaysia sdn bhd sartorius stedim switzerland ag switzerland member board director sartorius stedim australia pty ltd past directorship held past five year member board director none sartorius australia pty ltd member board director educational professional background denver instrument beijing co ltd diplomchemiker dr rer nat university degree member board director chemistry molecular biology msc doctorate sartorius scientific instrument beijing co ltd chemical engineering member board director sartorius hong kong ltd research associate institute member board director chemical engineering sartorius stedim switzerland ag university hanover germany member board director sartorius ag goettingen germany sartorius japan kk recent position vice president member board director rd technology sartorius stedim japan kk member board director sartorius korea ltd corporate governance board director committee past directorship held past five year research later university within group california berkeley california usa member board director sartorius stedim sus inc psa automobile citroën member board director head department charge sartorius stedim india pvt ltd overall manufacturing planning member board director programming sartorius stedim biotech beijing co ltd renault automation robotics managing director geschäftsführer vice president strategic planning sartorius technology service gmbh ceo chairman board managing director geschäftsführer hightech startup company specializing sartorius food beverage gmbh artificial intelligence cognitech managing director sartorius stedim poland sp zoo consultant human resource managing director sartorius stedim hungária kft management company executive especially multicultural educational professional background industriekauf environment mann vocational diploma industrial business administration ceo stedim biosystems executive vice president sarstedt ag nuembrecht germany sartorius stedim biotech general manager sarstedt ab sweden since managing director l l conseil sartorius ag goettingen germany may sarl management consulting service recent position management human resource senior vice president sale marketing biotechnology division since managing director sartorius stedim bernard lemaître biotech gmbh goettingen germany since member executive board nonexecutive member sartorius ag goettingen germany date birth december currently responsible marketing nationality french sale service first appointment june mandate renewed april liliane de lassus appointed date annual general shareholder meeting approve nonexecutive member financial statement fiscal year ending date birth december december nationality french number sartorius stedim biotech share held first appointment june mandate renewed april appointed date annual general shareholder current directorship position outside meeting approve financial statement group fiscal year ending december président financière de la seigneurie sa member board director senova system inc number sartorius stedim biotech share held member board director sycovest asset management paris current directorship position outside group member supervisory board managing director l l conseil sarl management azulis capital sa paris consulting service human resource management solon venture ltd london qualium investment sa paris educational professional background phd organic chemistry mba past directorship held past five year master degree sanskrit outside group member supervisory board intrasense sa scientific employee charge research french cnrs educational professional background national center scientific founder ceo chairman stedim sa corporate governance board director committee arnold picot university professor faculty business administration technical nonexecutive member university munich director date birth december institute general industrial nationality german business administration since university professor faculty first appointment june business administration university mandate renewed april munich director institute appointed date annual general information organization shareholder meeting approve management financial statement fiscal year ending konrad adenauer visiting professor december georgetown university washington dc usa number sartorius stedim biotech share held current directorship position within henri riey group chairman supervisory board nonexecutive member sartorius ag independent member chairman supervisory board date birth november sartorius stedim biotech gmbh nationality monegasque past directorship held past five year first appointment june within group mandate renewed april chairman supervisory board appointed date annual general sartorius weighing technology gmbh shareholder meeting approve financial statement fiscal year ending current directorship position outside december group member supervisory board takkt ag number sartorius stedim biotech share held member supervisory board wissenschaftliches institut für infrastruktur und current directorship position outside kommunikationsdienste gmbh und wikconsult group gmbh president aidea president groupe hr sa past directorship held past five year director princess grace monaco foundation outside group vice chairman supervisory board past directorship held past five year etelon esolutions ag outside group none educational professional background educational professional background diplôme institut supérieur de gestion france bankkaufmann diplomkaufmann banker university degree earned french higher institute degree business administration dr rer pol post business management institut supérieur de gestion doctoral lecture qualification venia legendi betriebs wirtschaftslehre authorization teach business fund manager paribas bank managerial economics university fund manager responsible european equity fund management research assistant assistant team barclays bank france professor university munich head research barclays asset university professor faculty management europe business administration university executive vice president barclays hanover germany director asset management charge institute management fund management business organization cfo hendyplan sa visiting scholar stanford university california usa corporate governance board director committee registered address information regard social mandate member accordance bylaw sartorius stedim board director general manage biotech sa company diretor owns personally ment domiciled company headquarters least one share company director fulfill mentioned threshold independent director regard number mandate listed company pursuant principle good corporate governance independent member may executive director maximum two principal shareholder employee former group mandate company belonging group employee supplier banker group major customer may link likely non executive director maximum four impair judgment mandated company belonging group sartorius stedim biotech sa board director company knowledge within last five year includes two independent director mr liliane de member board director lassus mr henri riey convicted fraud last five criterion needed qualify independent year subject official public director following investigation sanction statutory regulatory authority may employee senior executive employee director parent company associated capacity manager one consolidated company may bankruptcy receivership liquidation five previous year past five year may senior executive company disqualified court acting company directly indirectly hold capacity member administrative director position employee management supervisory body issuer senior executive company either acting capacity management currently less five year executive conducting business issuer hold director position past five year may significant client supplier business company knowledge family relationship exist banker investment banker company among member company board director group company group represents significant part business furthermore company knowledge conflict interest duty member may close family tie one board director private interest senior executive duty director must inform board soon aware conflict interest may auditor company even possibility potential conflict must five past year refrain participation discussion relevant subject matter voting may director company associated resolution twelve year company knowledge settlement agreement reached shareholder client supplier others appoint member board director company knowledge service contract linking board member sartorius stedim biotech group granting benefit corporate governance board director committee audit committee audit committee currently composed four member mr henri riey chairman committee since december mr arnold picot mr liliane de lassus mr bernard lemaître chairman audit committee mr de lassus independent chairman board director also ceo group permanent guest audit committee voting right audit committee met five time fiscal remuneration committee remuneration committee currently composed four member mr arnold picot chairman committee since june mr liliane de lassus mr henri riey mr bernard lemaître two four member remuneration committee independent remuneration committee met fiscal company decided move forward taking account best practice corporate governance code mr joachim kreuzburg executive board member replaced committee mr liliane de lassus information organization function activity committee fiscal please refer chairman report pursuant article l french commercial code included publication following page corporate governance executive committee executive committee executive committee manages operational business company decides strategic important topic relating company provided decision interfere responsibility board director executive committee also implement decision resolution board director daily business composed following person joachim kreuzburg volker niebel reinhard vogt oscarwerner reif joerg pfirrmann dominique baly executive committee met twelve time fiscal corporate governance chairman report pursuant article l french commercial code chairman report pursuant article l french commercial code pursuant article l french decided go joint chairman ceo commercial code chairman board board director two separated function director u report cover fiscal year corporate governance structure implemented ended december present composition mist french listed company board board director application director allow u simplify daily business principle balanced representation men increase efficiency addition approach take woman condition preparation account company owned majority organization work board director shareholder following implementation internal controlling control procedure corporate governance best practice due historical implemented company within group reason related shareholding company composition board director pursuant last paragraph article l committee give majority shareholder french commercial code company possibility get fair balance representation independent auditor prepare report director representing shareholder independent concerning report chairman board member executive director reason director internal control risk management contrary afepmedef recommendation gradual procedure relative preparation processing renewal director membership accounting financial information implemented top company closely related german regulation regard corporate governance code code cancelled gradual corporate governance code renewal recommendation recently addition board director composed woman since fiscal sartorius stedim biotech sa compliance afepmedef code board director therefore decided adopt requiring however company working afepmedef recommendation reference code getting conform corporate governance best corporate governance see wwwmedeffr practice follow topic coming year indeed possible change structure afepmedef corporate governance code board considered fiscal code defines set regulation good regard structure general regard responsible corporate governance follows independent member participation woman comply explain principle implemented board eg board discus change country european union listed current onetier structure two tier structure company comply recommendation executive supervisory board andor code must explain corporate add another independent woman board governance report threshold independent member audit committee reached company level sartorius stedim biotech sa essentially complies practical majority shareholder code though sartorius stedim biotech sa need however two four independent member explain certain divergence code last chairman remuneration committee independent member company decided board sartorius stedim biotech sa composed apply afepmedef recommendation currently independent member accordance order get chairman remuneration afepmedef independency criterion committee group level consistent according code board director sartorius stedim biotech sartorius ag company comprised least independent director board director corporate governance chairman report pursuant article l french commercial code condition preparation organization mission mentioned summarize internal work board director bylaw board director internal rule regulation activity report board director fiscal procedure governing organization functioning board director defined board director met sept time fiscal internal rule regulation board year average attendance board director deal matter board reviewed approved corporate concerning proper operation company consolidated account take decision subject concern board director considered debated following meeting mission strategic direction major group project main mission board director annual halfyear quarterly financial follows statement budget presented executive management board director shall define company information financial structure cash strategic goal assess overall flow item perspective least year proposed significant offbalance sheet commitment ceo ensure goal implemented risk indicator group shall also appoint corporate officer responsible internal organization project managing company pursuit strategy stock market performance review delegation authority selfassessment board member implementation syndicated loan sartorius board director shall review management stedim biotech group group monitor quality information legal reorganization split sartorius stedim provided shareholder market biotech sa activity pure holding company financial statement material event manufacturing company occur especially company shareholding renewal mandate chairmanchief executive officer two executive vice president board director responsible approving election member audit committee strategic investment project transaction remuneration committee particular acquisition disposal likely strategy partnershipacquisitions materially affect company result structure lonzatap biosystems plc balance sheet risk profile board member carried formal assessment board director shall deliberate prior work board director questionnaire making change management structure sent board member summary company shall informed principal result show positive overall assessment organizational change board performance selfassessment show director consider well informed board director shall examine corporate executive management company belief consolidated account approve manage ceo moderating properly discussion ment report section annual report board director dealing corporate governance setting company policy respect committee chairman submitted committee remuneration stock option work report board discussion board director shall convene general independent auditor invited two board shareholder meeting propose change meeting article association corporate governance chairman report pursuant article l french commercial code information provided director audit committee duty field accounting policy internal controlling consist board meeting director receive report mainly agenda item require prior consideration due time following notification examining annual corporate consolidated account reviewing halfyearly annual corpus preliminary figure annual interim tion consolidated account including note statement generally sent director least financial statement management one week meeting audit committee port presented board director always held day day annual general shareholder meeting convened board meeting approve statement fiscal present ing observation recommendation addition board meeting chairman regularly board director informs director event development ensuring suitability consistent application may material impact group operation accounting method procedure chosen information previously communicated company guaranteeing correct appli board cation examining accounting treatment signifi member board director receive copy cant transaction carried company press release published company director may time request audit committee duty area external information chairman board controlling consist shall assess relevance request submitting recommendation board direc tor concerning statutory auditor ap board committee pointment reappointment annual general shareholder meeting audit committee remuneration analyzing issuing opinion definition committee responsible studying making scope timetable assignment fee preparation board main deliberation analyzing independence legal auditor order improve board efficiency audit committee duty field risk board meeting preceded meeting analysis prevention consist least one two committee depending item agenda committee report defining internal audit plan group com board work observation submit panies obtaining report audit carried opinion proposal recommendation defining necessary action plan imple menting new procedure respective compa procedure committee also defined ny internal rule regulation examining company exposure significant risk risk mapping duty audit committee verifying appropriate application internal control accounting financial reporting procedure audit committee assist board director company accounting policy reporting audit committee duty area financial treasury hedging instrument internal communication consists reviewing company external controlling financial communication risk proposed financial communication respect management publication halfyearly annual corporate account quarterly result corporate governance chairman report pursuant article l french commercial code committee may also perform activity remuneration committee deliberated main deemed necessary appropriate committee following topic board director reviewing remuneration corporate officer activity report audit committee fiscal reviewing payment director fee reviewing nomination renewal mem audit committee met five time fiscal bers board director year average attendance validation respect balanced representation men woman board director audit committee dealt following major topic within scope remuneration committee consulted board director proposal examining corporate consolidated annual concerning account reviewing financial statement quar terly halfyearly annual corporate consol total budget allotted director fee idated account including implementation term allocation thereof taking account specific action related ifrs standard actual presence director board meeting working hedging instrument possibly committee meeting review internal audit work fixed remuneration corporate officer review quarterly risk management report term variable remuneration approval auditor fee general policy granting share subscrip implementation syndicated loan sartorius tion option share purchase option free allot stedim biotech sa ment company share asset contribution project policy director nomination renewal june december audit ac count auditor presented essential mandate joachim kreuzburg result audit option decided reinhard vogt volker niebel arnold picot bernard lemaître liliane de lassus henri riey board duty remuneration committee director member renewed purpose remuneration committee help company board director establish limitation power chairman remuneration policy corporate officer chief executive officer particular incentive mechanism granting share subscription option share purchase option june board director voted free allotment share company may combine function chairman chief introduce executive officer without limitation power included internal regulation remuneration committee also board director mainly strategic responsibility give recommendation regard investment project transaction especially new potential director committee member acquisition disposal may lead material profit loss impact procedure concern activity report remuneration committee operation one million euro remuneration committee met fiscal year average attendance corporate governance chairman report pursuant article l french commercial code remuneration senior executive remuneration oscarwerner reif volker senior nonexecutive board member niebel discussed within remuneration committee mandataires sociaux subsequently voted annual general shareholder meeting sartorius stedim biotech gmbh total remuneration including benefit paid oscarwerner reif volker niebel year senior executive chairman employment contract remuneration consists board director chief executive officer fixed variable component line director including sharebased payment disclosed respective degree responsibility corporate governance report sartorius stedim biotech group see page internal control procedure remuneration committee set review remuneration board director executive member furthermore remuneration committee introduction also responsible checking annual director fee paid director objective defined chairman internal control system sartorius stedim biotech dr joachim kreuzburgs reinhard vogts follows remuneration determined annually sartorius ag supervisory board remuneration prevent risk would endanger quality consists fixed variable component asset sartorius stedim biotech even exist line respective area responsibility ence variable portion contains short mid longterm ensure executive management activity component shortterm component paid transaction completed conduct employ every year mid term component paid every ee comply guideline defined executive three year based average achieved management applicable law regulation target threeyear term long term fundamental value standard internal rule component comprised phantom stock plan business ethical code convention subject risk remuneration component healthcare industry depends development sartorius ag share ensure accounting financial information price period least four formerly three management data provided executive year year payable price exceeds management company accurately reflect least formerly per year relative time operation sartorius stedim biotech phantom stock assigned share price prevent risk arising operation error fraud outperformed tecdax comparative index especially accounting financial area amount paid capped maximum time share price time phantom stock assigned based case actual scope internal control annual tranche concerned use component designed longterm incentive effect internal control system described cover entail risk recommendation adopted parent company affiliate german french corporate governance code date payment made dr kreuzburg reinhard vogt according phantom stock plan component internal control part remuneration cross charged annually environment internal control sartorius stedim biotech group core business people individual attribute including integrity ethical value expertise environment operate engine drive organization foundation support company corporate governance chairman report pursuant article l french commercial code risk assessment process risk mapping audit committee company must aware deal audit committee responsible carrying risk face must set objective integrate necessary review evaluation internal sale production marketing financial controlling procedure including relating activity organization operates financial information also assist concert must also establish mechanism preparation group consolidated financial identify analyze manage related risk statement information audit committee see page control activity risk management control activity undertaken every level group ensure internal control sartorius stedim biotech group inevitably efficient checking accuracy completeness exposed wide variety risk nature authorization validation recording transaction operation around world accordingly internal ensuring different people discharge different risk management system set help duty reduce risk error fraud identify assess manage risk efficiently within risk management system ad hoc information communication committee comprised representative different department regularly study current issue risk availability accurate reliable complete management enables committee provide information essential achieve business executive management overview risk objective enable proper reporting party company exposed enabling take concerned compliance applicable law appropriate action required regulation internal auditing department monitoring control management internal auditing department charge responsibility authority must defined monitoring effectiveness suitability risk understood level company internal management internal control system control function effectively duty must sartorius stedim biotech group company well assigned way person work always compliance activity process internal checked approved different person external rule standard provides size local unit concerned permit independent auditing consulting service responsibility initiating authorizing recording focus primarily compliance relevant legal processing transaction must always assigned provision improvement business process different individual company ensure independence internal auditor audit committee receives unit management responsible maintaining least year report internal auditing internal check internal control time department work done according audit plan established committee finding regard group affiliate internal controlling role finance controlling department executive management finance controlling department track chairman chief executive officer monitor operation project optimize responsible internal control system group profitability cash flow providing management level also responsible internal external stakeholder reliable development operation monitoring management information internal control controlling system providing necessary assurance step two department define group accounting implemented rule method principle financial process fiveyear business plan budget etc well reporting tool order monitor daytoday business corporate governance chairman report pursuant article l french commercial code procedure preparing group financial financial information reporting statement accounting financial information group rule procedure relation financial reporting accounting set accounting account subsidiary prepared reporting manual application compliance accordance group accounting policy principle rule procedure data adjusted necessary produce direct responsibility finance director company account comply applicable subsidiary must ensure information provided local legal tax provision integrated consolidation via management information system complies fully software used management reporting applicable disclosure requirement purpose produce group financial statement executive management review effectiveness internal controlling financial reporting regularly group decided implement hard close particular verifies transaction process november order anticipate recorded consistently accordance ifrs improve annual audit international accounting standard applied group set accounting reporting accounting standard manual order ensure pertinence transaction asset recognized within time set consolidated financial statement prepared accordance ifrs accounting standard currently adopted european union internal control consolidated financial statement comply accounting rule method detailed note internal control perspective group consolidated financial statement focused following year role group finance controlling department training code conduct anticorruption code finance controlling department check quality reporting package submitted collaborator consult sartorius code subsidiary focusing primarily following conduct sartorius anticorruption code element checking corporate data consolidated initial training process closed transfered adjustment entered locally intercompany controlled operation elimination accounting treatment non recurring transaction reporting period verifying principal movement opening midterm prospect closing balance sheet prepare cash flow statement group continue work internal control issue strengthening approach risk mapping finance department also verifies result risk management process based procedure including currency translation element amf internal control reference intercompany elimination etc framework hereto group risk management handbook revised expected key point review include preparation enter force within short addition process validation statement change defining mandatory minimum standard internal shareholder equity cash flow statement control applying group company initiated pursued aubagne february chairman joachim kreuzburg corporate governance remuneration executive nonexecutive member board remuneration executive nonexecutive member board table summarizing remuneration well option share granted corporate officer joachim kreuzburg oscarwerner reif chairman board chief executive officer executive vice president research development k year year k year year due remuneration due remuneration option valuation granted option valuation granted reporting period reporting period valuation performance valuation performance share granted previous year share granted previous year total total volker niebel summary remuneration executive vice president operation corporate officer k year year joachim kreuzburg chairman board chief executive officer due remuneration option valuation granted reporting period year year valuation performance due paid due paid share granted previous year k amount amount amount amount total fixed remuneration variable remuneration reinhard vogt longterm incentive executive vice president marketing sale service exceptional remuneration k year year director fee due remuneration benefit kind option valuation granted total reporting period valuation performance joachim kreuzburg receives salary sartorius ag share granted previous year duty performed entire sartorius group total remuneration determined annually supervisory board sartorius ag variable remuneration contains component based economic success group particular sale revenue profit ratio net debt ebitda addition pension plan addition phantom stock plan one longterm component including valuation component granted prior year company car corporate governance remuneration executive nonexecutive member board volker niebel oscarwerner reif executive vice president operation executive vice president research development year year year year due paid due paid due paid due paid k amount amount amount amount k amount amount amount amount fixed fixed remuneration remuneration variable variable remuneration remuneration exceptional exceptional remuneration remuneration director fee director fee benefit benefit kind kind total total volker niebel receives salary sartorius stedim oscarwerner reif receives salary sartorius stedim biotech gmbh duty performed sartorius biotech gmbh duty performed sartorius stedim biotech group stedim biotech group variable remuneration contains component variable remuneration contains component based economic success group particular based economic success group particular sale revenue profit ratio net debt sale revenue profit ratio net debt ebitda ebitda company car company car reinhard vogt executive vice president marketing sale service table director meeting attendance fee remuneration received year year nonexecutive corporate officer due paid due paid k amount amount amount amount k year year fixed bernard lemaître remuneration director fee variable remuneration remuneration longterm arnold picot incentive director fee exceptional remuneration remuneration liliane de lassus director fee director fee benefit kind remuneration total henri riey director fee reinhard vogt receives salary sartorius ag remuneration duty performed entire sartorius group remuneration determined annually supervisory total board sartorius ag variable remuneration contains component based economic success group particular sale revenue profit ratio net debt ebitda addition pension plan addition phantom stock plan one longterm component including valuation component granted prior year company car corporate governance remuneration executive nonexecutive member board stock option granted reporting period executive corporate officer issuer company group valuation number option option regard granted price name executive corporate date nature calculation reporting exercised officer plan option method period option window period joachim kreuzburg volker niebel none reinhard vogt oscarwerner reif total stock option exercised performance share available reporting period corporate officer corporate officer number number exercised share name executive date stock price available corporate officer plan option exercise performance share available date reporting acquisition joachim kreuzburg corporate officer plan period condition volker niebel none joachim kreuzburg none reinhard vogt oscarwerner reif volker niebel applicable total reinhard vogt none oscarwerner reif applicable liliane de lassus applicable bernard lemaître applicable henri riey applicable total performance share bonus share allocated corporate officer within framework l article following commercial law subjected additional requirement laid recommendation afepmedef october corporate governance remuneration executive nonexecutive member board performance share granted corporate officer valuation performance share granted share asm reporting according period corporate officer number consolidated issuer date share granted account date date performance company group plan year methodology acquisition availability conditions joachim kreuzburg jan jan volker niebel reinhard vogt jan jan oscarwerner reif liliane de lassus bernard lemaître henri riey total performance share comprised phantom stock plan phantom stock plan used variable incentive component includes risk portion remuneration component depends development sartorius ag share price period least four formerly three year payable price exceeds least formerly per year relative time phantom stock assigned share price outperformed tecdax comparative index amount paid capped maximum time share price time phantom stock assigned based case actual annual tranche concerned use component designed longterm incentive effect entail risk recommended french german corporate governance code corporate governance remuneration executive nonexecutive member board stock option granted historical information plan n plan n plan n plan n plan n plan n plan n plan n annual shareholder meeting board director meeting total number stock subscribed bought thereof following people joachim kreuzburg ceo chairman board reinhard vogt volker niebel none arnold picot oscarwerner reif bernard lemaître liliane de lassus henri riey starting point stock option expiration date price exercised modality number stock option suscribed dec number erased stock option stock option yet exercised stock option granted top ten noncorporate officer exercised total number stock option granted top granted average employee non corporate officer stock price plan plan plan plan plan plan plan plan exercised option n n n n n n n n option granted reporting period issuer company group top employee issuer company group lead maximum number option owned issuer company group exercised reporting period top employee lead maximum number corporate governance remuneration executive nonexecutive member board additional information executive board member indemnity due compensation regard employment additional termination contract non compete corporate officer contract pension plan position clause indemnity yes yes yes yes joachim kreuzburg ceo chairman reinhard vogt none oscarwerner reif none volker niebel none none joachim kreuzburg service contract without social security component sartorius ag duty performed ceo entire sartorius group including sartorius lab product service standard practice germany reinhard vogt service contract without social security component sartorius ag duty performed member executive board entire sartorius group including sartorius lab product service standard practice germany oscarwerner reif volker niebel employment contract sartorius stedim biotech gmbh duty performed managing director company standard practice germany common pension plan place sartorius ag level joachim kreuzburg level entitlement benefit paid company pension plan depends respective tenure severance cap member executive committee remuneration two year based actual remuneration time termination employment contract case employment contract last less two year severance payment capped amount remaining remuneration employment contract joachim kreuzburg reinhard vogt mandatory noncompete clause time appointed member executive board sartorius ag time period two year end appointment member executive board sartorius ag got additional noncompete clause grant indemnity half received gross salary per year noncompete period noncompete period two year twoyear period end employment contract sartorius stedim biotech gmbh volker niebel oscarwerner reif bound noncompetition clause grant compensation equal half annual gross salary noncompetition period noncompete period two year additional information remuneration executive board member general fixed remuneration total value remuneration executive company similar company remuneration member reflects scope responsibility comprised fixed variable component executive member concerned executive member reviewed annually ensure remains personal performance company economic appropriate variable remuneration component situation sustainable progress addition paid addition fixed base salary represent extent amount remuneration typical approximately half total remuneration excluding considered taking account peer company pension commitment fringe benefit case remuneration structure place area target achievement corporate governance remuneration executive nonexecutive member board variable remuneration issue shadow share called phantom stock executive member treated variable portion remuneration contains owner certain number share sartorius ag component paid annually without however entitled receive dividend component determined multiyear assessment development value phantom stock category component making one linked development sartorius share half target achievement possible increase decrease share price taken account later phantom stock annually paid variable remuneration valuated based share price time equivalent paid provided associated portion variable remuneration paid condition met phantom stock cannot traded annually consists following weighted entail share subscription right component sale revenue order intake ebita ratio net debt ebitda minimum target according sartorius phantom stock plan achievement required component executive member credited beginning amount paid depends degree every year phantom stock unit valued target achieved cap provided agreed monetary sum value phantom stock variable component paid paid entire annual tranche payment requested earliest element mentioned fine compared period four year later eight year budget approved annualy board director order pay concerned amount executive member entitled receive payment phantom stock unit share price b variable remuneration consolidated net profit time payment request appreciated least per year relative time phantom stock component determined multiyear assessment assigned share price outperformed depend degree target achieved tecdax comparative index phantom stock consolidated net profit considered plan rule subsequent change parameter context used comparative stock valuation amount paid capped maximum time share consolidated net profit price time phantom stock assigned based case actual annual tranche subordinate target basis assessment concerned consolidated net profit minority interest excluding amortization impairment value assignment phantom stock payment intangible asset due business combination monetary equivalent depend mean value pursuant ifrs target achievement assessing calculated average price class annual variable remuneration based average sartorius ag share closing auction xetra taken period three fiscal year beginning trading frankfurt stock exchange last smooth amount paid partial day trading previous year day payment amounting target achievement trading prior submission payment request fiscal year effected overpayment serf compensate shortterm result partial payment offset fluctuation share price following year remuneration component fixed variable cap component payment phantom stock blocked four provided well week preceding scheduled publication date quarterly preliminary yearend result c variable remuneration phantom stock plan day trading stock exchange following actual publication quarterly preliminary phantom stock plan yearend result blackout period intended prevent executive board member profiting joachim kreuzburg reinhard vogt access insider knowledge phantom stock plan responsibility sartorius ag level corporate governance remuneration executive nonexecutive member board pension commitment severance cap executive board member receive pension commit service contract concluded connection ments reappointed first time new appointment reappointments include level entitlement benefit paid severance pay cap maximum two annual company pension scheme calculated based salary cover case membership salary german federal civil servant executive board terminated prematurely salary class b ministry official according federal civil service remuneration act bundes fringe benefit besoldungsgesetz depended term respective appointment benefit company member executive board entitled pension scheme still granted form use company car reclaim expense incurred retirement pension old age invalidity business travel covered accident form survivor benefit surviving spouse insurance insurance fringe benefit child decedent member addition receiving remuneration component turned shall considered regular age mentioned insurance provides limit member shall automatically retire application deductible excess amount required law executive board member reappointed second time benefit company pension scheme used extended externally financed defined contribution plan commitment besides securing basic retirement amount commitment used provide thirdterm executive board member make contribution variable earnings company match contribution bonus amount practice modified resolution adopted supervisory board august upon reappointed first time executive board member receive externally financed defined contribution plan commitment addition securing basic retirement amount provides secondterm executive board member make contribution variable earnings company match contribution bonus amount remuneration component reporting year remuneration policy amended include rule authorize supervisory board grant special remuneration according equitable discretion executive board member latter extraordinary performance corporate governance statutory auditor report prepared accordance article l statutory auditor report prepared accordance article l statutory auditor report prepared accordance article l french commercial code code de commerce report prepared chairman board director sartorius stedim biotech free translation english report issued french information internal control risk provided solely convenience english speaking user management procedure relating report read conjunction construed french preparation processing accounting law professional standard applicable france financial information year ended december professional standard require perform necessary procedure assess fairness shareholder information provided chairman report respect internal control risk management capacity statutory auditor sartorius stedim procedure relating preparation processing biotech accordance article l accounting financial information french commercial code code de commerce procedure consist mainly hereby report report prepared chairman company accordance article l obtaining understanding internal control french commercial code code de commerce risk management procedure relating year ended december preparation processing accounting financial information information pre chairman responsibility prepare submit sented chairman report based board director ou supervisory board approval existing documentation report internal control risk management procedure obtaining understanding work involved implemented company provide preparation information exist information required article l french ing documentation commercial code code de commerce relating matter determining material weakness internal corporate governance control procedure relating preparation processing accounting financial infor role mation would noted course work properly disclosed chairman report report matter information contained chairman report respect basis work matter report internal control risk management procedure information relating company internal relating preparation processing control risk management procedure relating accounting financial information preparation processing accounting financial confirm report also includes information contained report prepared information required article l chairman board director article l french commercial code code de commerce french commercial code code de commerce noted role verify fairness information information confirm report prepared chairman conducted work accordance board director also contains professional standard applicable france information required article l french commercial code code de commerce marseille february ernst young audit deloitte associés xavier senent christophe perrau corporate governance independent auditor fee independent auditor fee principal independent auditor ernst young audit deloitte et associés avenue du prado bp marseille place de la joliette le dock atrium cedex france bp marseille cedex france represented xavier senent represented christophe perrau first commissioned combined general first commissioned annual general share shareholder meeting june date holder meeting may date commission commission expires annual general shareholder expires annual general shareholder meeting meeting approve financial statement approve financial statement member compagnie régionale de versailles member compagnie régionale de versailles independent auditor fee ernst young deloitte k audit independent audit certification parent company consolidated financial statement parent company subsidiary service directly related audit service parent company subsidiary subtotal service legal tax corporate information technology subtotal total corporate governance independent auditor fee substitute independent auditor auditex beas tour ernst young faubourg de larche villa houssay neuilly sur seine france parisla défense first commissioned annual general share represented alain pons holder meeting april date commission commissioned annual general shareholder expires annual general shareholder meeting meeting may date commission expires approve financial statement annual general shareholder meeting approve financial statement member compagnie régionale de versailles member compagnie régionale de versailles total corporate governance independent auditor fee consolidated financial statement note consolidated financial statement note statement profit loss comprehensive income statement profit loss comprehensive income note month month k k sale revenue cost sale gross profit sale selling distribution cost research development cost general administrative expense operating income expense earnings interest tax ebit financial income financial expense financial result profit tax income tax net profit period attributable equity holder sartorius stedim biotech noncontrolling interest earnings per share diluted earnings per share presentation statement profit loss adjusted compared previous year detail see chapter statement comprehensive income month month k k net profit period cash flow hedge income tax cash flow hedge net investment foreign operation income tax net investment foreign operation currency translation difference item probably reclassified profit loss net tax actuarial gain loss defined benefit obligation income tax actuarial gain loss item reclassified profit loss net tax total comprehensive income attributable equity holder sartorius stedim biotech noncontrolling interest presentation comprehensive income includes retroactive application ia r note consolidated financial statement integral part statement consolidated financial statement note statement financial position statement financial position note dec dec k k noncurrent asset goodwill intangible asset property plant equipment investment nonconsolidated subsidiary receivables asset deferred tax asset current asset inventory trade receivables current tax asset asset cash cash equivalent total asset equity issued capital capital reserve retained earnings including net profit noncontrolling interest noncurrent liability pension provision deferred tax liability provision loan borrowing liability current liability provision trade payable loan borrowing current tax liability liability total equity liability figure adjusted final purchase price allocation cell culture medium business lonza retroactive application ia r consolidated financial statement note statement cash flow statement cash flow month month k k profit tax financial result earnings interest tax ebit depreciation amortization fixed asset increase decrease provision gain disposal fixed asset income tax paid gross cash flow operating activity increase decrease receivables increase decrease inventory increase decrease liability net cash flow operating activity capital expenditure proceeds disposal fixed asset payment net cash flow investing activity payment acquisition consolidated subsidiary business operation net cash acquired proceeds disposal consolidated subsidiary business operation net cash flow investing activity acquisition change capital interest received interest paid financial charge dividend paid shareholder sartorius stedim biotech sa noncontrolling interest gross cash flow financing activity loan borrowing raised loan borrowing repaid net cash flow financing activity net increase decrease cash cash equivalent cash cash equivalent beginning period net effect currency translation cash cash equivalent cash cash equivalent end period consolidated financial statement note statement change equity statement change equity foreign cash flow currency non issued capital hedging pension retained translation group controlling total k capital reserve reserve reserve earnings reserve equity interest equity balance jan net profit period cash flow hedge actuarial gain loss defined benefit obligation currency translation difference net investment foreign operation related deferred tax comprehensive income period total comprehensive income stock option dividend change balance dec jan net profit period comprehensive income period total comprehensive income stock option dividend change balance december consolidated financial statement note note financial statement note financial statement general information consolidated financial statement prepared euro unless otherwise specified amount sartorius stedim biotech leading provider disclosed thousand euro abbreviated k cuttingedge equipment service case sum figure given development quality assurance production report may precisely equal stated total process biopharmaceutical industry percentage may exact due rounding integrated solution covering fermentation filtration purification fluid management cell culture medium consolidated financial statement approved supporting biopharmaceutical industry around board director february world develop produce drug safely timely submitted approval shareholder economically nextgeneration process meeting april sartorius stedim biotech focus singleuse technology addedvalue service meet rapidly changing technology requirement change presentation statement industry serf strongly rooted scientific profit loss statement community closely allied customer technology partner company dedicated fiscal sartorius stedim biotech group philosophy turning science solution slightly changed reporting format statement profit loss order follow headquartered aubagne france sartorius stedim established international reporting practice thus biotech sa listed euronext paris isin code provide financial data best comparable fr manner relevant change relate amortization well tax shown compliance european regulation functional expense change cost allocation july requiring listed company impact net profit use international accounting standard con sartorius stedim biotech group solidated financial statement sartorius stedim biotech group year ended december following table translates business figure compliant standard interpretation financial year new format ifrs ifric iasb adopted european union available following site httpeceuropaeuinternal_marketaccountingiasind ex_enhtm consolidated financial statement note note financial statement restatement k restatement amortization tax restatement sale revenue cost sale gross profit sale selling distribution cost research development cost general administrative expense operating income expense earnings interest tax amortization ebita amortization earnings interest tax ebit financial income financial expense financial result profit tax income tax tax net profit period furthermore slight change applied ia employee benefit revised referred presentation statement change equity following ia r contains revised statement cash flow especially accounting rule defined benefit pension plan subtotal gross cash flow operating activity severance agreement contrary previous implemented operating cash flow rule ia r requires past service cost change working capital recognized immediately profit loss addition net interest cost calculated net pension liability applying discount rate effect new financial reporting highquality corporate bond recognized standard profit loss measurement effect resulting actuarial gain loss effect asset compared yearearlier consolidated financial ceiling recognized outside profit loss statement following new amended standard statement comprehensive income net interest obligatorily applied first time expense continues recognized financial result described change lead ifrs fair value measurement provides uniform significant change statement financial definition fair value measured fair position statement profit loss value defined price would group already recognize actuarial gain received sell asset paid transfer liability loss comprehensive income ifrs also requires specific note previous period consolidated financial statement asset liability measured fair value ia r specifies severance payment earned future period must recognized pursuant amendment ia presentation profit loss respective period service financial statement published june revision led change accounting item comprehensive income payment employee preretirement part first time reported separately according whether time working agreement partial retirement may subsequently become reclassifiable provision germany past provision profit loss established time offer respective working agreement made agreement concluded even service remained provided employee future consolidated financial statement note note financial statement sartorius stedim biotech applying ia r amendment ia deferred tax recovery retrospectively data statement underlying asset financial position january statement profit loss statement annual improvement ifrss issued comprehensive income restated including may relating tax impact ifric stripping cost production phase furthermore following standard surface mine interpretation applied initially amendment mentioned necessarily amendment ifrs severe hyperinflation applicable group firsttime application removal fixed date firsttime adopter result material impact group financial statement sartorius stedim biotech amendment ifrs government loan following standard interpretation revision amendment ifrs offsetting financial asset amendment yet applied financial liability consolidated financial statement reporting year yet adopted eu application obligatory applicable endorsement financial standard interpretation title year eu commission standard ifrs consolidated financial statement january yes ifrs joint arrangement january yes ifrs disclosure interest entity january yes amendment ifrs ifrs ifrs transition guidance january yes amendment ifrs ifrs ia investment entity january yes revised ia separate financial statement january yes revised ia investment associate joint venture january yes amendment ia offsetting financial asset financial liability january yes recoverable amount disclosure nonfinancial amendment ia asset january yes novation derivative continuation hedge amendements ia accounting january yes amendment ia employee contribution july various annual improvement ifrss cycle july various annual improvement ifrss cycle july ifrs financial instrument published interpretation ifric levy january required applied endorsed eu commission standard may provide earlier mandatory application process measuring potential impact change consolidated financial statement standard interpretation consolidated special purpose entity financial statement sartorius stedim biotech associate joint operation presently firsttime group progress group anticipate application planned reporting period stage analysis significant impact standard interpretation amendment consolidated account likewise firsttime enter force application ifrs lead consolidated financial statement note note financial statement significant accounting policy significant acquisition purchase price allocation carried assistance independent thirdparty valuation specialist basis preparation valuation based information available acquisition date consolidated financial statement group based principle historical cost expense directly related business combination acquisition construction production reported profit loss period exception item reflected fair value financial asset held trading available sale derivative foreign currency translation consolidated financial statement sartorius consolidation stedim biotech group prepared thousand euro annual financial statement consolidated financial statement sartorius individual company foreign currency transaction stedim biotech group include annual financial translated exchange rate applicable statement company controlled time transaction monetary asset debt directly indirectly sartorius stedim biotech sa whose value given foreign currency term ia consolidated financial statement translated exchange rate balance sheet accounting investment subsidiary date rate gain loss recognized controlling interest exists sartorius stedim profit loss period biotech sa subsidiary power govern financial operating policy enterprise subsidiary annual financial statement prepared obtain economic benefit activity foreign currency translated pursuant enterprise included consolidated financial ia effect change foreign exchange statement time sartorius stedim rate accordance concept functional biotech sa subsidiary acquired control currency foreign subsidiary regarded longer included time control independent subdivision sartorius stedim transferred entity outside group biotech group balance sheet item translated exchange rate balance sheet subsidiary included basis date income expense item converted annual financial statement reporting average rate translation difference period parent company using uniform group resulting use different exchange rate recognition measurement method balance sheet item statement profit loss recognized comprehensive intragroup asset liability equity income income shareholder equity expense cash flow relating transaction tween member group eliminated full certain defined loan granted longterm basis consolidation group applies principle net investment foreign operation foreign currency translation difference resulting loan recognized business combination comprehensive income according ia business combination measured according acquisition method identifiable acquired asset assumed liability potential liability recorded fair value date combination consolidated financial statement note note financial statement exchange rate major currency item general administrative expense includes euro considered follows mainly employee benefit expense cost material general administrative area yearend exchange rate average exchange rate profit loss item cannot allocated one mentioned functional area recognized usd income expense includes essentially gbp effect currency translation sale fixed asset jpy allowance trade receivables reorganization inr extraordinary expense income grant cny related income recognized income reasonable assurance condition attached grant complied sale revenue grant received recognized period necessary match systematic basis revenue derived selling product cost intended compensated rendering service recognized sale revenue operational revenue recognized operating income sale recognized borrowing cost statement profit loss significant risk reward ownership good borrowing cost expensed incurred unless transferred customer company retains directly attributable acquisition neither continuing managerial effective control construction production qualifying asset good sold amount revenue cost therefore part cost asset incurred incurred measured reliably qualifying asset defined asset take sufficiently probable economic period least twelve month get ready benefit associated transaction flow intended use company income tax functional cost current income tax determined based general operating expense type assigned respective local taxable income period local function following functional area tax rule addition current income tax include corresponding profit cost center expense adjustment uncertain tax payment tax refund relating crossfunctional initiative project period yet assessed change deferred tax assigned respective functional cost based asset liability included income tax ex appropriate allocation principle cept change recognized comprehensive income directly equity item cost sale report cost product sold acquisition cost merchandise sold deferred tax asset liability determined based besides directly imputable expense raw temporary difference carrying material supply employee benefit expense amount tax basis asset liability energy expense cost sale also includes including difference consolidation loss carry overhead allocated manu forward tax credit measurement based facturing area corresponding depreciation tax rate expected effective period ich amortization asset realized liability settled selling distribution cost pertain particular purpose tax rate tax rule used cost sale marketing organization enacted substantively enacted distribution advertising market research reporting date deferred tax asset recognized extent probable taxable profit research development cost comprise cost level relevant tax authority available research product process development unless utilization deductible temporary recognized asset amortization capitalized difference loss carried forward development cost also indicated item consolidated financial statement note note financial statement goodwill capitalized development cost essentially cover cost allocated staff involved rd goodwill represents future economic benefit raw material supply outside service arising asset acquired business directly attributable overhead intangible asset combination individually identified generated internally amortized straight line separately recognized basis useful life generally exceed four year according ia goodwill acquired business combination may amortized rather must internally generated intangible asset may tested annually impairment soon recognized development cost included indication asset impairment period incurred cost research activity reported expense period purpose impairment testing goodwill must incurred allocated acquirer cashgenerating unit cgus expected benefit amortization intangible asset based synergy combination cashgenerating following period useful life unit cgu represents lowest level within entity goodwill monitored internal software year management purpose may larger customer relation technology year segment brand name na intangible asset property plant equipment intangible asset acquired stated cost less property plant equipment item reported accumulated regular amortization calculated cost subject depreciation depreciated according straightline method useful life scheduled straightline method applied intangible asset period depreciation reported consolidated financial asset expected contribute directly indirectly statement cash flow entity depreciation fixed asset based following cost incurred within scope development period useful life new product method capitalized internally generated intangible asset following building year criterion met machinery year factory office equipment year technical feasibility completing intangible asset available use sale intention complete intangible asset impairment intangible tangible asset use sell book value carrying amount property plant ability use sell intangible asset equipment intangible asset examined whether indication asset might demonstration intangible asset impaired pursuant ia impairment asset generate probable future economic benefit asset impaired recoverable amount asset estimated recoverable amount asset availability adequate technical financial cashgenerating unit higher fair value resource complete development less cost sell asset cgu value use sell intangible asset use event individual asset recoverable amount cannot estimated recoverable amount ability measure reliably expenditure asset cashgenerating unit cgu estimated attributable intangible asset development consolidated financial statement note note financial statement estimated recoverable amount asset inventory cgu go book value carrying amount carrying amount reduced recoverable amount raw material supply including merchandise reported inventory average cost cause asset impairment removed principle finished good work progress book value asset cgu credited reported cost conversion cost includes newly estimated recoverable amount however direct cost allocated material book value increase limited value appropriate portion production asset cgu would asset impairment material handling overhead general administrative loss would assessed previous financial expense fixed asset normal depreciation year amortization rate provided expense caused production lease inventory must evaluated lower amount cost net realizable value net realizable lease considered agreement whereby lessor value represents estimated selling price conveys lessee return payment series ordinary course business less estimated cost payment right use asset agreed completion estimated cost necessary period time according ia lease classified marketing sale distribution inventory either operating finance lease finance risk exist risk reduced shelf life lease lease transfer substantially risk result storage period limited usability reward incidental ownership asset inventory marked accordingly lease designated operating lease group lessee finance lease amount trade receivables equal fair value leased property lower present value minimum lease trade receivables reported payment recognized asset balance discernible risk covered book value trade sheet simultaneously recognized financial receivables receivables representative liability minimum lease payment essentially fair value considering maturity date consist finance charge reduction credit risk determining recoverability trade outstanding liability measured according receivables group considers change effective interest method leased asset credit quality date credit originally depreciated straightline basis period granted expected useful life shorter lease term group lessor finance lease sale revenue construction contract equal net investment lease recognized well lease receivable leasing construction contract contract specifically rate receives also apportioned negotiated construction asset finance charge reduction liability according combination asset closely interrelated effective interest method interdependent term design technology function ultimate purpose use operating lease lease rate paid outcome construction contract lessee recognized expense lease estimated reliably revenue constructiontype rate received lessor recognized income project generally recognized respectively leased asset continues percentageofcompletion method based recognized lessor balance sheet property percentage cost date compared total plant equipment estimated contract cost expected loss construction contract recognized expense immediately consolidated financial statement note note financial statement contract disclosed receivables liability agreement supplier dealer including percentage completion cumulative work leasing contract restructuring provision contract cost contract result exceeds recognized group detailed formal plan advance payment received construction contract either commenced implementation recognized receivables amount due announced customer balance deduction advance payment received negative obligation construction contract recognized liability financial instrument amount due customer financial instrument contract give rise financial asset one entity financial pension obligation liability equity instrument another entity financial asset mainly include cash cash pension provision similar obligation equivalent availableforsale financial asset trade recognized consolidated financial statement loan receivables derivative financial sartorius stedim biotech group accordance instrument positive fair value actuarial principle ia employee benefit stipulates projected unit credit method financial liability group mainly comprise loan method measurement addition known bank trade payable finance lease payable pension life expectancy expected cash derivative financial instrument negative fair value method take account future salary value pension increase initially financial instrument recognized actuarial gain loss recognized fair value transaction cost directly attributable comprehensive income directly equity pension acquisition issue financial instrument reserve according standard ia r recognized determining carrying amount financial instrument measured fair value profit loss subsequently financial provision asset liability measured according category cash cash equivalent availablefor provision recognized liability third sale financial asset loan receivables financial party incurred outflow resource liability measured amortized cost financial probable amount obligation asset liability classified held trading reasonably estimated amount recognized assigned provision represents best estimate obligation balance sheet date provision original maturity one year cash cash equivalent discounted present value expenditure expected settle obligation end group considers highly liquid investment reporting period less three month maturity date acquisition cash equivalent mainly includes provision regularly reviewed adjusted check cash hand deposit bank cash information becomes available cash equivalent measured cost circumstance change provision warranty cost based historical experience restructuring provision set connection program materially change scope business performed segment business unit manner business conducted case restructuring expense include termination benefit compensation payment due termination consolidated financial statement note note financial statement investment statement cash flow investment nonconsolidated subsidiary statement cash flow cash flow present associate security measured cost ed according allocation operating activity active market exists share security investing activity financing activity fair value asset cannot reliably measured instance cash flow operating activity determined using indirect method ie expense without effect payment added loan receivables profit tax income without effect payment subtracted cash flow financial asset classified loan receivables financing activity composed primarily change measured amortized cost using effective equity addition repayment loan interest method less impairment loss impairment loss trade receivables recognized using separate allowance account critical accounting judgment key source estimation uncertainty financial liability preparation consolidated financial statement management u estimate financial liability measured except derivative assumption based best knowledge financial instrument amortized cost using current future situation period however effective interest method actual result may differ estimate estimate assumption revised regular basis impact change immediately derivative financial instrument recognized income expense period derivative financial instrument foreign addition group management exercise judgment currency exchange contract interest rate swap defining accounting treatment specific trans contract measured fair value derivative action existing standard financial instrument classified held trading interpretation specifically treat accounting unless designated hedging instrument problem concerned hedge accounting applied change fair value derivative financial instrument assumption estimate primarily concern recognized either net income case following topic hedge comprehensive income business combination cash flow hedge accounting business combination requires effective portion change fair value asset acquired liability assumed derivative instrument designated cash flow hedge recorded respective fair value date recognized comprehensive income group obtains control application ineffective portion recognized immediately net acquisition method requires certain estimate income financial result amount accumulated assumption made especially concerning fair equity reclassified net income value acquired intangible asset property period hedged item affect net income plant equipment liability assumed acquisition date useful life acquired intangible asset property plant equipment measurement based large extent anticipated cash flow actual cash flow vary used calculating fair value may materially affect group future result operation consolidated financial statement note note financial statement impairment asset due changing market economic condition underlying key assumption may differ actual impairment test conducted certain event lead development may lead significant change assumption asset might impaired pension postemployment benefit obligation case carrying amount asset compared recoverable amount difference recognized full directly higher net realizable value value use equity period occur without calculation value use generally based affecting profit loss sensitivity analysis see discounted cash flow method using cash note pension employee benefit provision flow projection five year projection take account past experience represent management best estimate future sale provision contingent liability revenue cost development cash flow contingent asset planning period extrapolated using individual growth rate key assumption management provision recognized legal constructive based determination value use include obligation exist balance sheet date estimated growth rate weighted average cost determine amount obligation certain esti capital tax rate estimate mate assumption applied including material impact respective value evaluation probability amount ultimately amount impairment cost incurred typically significant estimate carrying amount exceeds recoverable amount involved determination provision related impairment loss recorded onerous contract warranty cost asset retirement obligation legal proceeding intangible asset income tax capitalization selfconstructed intangible asset also includes certain level estimation group operates various tax jurisdiction assumption eg evaluation feasibility therefore determine tax position development project expected market prospect respective local tax law tax authority view determination useful life complex subject different interpretation taxpayer local tax authority trade receivables deferred tax asset recognized deductible temporary difference unused tax allowance doubtful account involves loss extent probable future significant management judgment review taxable profit available individual receivables based individual customer deductible temporary difference unused tax creditworthiness current economic trend well loss utilized future development analysis historical bad debt portfolio uncertain partly beyond management control basis assumption necessary estimate future taxable profit well period deferred tax asset recover employee benefit pension provision estimate revised period obligation pension postemployment sufficient evidence revise assumption benefit determined accordance actuarial management considers probable portion valuation valuation rely key assumption deferred tax asset cannot realized including discount rate expected salary increase corresponding valuation allowance taken account mortality rate discount rate assumption determined reference yield highquality corporate bond appropriate duration currency end reporting period consolidated financial statement note note financial statement operating segment extraordinary item expense income exceptional onetime nature accordingly according ifrs operating segment distort sustainable profitability segment identification reportable operating segment material impact net worth financial based management approach ie position earnings group example segment defined analogously internal item restructuring expense large group project control reporting structure entity therefore well proceeds loss disposal sale area activity considered operating transfer financial asset property plant segment business activity may result equipment provided recur revenue expense operating result rent nature regularly reviewed entity chief operating decision maker executive committee previously sartorius stedim biotech group board director discrete financial information also used underlying ebita key performance available internal reporting internal control indicator figure referred earnings reporting within sartorius stedim biotech based interest tax amortization amortization approach operating total solution resulting recognition intangible asset provider customer accordingly arising business combination chapter identification sartorius stedim biotech reportable contains reconciliation table former format operating segment biopharm statement profit loss including item amortization key performance indicator operating segment sartorius stedim biotech group segment asset segment liability socalled underlying ebitda ebitda corresponds reported regular basis chief operating earnings interest tax depreciation decision maker therefore part amortization underlying ebitda mean ebitda segment report adjusted extraordinary item connection biopharm group k change change sale revenue underlying ebitda sale revenue ebit sale revenue employee december consolidated financial statement note note financial statement reconciliation segment profit loss country allocated asia pacific region market segment primarily consists k latin america africa underlying ebitda segment key figure geographical area refer depreciation company location except sale revenue amortization reported according customer location extraordinary effect ebit noncurrent asset correspond property plant financial result equipment well intangible asset profit tax group affiliate allocated various region european region following country account material noncurrent asset supplementary information region germany million million france million million provide additional information required ifrs goodwill resulting reverse acquisition stedim table present supplementary associated intangible asset information geographical region european presented noncurrent asset europe region includes market western eastern europe north american region comprised amount sale revenue single customer u marketplace canadian market japan exceed consolidated sale revenue china australia south korea india well europe north america k change change sale revenue total noncurrent asset employee december asia pacific market group k change change change sale revenue total noncurrent asset employee december scope consolidation financial statement following subsidiary included scope consolidation cause figure minor importance sartorius stedim hungary sessing financial position group sartorius stedim poland sartorius icr russia sale revenue total asset non tap biosystems phc ltd uk consolidated company group tap biosystems ltd uk figure sartorius stedim financiére sa france sartorius stedim integrated service sarl tunisia financial statement following company sartorius stedim biotech sarl tunisia included group financial statement consolidated financial statement note note financial statement ownership europe sartorius stedim biotech sa aubagne france parent company sartorius stedim belgium nv vilvoorde belgium sartorius stedim nordic taastrup denmark sartorius stedim biotech gmbh goettingen germany sartorius stedim plastic gmbh goettingen germany sartorius stedim system gmbh guxhagen germany sartorius stedim uk ltd epsom uk sartorius stedim lab ltd louth uk tap biosystems group ltd royston uk tap esop management ltd royston uk automation partnership cambridge ltd royston uk sartorius stedim fmt sa aubagne france sartorius stedim france sa aubagne france sartorius stedim aseptics sa lourdes france sartorius stedim ireland ltd dublin ireland sartorius stedim italy spa florence italy sartorius stedim netherlands bv rotterdam netherlands sartorius stedim austria gmbh vienna austria sartorius stedim switzerland ag tagelswangen switzerland sartorius stedim spain sa madrid spain north america sartorius stedim filter inc yauco puerto rico sartorius stedim north america inc bohemia new york usa automation partnership inc greenville usa asia pacific sartorius stedim australia pty ltd dandenong south victoria australia sartorius stedim biotech beijing co ltd beijing china sartorius stedim india pvt ltd bangalore india sartorius stedim japan kk tokyo japan sartorius korea biotech co ltd seoul south korea sartorius stedim malaysia sdn bhd kuala lumpur malaysia sartorius stedim singapore pte ltd singapore market sartorius stedim bioprocess sarl mhamdia tunisia associate joint venture included scope consolidation company consolidated full ownership rate equal share voting right company sartorius korea biotech included scope consolidation due contractual agreement call option consolidated financial statement note note financial statement statement cash flow following table show preliminary final purchase price allocation statement cash flow show impact cash inflow outflow cash cash equivalent preliminary fair group cash flow classified value fair value acquisition date operating investing financing activity according date acquisition ia statement cash flow k k trademark right use context cash equivalent asset customer relationship converted cash within short maturity generally net asset acquired less three month amount considered statement cash flow includes mainly cash hand purchase price bank balance similar item equal goodwill amount statement financial position following noncash transaction concluded reflected statement cash flow intangible asset identified purchase price allocation right use trademark lonza acquisition cell culture medium business customer relationship connection december lead cash outflow cell culture medium business assumed useful payment million made life acquired asset year trademark recognized cash flow investing year customer relation respectively activity acquisition recognized goodwill represents asset capital expenditure finance lease amounted separately identified recognized million million also generate economic benefit group especially expansion group portfolio strengthened position relevant business combination biopharm market well synergy resulting combination named acquisition cell culture medium business deferred tax recognized upon initial lonza consolidation due structure transaction future period deferred tax liability december sartorius stedim biotech recognized arising taxable temporary difference acquired exclusive sale marketing right full amount goodwill deductible cell culture medium business swisslocated local tax purpose life science company lonza taken respective employee acquisition treated according ifrs business combination acquisition tap biosystems group plc purchase price determined present value future cash payment st tranche december sartorius stedim biotech two tranche year acquired share british tap biosystems group plc company primarily specializes design development small scale multi parallel fermentation system particularly biopharmaceutical application addition company array product cover automated cell culture system bioprocessing bench top equipment biotech application consolidated financial statement note note financial statement acquisition sartorius stedim biotech extends current portfolio fermentation business multiparallel small scale bioreactors range milliliter milliliter tap portfolio stand gain substantial market penetration based sartorius stedim biotech greater sale strength global reach well benefit synergy related product fluid management cell culture medium business purchase price allocation made provisional basis timeframe acquisition balance sheet date sufficient gather relevant information fair value acquiree preliminary fair value acquisition date k intangible asset property plant equipment inventory trade receivables asset cash cash equivalent deferred tax net provision loan borrowing liability net asset acquired purchase price goodwill purchase price paid cash acquisition related cost amounting k recognized expense statement profit loss acquisition closed right balance sheet date inclusion tap group minor impact consolidated sale revenue earnings acquisition made january sale would approx million net result approx million excluding synergy hypothetical financing cost consolidated financial statement note note statement profit loss note statement profit loss sale revenue employee benefit expense sale revenue broken geographical item broken follows area consists following month month month month k k k k wage salary france social security germany expense retirement country benefit pension total total amount k earned operating income expense subsidiary sartorius group k month month k k sum approximately million earned providing service approx million currency translation gain income decrease allowance bad debt income release use functional cost provision liability income grant statement profit loss built according income cost sale format ie expense operating income allocated relevant function production sale marketing research development general currency translation loss administration extraordinary expense allowance bad debt operating expense nature reconciled expense profit loss statement nature note operating expense total operating material expense employee benefit expense income expense follows item reported income grant discloses raw material supply grant expense essentially related research development project recognized item consists following income soon sufficiently reliable indication necessary prerequisite met month month k k income fiscal includes income acquired cell culture medium business purchase consumed cost purchased service extraordinary item amounted million total previous year million essentially cover onetime expense strategic group project integration acquisition related item consolidated financial statement note note statement profit loss financial result considering french german average tax rate impact tax legislation expected tax rate sartorius stedim biotech group month month roughly following table k k describes difference tax expense interest similar income expected income tax expense reported affiliated particular financial year company income derivative financial instrument month month financial income k k financial income expected tax expense interest similar expense affiliated difference group company average income tax rate expense derivative financial permanent difference instrument taxfree income interest expense pension tax exemption financial expense financial expense total total effective tax rate income tax profit loss statement nature month month k k month month k k current income tax sale revenue deferred tax purchase consumed total cost purchased service personnel cost amortization matter principle income tax france depreciation calculated estimated taxable profit operating cost year germany rate applied subtotal taxable income income generated outside operating profit ebit france germany taxed particular rate financial income expense valid corresponding country income tax noncontrolling interest group net profit consolidated financial statement note note statement profit loss earnings per share according ia earnings per share earnings per share class share must determined separately basic earnings per share basic eps calculated basis weighted average number ordinary share period diluted earnings per share measured taking account share subscription option outstanding end period certain group employee acquired entitlement subscribe total share december therefore diluted net earnings per share calculated basis financial year item including number existing potential future share including optional share treasury share included calculation earnings per share net profit tax k group net profit tax k earnings per share diluted earnings per share number share statutory level treasury share share buyback program average amount dilution stock option exercized number share used earnings per share calculation future option potential option number share used diluted earnings per share calculation consolidated financial statement note note individual balance sheet item note individual balance sheet item goodwill intangible asset cgu represents lowest level within entity goodwill monitored internal management purpose may larger segment goodwill combination former sartorius biotechnology division former stedim group newly goodwill founded sartorius stedim biotech group follows k strategy total solution provider customer gross book value jan various interdependency within currency translation business lowest level goodwill change scope consolidation monitored biopharm segment therefore acquisition acquired goodwill allocated cgu gross book value dec amortization impairment loss impairment test conducted jan measure recoverable amount basis currency translation value use particular cashgenerating unit amortization impairment loss biopharm segment cash flow forecast consider amortization impairment loss previous experience generally based group dec management forecast period three five net book value dec year calculation based terminal year growth rate year rate goodwill derived market expectation forecast k significant growth rate targeted biopharma gross book value jan ceutical market major growth driver currency translation sartorius stedim biotech group aging change scope consolidation people increase population improved acquisition access drug emerging market well gross book value dec ongoing paradigm shift reusable product amortization impairment loss jan singleuse product utilized biomanufacturing currency translation biopharmaceutical industry amortization impairment loss amortization impairment loss discount rate applied correspond weighted dec capital cost rate recognized follows net book value dec item reported goodwill amount tax tax tax tax k capitalized difference asset biopharm resulting business combination according segment ia goodwill acquired business combination may amortized rather must tested annually impairment soon impairment test result indication asset impairment recognition impairment loss context various sensitivity analysis based realistic variation increase recorded concern acquisition assumption disclosed result cell culture medium business swiss impairment either following variation would entity lonza acquisition refers tap theoretically represent breakeven point biosystems see note purpose impairment testing goodwill must discount rate wacc tax allocated acquirer cashgenerating terminal growth rate unit cgus expected benefit cash flow synergy combination cashgenerating unit consolidated financial statement note note individual balance sheet item intangible asset patent capitalized licence customer development payment similar right brand name relationship cost account total k k k k k k gross book value jan currency translation change scope consolidation acquisition capital expenditure disposal transfer gross book value dec amortization impairment loss jan currency translation amortization impairment loss disposal transfer amortization impairment loss dec net book value dec patent capitalized licence customer development payment similar right brand name relationship cost account total k k k k k k gross book value jan currency translation change scope consolidation acquisition capital expenditure disposal transfer gross book value dec amortization impairment loss jan currency translation amortization impairment loss disposal transfer amortization impairment loss dec net book value dec consolidated financial statement note note individual balance sheet item stedim brand name acquired considered relationship amounted million indefinite useful life therefore million year ended december amortized foreseeable limit period remaining period useful life nine year brand name expected generate net cash inflow group brand name development cost k tested annually impairment soon recognized asset k indication asset impairment capitalized development cost essentially covered cost allocated staff involved rd integration stedim brand raw material supply outside service sartorius stedim biotech brand separate directly attributable overhead internally generated measurement relevant cash flow longer intangible asset amortized according possible therefore separate impairment test straightline method useful life carried recoverability brand usually exceed four year name considered level biopharm segment cashgenerating unit cgu amortization intangible asset allocated corresponding function statement profit customer relationship obtained part loss capitalized development cost amortization reverse acquisition stedim constitute material disclosed research development cost intangible asset book value customer property plant equipment factory office payment land building technical equipment account machinery construction improvement equipment equipment progress total k k k k k gross book value jan currency translation change scope consolidation acquisition capital expenditure disposal transfer gross book value dec depreciation jan currency translation depreciation disposal transfer depreciation dec net book value dec consolidated financial statement note note individual balance sheet item factory office payment land building technical equipment account machinery construction improvement equipment equipment progress total k k k k k gross book value jan currency translation change scope consolidation acquisition capital expenditure disposal transfer gross book value dec depreciation jan currency translation depreciation disposal transfer depreciation dec net book value dec depreciation included income statement capitalized property plant equipment include according use asset cost sale asset held finance lease amounting selling distribution cost research k k cost acquisition development cost general administrative expense asset total k operating expense rental payment amounting million fiscal significant million made asset leased impairment loss recognize intangible asset operating lease property plant equipment deferred tax deferred tax asset deferred tax liability dec dec dec dec k k k k intangible asset tangible asset inventory receivables current asset provision liability gross amount carry forward taxable loss offset net amount change thereof recognized profit loss consolidated financial statement note note individual balance sheet item deferred tax asset k cash flow hedge balance sheet date group unused tax actuarial gain loss loss amount carried forward million defined benefit obligation deducted future taxable profit million net investment foreign deferred tax amount reported approx operation million loss million total concerning remaining loss carried forward deferred tax amount recognized lack visibility future taxable profit inventory like deferred tax asset dec dec k k relation company reported loss year review earlier reporting year raw material supply work progress finished good merchandise deferred tax liability payment account total deferred tax liability connection intangible asset refer asset acquired business combination consequently mainly linked customer relationship dec dec k k addition group recorded deferred tax liability gross amount inventory tax amount million approx million writedowns cumulative undistributed earnings subsidiary net amount inventory million effect group considers cumulative undistributed earnings intended systematically reinvested current trade receivables subsidiary rather might used pay dividend france germany dec dec k k group recognize deferred tax liability trade receivables third party remaining retained earnings subsidiary amount due earnings intended reinvested customer contract work operation dividend paid receivables subsidiary amount dividend taxed sartorius ag group french german taxation rule applicable trade receivables withholding tax furthermore additional income tax consequence could arise case intermediate holding company therefore receivables subsidiary sartorius ag possible estimate amount taxable temporary group item refers company sartorius difference undistributed earnings group fiscal previous year tax effect group transferred million hedging instrument deferred tax asset trade receivables item unrelated entity recognition actuarial gain loss million factoring program pension reserve recognized directly group provided transferee credit consolidated equity likewise amount current guarantee part expected loss income tax incurred net investment foreign receivables transfer qualify operation recognized comprehensive derecognition ia accordingly group income deferred current income tax continues recognize full carrying amount recognized comprehensive income receivables recognized cash received disclosed follows table transfer secured borrowing consolidated financial statement note note individual balance sheet item group business area group aging trade receivables past due carry longterm construction contract impaired customerspecific contract recognized application ia construction contract based dec dec percentage completion method k k day item amount due customer contract day work represents net amount cost incurred plus day recognized profit less recognized loss progress day billing connection construction contract day aggregate amount cost incurred recognized total profit loss project progress reporting date k k project advance payment k k recorded year contract revenue trade receivables k k project progress k k past due reporting date valuation allowance made material trade receivables reported change creditworthiness debtor discernible risk covered book value trade could expected would pay amount receivables receivables representative outstanding trade receivables yet due fair value considering maturity date financial asset written credit risk determining recoverability trade indication impairment receivables group considers change credit quality date credit originally granted significant concentration asset credit risk due large base unrelated customer accordingly necessary make dec dec k k provision cover risk beyond allowance already considered derivative financial instrument financial asset asset incl prepaid development trade allowance expense total dec dec k k valuation allowance beginning year issued capital increase year derecognition december group share capital totaled consumption k equity structure reflects issued recovery amount previously impaired share legal parent company sartorius stedim foreign currency translation biotech sa comprise share difference par value share fully paid valuation allowance end year december december dilutive instrument share subscription option plan share registered name owner least four year benefit double voting right consolidated financial statement note note individual balance sheet item agm held april authorized sartorius pension employee benefit provision stedim biotech sa introduce share buyback program maximum period eighteen month october defined contribution plan end december sartorius stedim sartorius stedim biotech group company biotech sa bought back treasury share make payment defined contribution plan amount million share primarily relating governmentrun pension plan repurchased related party see note country percentage company pay movement recorded year social security contribution national insurance contribution oldage retirement benefit cannot reliably determined total expense recognized remaining company amounted dividend k k board director submit proposal annual general shareholder meeting payment defined benefit plan dividend year ended december follows payment net dividend per share pension provision similar obligation ie total disbursement recognized consolidated financial statement sartorius stedim biotech group accordance actuarial principle actuarial gain loss dec dec shown directly comprehensive income number share according standard ia r actuarial gain beginning period transferred pension reserve stock option exercised essentially resulted change discount rate increase capital totaled k actuarial loss k number share end period nominal value per share amount k relates particular issued capital amount k pension provision retirement pension plan germany provision totaled k primarily relate direct commitment defined benefit pension plan commitment employee earn benefit year service rendered company benefit earned depend salary level age respective employee pension benefit generally funded asset assumed discount factor reflect interest rate paid reporting date prime corporate industrial bond matching maturity denominated relevant currency corporate bond available matching long term maturity insufficiently available matching interest rate determined extrapolation consolidated financial statement note note individual balance sheet item measurement postemployment benefit statement profit loss current service obligation based following actuarial cost disclosed according assignment assumption employee respective function amount included consolidated statement germany financial position arising group obligation respect defined benefit plan follows dec dec discount rate dec dec jan k k k future salary increase present value future pension increase obligation fair value plan asset net liability france dec dec present value defined benefit obligation discount rate developed follows future salary increase future pension increase k k present value amount reported statement profit obligation jan loss comprehensive income consist current service cost following past service cost interest cost actuarial gain loss k k currency translation current service cost difference past service cost retirement benefit paid reporting year net interest expense employee contribution component defined benefit cost recognized contribution plan profit loss participant return plan asset excl change scope interest consolidation actuarial gain loss change component defined present value benefit cost recognized obligation dec comprehensive income total consolidated financial statement note note individual balance sheet item actuarial gain loss defined benefit sensitivity analysis obligation allocated follows increase decrease actuarial assumption would following impact defined k k benefit obligation experience adjustment change demographic k assumption change financial demographic assumption assumption life expectancy year year total effect financial assumption plan asset discount rate bps bps effect future salary increase bps bps k k effect plan asset jan future pension increase bps bps interest income effect return plan asset excl interest actuarial gain loss sensitivity analysis presented may group contribution representative actual change defined payment benefit obligation unlikely change currency translation difference assumption would occur isolation one another employee contribution furthermore present value defined benefit employer contribution obligation calculated using method contribution plan applied calculating defined benefit participant obligation liability recognized statement change scope financial position projected unit credit method consolidation change plan asset dec maturity analysis undiscounted cash flow defined benefit composition plan asset obligation allocated maturity follows plan asset primarily refer insurance dec contract germany switzerland k major equity debt investment included year subsidiary south korea deposited amount year million local bank cash cash year equivalent year total weighted average duration defined benefit obligation year consolidated financial statement note note individual balance sheet item noncurrent provision payment employee early retirement plan total k k k balance jan currency translation consumption reversal addition reclassification balance dec payment employee early retirement plan total k k k balance jan currency translation consumption reversal addition reclassification balance dec noncurrent provision comprise mainly provision noncurrent provision reported present partial retirement employee anniversary value reporting date discount rate bonus included item employee early retirement plan obligation arise mainly german group company provision accrued company anniversary partial retirement plan allow employee work parttime year actual retirement provision employee beneficiary early according ia r treatment severance retirement plan partial retirement maximum payment earned future period must period five year actuarial gain loss well recognized profit loss respective period past service cost obligation service explained section revision led recognized income expense change accounting payment employee preretirement parttime working agreement partial retirement provision germany past provision established time offer respective working agreement made agreement concluded even service remained provided employee future retroactive application ia r resulted adjustment statement financial position january k consolidated financial statement note note individual balance sheet item noncurrent liability loan borrowing balance current balance current dec dec dec dec k k k k liability bank finance lease liability total loan borrowing september sartorius stedim biotech took noncurrent liability longterm syndicated credit line million next five year agreement signed dec dec international bank syndicate led commerzbank ag k k nordlb addition syndicate participant derivative financial bnp paribas deutsche bank dz bank hsbc lbbw instrument société générale liability total transaction group putting financing broadbased international footing long term credit line based variable derivative financial instrument represent fair interest rate value interest rate swap agreement noncurrent liability include liability remaining purchase price cell culture medium business company lonza see chapter current provision financial current provision developed follows warranty total k k k balance jan currency translation consumption release addition change balance dec consolidated financial statement note note individual balance sheet item warranty total k k k balance jan currency translation change scope consolidation consumption release addition change balance dec measuring provision recognizable liability obligation based past business transaction past event probably resulting cash dec dec payment resource representative k k economic benefit whose amount derivative financial reliably estimated reported provision instrument tax social security provision considered result personnelrelated liability legal constructive obligation respect third liability party total provision entail mainly onerous contract uncertain employee benefit financial obligation contingent asset liability current liability like previous year significant contingent liability contingent asset trade payable reported group major financial obligation refer operate lease follows dec dec k k dec dec payment received k k account order operate lease trade payable third due within one year party due within year payable participation due thereafter payable subsidiary sartorius ag group total financial instrument financial risk payable subsidiary sartorius ag group refer company sartorius general information group section give overview impact financial instrument financial statement sartorius stedim biotech group provides additional information balance sheet item contain financial instrument consolidated financial statement note note individual balance sheet item derivative measured fair value determined b class financial instrument according marktomarket method recognized mathematical method used fair following table compare carrying amount value based market data available fair value category financial time value derivative calculated instrument reconcile balance reflect estimate market condition sheet item end year carrying carrying amount fair value amount fair value category acc dec dec dec dec ia k k k k investment nonconsolidated subsidiary available sale loan trade receivables receivables loan receivables asset receivables derivative financial instrument held trading hedging derivative financial instrument instrument asset ifrs receivables asset loan cash cash equivalent receivables financial liability loan borrowing cost finance lease liability ifrs loan borrowing financial liability trade payable cost trade payable ifrs trade payable derivative financial instrument held trading hedging derivative financial instrument instrument financial liability liability cost liability ifrs liability carrying amount financial instrument category shown following table dec dec k k available sale asset loan receivables held trading asset asset held hedging instrument financial liability cost held trading liability liability held hedging instrument fair value financial instrument level financial instrument calculated determined basis market information basis price quoted active market identical available balance sheet date asset liability level financial instrument allocated one three level fair value calculated basis input factor hierarchy accordance ifrs derivable observable market data basis consolidated financial statement note note individual balance sheet item market price similar instrument level net result financial asset liability held financial instrument calculated basis trading predominantly comprises change input factor derivable observable fair value derivative financial instrument well market data interest income interest expense financial instrument equity investment measured acquisition cost mainly investment nonconsolidated net result liability measured amortized cost subsidiary possible determine fair value mainly comprises effect foreign currency translation reliably due absence active market applies mainly share nonconsolidated total interest income expense financial asset subsidiary assumed carrying amount liability measured fair value without correspond fair value balance sheet recognition profit loss follows date financial instrument carried fair value month month k k balance sheet date derivative form forward contract interest rate swap agreement interest income valuation done based quoted foreign interest expense exchange rate available interest rate curve taking consideration counterparty risk level c capital risk management calculation fair value financial liability amortized cost especially loan bank sartorius stedim biotech group capital finance lease liability done level managed order maximize earnings calculation based market interest rate curve participating company optimizing ratio following zerocoupon method consideration equity liability furthermore ensure expected indicative credit spread group company operate premise goingconcern principle fair value remaining financial asset liability approximate carrying amount financial liability detailed regarded account predominantly shortterm maturity managed capital furthermore cash cash equivalent well equity capital net gain loss financial instrument goal financial risk management net gain loss various category financial instrument presented following table treasury department sartorius stedim biotech group centrally focused sartorius corporate administration gmbh subsidiary sartorius ag month month centralized treasury department performs service k k company sartorius group including sartorius available sale asset stedim biotech group coordinate access national loan receivables international financial market addition financial asset treasury department monitor control financial risk liability held trading internal risk reporting analyzes risk according financial liability cost degree scope essentially risk entail currency interest rate liquidity risk net result financial asset available sale sartorius stedim biotech group strives mini mainly comprises gain loss equity investment mize impact currency interest rate risk dividend gain disposal share using derivative financial instrument hedging transaction controlling carried net result loan receivables mainly different staff member moreover group includes effect currency translation internal auditing department regularly monitor change allowance use financial instrument trading derivative financial instrument done hedging purpose consolidated financial statement note note individual balance sheet item e management exchange rate risk group exposed currency risk one swap agreed amount foreign currency third sale revenue generated u dollar corresponding euro amount fixed exchange currency linked u dollar lesser rate several target date long profit extent foreign currency therefore derivative resulting exchange transaction financial instrument used hedge net exceed contractually defined limit currency exposure resulting currency translation sale revenue currency hedging foreign group strategy provides hedging one currency option forward contract used half year also hedging measure limited extent structured hedge transaction reviewed regular interval order adapt currency fluctuation forward contract secure right simultaneously create obligation sell established foreign balance sheet date forward contract currency amount exercise date specific carried amount million exchange rate euro independently million hedge risk fluctuation exchange rate actually valid date profit eur usd exchange rate amount cover loss resulting difference current roughly two third expected net exposure previously established exchange rate u dollar within period year furthermore generally measured income expense japanese yen amount jpy million statement profit loss jpy million hedged addition target profit forward following table show forward transaction concluded optimize hedging transaction well target profit forward contract transaction secure right create obligation balance sheet date fair value dec currency volume maturity k forward contract usd q usd q usd q usd q usd q usd forward contract jpy q jpy q jpy q jpy q jpy q jpy target profit forward usd q usd consolidated financial statement note note individual balance sheet item fair value dec currency volume maturity k forward contract usd q usd q usd q usd q usd forward contract jpy q jpy q jpy q jpy q jpy derivative financial instrument measured f interest risk management time acquisition cost fair value subsequent balance sheet date change value financing sartorius stedim biotech group derivative financial instrument recognized usually done german subsidiary sartorius statement profit loss balance sheet stedim biotech gmbh french parent company date derivative financial instrument serve sartorius stedim biotech sa ensure financing hedge cash flow risk qualified hedging group company using internal group loan relationship exists based criterion ia treasury hedging valuation adjustment loan taken variable interest recognized directly equity amount recognized rate group exposed interest rate risk equity included profit loss period control interest risk appropriate ratio hedged transaction affect result fixed variable loan maintained furthermore group concluded interest rate hedge form positive amount k interest swap cover majority positive impact k recognized loan outstanding variable interest rate result comprehensive income cash flow hedging reserve group receives particular variable interest effective hedging relationship rate valid market pay fixed interest rate ineffective portion k amount following table provides overview interest k transferred profit loss hedging contract available reporting date period k u dollar would depreciated euro equity would increased million million result would increased million million vice versa u dollar would appreciated euro resulting impact financial result would million million comprehensive income million million consolidated financial statement note note individual balance sheet item hedging volume hedging volume fair value fair value dec dec hedged interest dec dec instrument k k end term rate k k swap sep forward swap aug total group hedging strategy secure one variable interest rate amount million third risk exposure period hedged volume million million five year dec raised loan next five year g liquidity risk management maturity financial liability excluding derivative financial instrument show following pattern carrying amount cash flow dec dec year year year k k k k k loan borrowing finance lease trade payable liability excluding derivative financial liability carrying amount cash flow dec dec year year year k k k k k loan borrowing finance lease trade payable liability excluding derivative financial liability loan borrowing include liability arising following table illustrate liquidity analysis sale trade receivables factoring derivative financial instrument based program initiated undiscounted cash flow liability include liability acquisition cell culture medium business company lonza carrying amount cash flow dec dec year year year k k k k k interest rate swap derivative consolidated financial statement note note individual balance sheet item carrying amount cash flow dec dec year year year k k k k k interest rate swap derivative group control liquidity risk maintaining credit line additional facility bank continuously tracking forecasted actual cash flow managing maturity profile financial asset liability table provides overview credit line available reporting date credit line credit line credit line year year year interest rate used unused dec k k k dec dec syndicated credit line variable bilateral credit variable line fixed total credit line credit line credit line year year year interest rate used unused dec k k k dec dec syndicated credit line variable bilateral credit variable line fixed total market interest rate percentage agreement sartorius stedim biotech point higher interest expense statement required comply standard financial key ratio profit loss would million covenant context ratio net debt million higher million million underlying ebitda see glossary may greater would shown comprehensive interest coverage ratio underlying income part effective hedging transaction ebitda see glossary interest payable may lower essentially unchanged compared regard decrease interest rate previous financing december considered base interest rate resulting sartorius stedim biotech achieved following ratio impact financial result would million million equity dec dec million million k k k ratio net debt explained note september group ebitda put place syndicated loan agreement interest coverage credit line million term five year consolidated financial statement note note individual balance sheet item underlying ebitda corresponds ebitda sharebased payment earnings interest tax depreciation amortization adjusted extraordinary item net sharebased payment relate stock option plan debt defined outstanding bank loan less cash allocated group personnel cash equivalent held interest payable amount refers interest expense loan dec dec number number option option risk associated financial outstanding beginning period instrument allocated period cancelled period reporting date sartorius stedim biotech exercised period group exposed risk volatility lapsed period share price outstanding end period exercisable end period various stock option plan outstanding december december summarized follows number number number share number option option total date initial sub number share granted subject number general date number scribed director number subscribed target per bene meeting board share director initial subscrip exercisable formance ficiaries authorizing granted executive bene tion fiscal year dec dec valid plan approval subscribed executive concerned ficiaries price option june july june sept june nov total number number number share number option option total date initial sub number share granted subject number general date number scribed director number subscribed target per bene meeting board share director initial subscrip exercisable formance ficiaries authorizing granted executive bene tion fiscal year dec dec valid plan approval subscribed executive concerned ficiaries price option june july june sept june nov total cost fiscal k new additional service performed consideration allocation stock option granted option measured reference fair value option date allocation sartorius stedim biotech share purchase option order perform estimate group u allocated group senior binomialtype mathematic model managerial employee director fair value consolidated financial statement note note individual balance sheet item total fair value plan thus measured certain number phantom stock year recognized expense spread full vesting represent agreed amount money exercise period plan expense recognized stock possible four year personnel cost offset increase reserve depending certain requirement regarding cash received group upon exercise performance sartorius ag share option recognized cash cash equivalent stock paid amount based share corresponding item issued capital price exercise date payment capped reserve amount time share price time virtual option granted detail please level sartorius stedim biotech majority refer remuneration report shareholder sartorius ag sharebased payment exist form socalled phantom stock unit fair value phantom stock unit disclosed plan respective board member granted follows fair value granted number jan fair value phantom stock subscription particular yearend unit price year dec paid exercisable k k k tranche phantom stock unit tranche phantom stock unit tranche phantom stock unit tranche phantom stock unit total consolidated financial statement note disclosure disclosure consolidated financial statement prepared several service sublease agreement place going concern basis sartorius group company sartorius stedim biotech group company contract include mainly sublease office space material event reporting date central administrative function accounting controlling human resource management material event occurred reporting date respect relevant company charge rent salary social security cost expense service well prorated profit margin number employee service provide average workforce employed year important contract place one sartorius stedim biotech gmbh germany sartorius corporate administration gmbh germany affiliate sartorius ag related party company provides central service administrative function sartorius stedim biotech gmbh well majority shareholder sartorius stedim sartorius ag arm length term biotech sa sartorius ag hold either service approx million provided directly indirectly subsidiary vl sartorius stedim biotech gmbh million finance sa controlling stake company equity capital taking account treasury furthermore comparable service agreement share excluding treasury share group company rendered administrative voting right service worth million related party part group spent million transaction sartorius stedim biotech sa service received million million subsidiary presented note respectively amount includes charge related party company eliminated sartorius stedim biotech sa board member consolidation disclosed note million administrative service million detail transaction group related party primarily company group continued following belonging sartorius group disclosed contractual relationship related party sartorius group entity entity nonconsolidated sale revenue purchase receivables payable dec dec k k k k related party sartorius group sale revenue purchase receivables payable dec dec k k k k related party sartorius group consolidated financial statement note disclosure compensation key management personnel executive board management received following remuneration post long shortterm employment term termination sharebased benefit benefit benefit benefit payments k k k k k amount include dr joachim kreuzburgs reinhard vogts salary receive sartorius ag work performed entire sartorius group remuneration determined annually supervisory board sartorius ag amount remuneration component phantom stock plan depends development sartorius ag share price period least four year formerly three payable price exceeds established minimum share price appreciation outperforms comparative index use component designed longterm incentive effect subject risk suggested french german corporate governance code consolidated financial statement note statutory auditor report consolidated financial statement statutory auditor report consolidated financial statement free translation english statutory opinion consolidated financial statement give auditor report consolidated financial statement true fair view asset liability issued french language provided solely financial position group december convenience english speaking user result operation year ended accordance international financial reporting statutory auditor report includes information standard adopted european union specifically required french law report whether modified information presented without qualifying opinion draw attention opinion consolidated financial note note consolidated financial statement includes explanatory paragraph discus statement describes change made sing auditor assessment certain significant presentation statement profit loss accounting auditing matter assessment statement made purpose issuing audit opinion consolidated financial statement taken whole ii justification assessment provide separate assurance individual account caption information taken outside accordance requirement article l consolidated financial statement french commercial code code de commerce relating justification assessment bring report also includes information relating attention following matter specific verification information given management report note accounting policy assumption estimate consolidated financial statement refers report read conjunction significant judgment estimate made management construed accordance french law particularly concerning capitalization research professional auditing standard applicable france development expenditure impairment test goodwill asset indefinite useful life year ended december periodend company systematically shareholder performs impairment test goodwill asset indefinite useful life also assesses whether compliance assignment entrusted u indication loss value longterm asset annual general meeting hereby report according term condition defined note year ended december goodwill intangible asset consolidated financial statement audit accompanying consolidated financial statement sartorius stedim biotech work consisted assessing data assumption judgment estimate based reviewing justification assessment test basis calculation performed company comparing accounting estimate previous period specific verification required law corresponding achievement examining procedure implemented management approve consolidated financial statement approved estimate verifying note consolidated board director role express opinion financial statement provide appropriate disclosure consolidated financial statement based audit assumption option adopted company opinion consolidated financial statement assessment made part audit consolidated financial statement taken whole conducted audit accordance professional therefore contributed opinion formed standard applicable france standard require expressed first part report plan perform audit obtain reasonable assurance whether consolidated financial iii specific verification statement free material misstatement audit involves performing procedure using sampling required law also verified accordance technique method selection obtain audit professional standard applicable france information evidence amount disclosure presented group management report consolidated financial statement audit also includes matter report fair presentation evaluating appropriateness accounting policy used consistency consolidated financial statement reasonableness accounting estimate made well overall presentation consolidated marseille february financial statement believe audit evidence obtained sufficient appropriate provide ernst young audit deloitte associés basis audit opinion xavier senent christophe perrau annual financial statement sartorius stedim biotech sa note finacial statement note annual financial statement annual financial statement parent company balance sheet asset thousand depreciation amortization material event gross provision net net fiscal year page dec dec dec dec intangible asset property plant equipment financial investment total noncurrent asset inventory work progress receivables trade receivables third party receivables marketable security deposit cash equivalent total current asset prepaid expense currency translation adjustment total asset parent company balance sheet equity liability thousand material event fiscal year page dec dec share capital share premium reserve retained earnings carried forward profit period regulated provision total equity provision liability charge total provision liability charge loan borrowing trade payable tax social charge payable liability noncurrent asset liability total liability currency translation adjustment total equity liability finacial statement note annual financial statement parent company income statement thousand material event fiscal year page dec dec sale revenue inventory movement capitalized production cost depreciation amortization reversal operating income expense reallocation purchase consumed external charge service tax duty personnel cost addition amortization depreciation provision operating expense operating profit ebit net financing income expense profit loss ordinary activity exceptional income expense income tax net profit loss finacial statement note annual financial statement materiel event fiscal year accounting principle method th april shareholder parent company financial statement year company sartorius stedim biotech sa approved ended december prepared th resolution extraordinary shareholder presented accordance french accounting rule meeting proposed draft partial asset compliance principle prudence contribution company sartorius stedim reporting distinct financial year pre biotech sa made contribution sartorius stedim fmt sumption going concern annual financial sa complete autonomous branch statement prepared accordance activity management fluid provision french commercial code accounting decree november crc regulation asset transferred valued april revision french liability assumed therefore net chart account asset contributed sartorius stedim biotech sa listed compartment transaction completed october euronext paris stock exchange isin fr code retroactive effect january also prepares consolidated financial statement accordance ifrs standard largely explains significant change adopted european union december recorded balance sheet find detail following chapter noncurrent asset sartorius stedim biotech sa includes activity holding sartorius stedim biotech noncurrent intangible tangible asset valued group ownership share subsidiary also acquisition cost excluding cost incurred cover real estate related activity holding acquisition manufacturing activity site aubagne therefore sartorius stedim biotech sa present intangible asset property plant equip income statement including ment company applied french regulation crc recodified article regulation income expense rental business crc relative amortization depreciation impairment asset according income expense arising holding component approach activity mainly dividend th july sartorius stedim biotech sa acquired intangible asset leasing contract building warehousestorage located aubagne following thus valuated heading incorporation cost patent software entire property amount k including land building asset amortized straightline basis using following indicative useful life incorporation cost one five year software one three year patent twenty year part implementation integrated software direct labor cost concerned included amount capitalized cost function time elapsed intangible asset valued acquisition cost less amortization impairment reported ongoing basis finacial statement note annual financial statement property plant equipment inventory work progress property plant equipment ppe recognized value merchandise supply determined acquisition value including installation cost using fifo method storage acquisition cost asset included depreciation calculated standard work progress finished product valuated economic life asset using straightline production cost using full industrial cost method method writedown provision made appropriate noncurrent asset depreciated realizable value prospect use straightline basis using following indicative sale inventory lower period use gross carrying value building twenty forty year improvement fixture fitting ten fifteen year receivables payable plant equipment four ten year office equipment three five year receivables payable recorded nominal motor vehicle four five year value property plant equipment valued receivables whose collection doubtful subject acquisition cost less depreciation impairment provision doubtful debt reported ongoing basis currency translation adjustment financial investment foreign currencydenominated receivables investment relate mainly shareholding liability converted recognized based subsidiary treasury share held within december exchange rate difference observed scope share buyback program recorded historical cost posted currency acquisition cost including fee linked translation adjustment item acquisition unrealized loss resulting currency translation writedown provision may established take recognized currency translation loss account particular either stock exchange value receivable liability price underlying asset subsidiary hedged forward transaction financial position prospect shareholding subsidiary subject impair ment test finacial statement note annual financial statement noncurrent asset thousand intangible asset contribution gross value dec increase decrease asset transfer dec incorporation cost patent software license business goodwill intangible asset progress total amortization depreciation net amount property plant equipment contribution gross value dec increase decrease asset transfer dec land building plant equipment property plant equipment progress total contribution amortization depreciation dec addition release asset transfer dec building plant equipment total property plant equipment net net variation tangible asset k primarily due transfer manufacturing activity sartorius stedim biotech sa sartorius stedim fmt sa amount k element corresponding leasing contract leaseback new building amount k finacial statement note annual financial statement financial investment contribution investment dec increase decrease asset transfer dec shareholding writedown shareholding deposit guarantee treasury share writedown treasury share total following included financial investment treasury share item corresponds share buyback program implemented following approval share capital sartorius stedim seventh eighth resolution annual bioprocess sarl tunisian company general shareholder meeting april end number share rose share capital sartorius stedim repurchased average price biotech gmbh company governed german law total amount following merger sartorius stedim group june share capital sartorius stedim aseptics sa french company acquired share capital sartorius stedim fmt sa french company created connection contribution asset transfer investment k inventory trade receivables thousand inventory yearend contribution asset inventory dec transfer dec raw material consumables work progress finished good merchandise gross value depreciation writedown raw material consumables depreciation writedown work progress finished good depreciation writedown merchandise depreciation writedown inventory net diminution recorded correponds inventory transfer entity sartorius stedim fmt sa frame contribution asset transfer finacial statement note annual financial statement maturity receivables yearend thousand type receivable net amount less year year deposit guarantee noncurrent asset advance payment account trade receivables personnel social security tax duty group receivables current asset prepaid expense total receivables group item receivables group subsidiary k relates current account cash advance provided sartorius stedim biotech gmbh sartorius stedim fmt sa sartorius stedim france tax duty k item primarily entail net tax receivable including french tax relief system k vat receivables maturity liability yearend thousand less type liability net amount year year year loan borrowing credit institution originally less year originally year current bank overdraft accrued interest trade payable including bill exchange advance payment account order tax social security payable liability noncurrent asset group associate total liability finacial statement note annual financial statement accrued expense included account represented k concerned following item type expense dec accrued banking charge supplier invoice received paid vacation including social charge bonus including social charge profit sharing social security payable tax payable employee profit sharing total charge payable parent company statement change equity thousand equity december share capital k annual general shareholder meeting april comprising share par value approved appropriation net profit change equity result year k follows following event allocation retained earnings exercise stock option resulting issue carried forward k share par value total k paid legal reserve k k share premium associated share dividend total k net dividend per capital increase share paid treasury share excluded equity appropriation appropriation profit profit change increase decrease number share share capital share premium merger premium legal reserve reserve balance carried forward dividend paid net profit appropriated profit reporting year regulated provision total stock option number share subscription option vested exercised date part policy motivating group senior executive sartorius stedim biotech sa granted potential stock option issued stock option number employee depending achievement future target finacial statement note annual financial statement risk provision thousand provision provision addition release contribution provision type provision dec asset transfer dec regulated provision accelerated amortization depreciation subtotal provision liability charge exchange risk cost taxation subtotal grand total market risk exposure operating cash flow risk december net amount foreign currency current asset liability finacial statement note annual financial statement current future tax position thousand january company chose adopt future income tax position result french tax integration regime within framework tax group lead company tax paid advance expense recognized group sartorius stedim biotech sa fiscal year deductible subsequent member company tax integration group fiscal year tax relief sartorius stedim aseptics sa sartorius stedim france sa sartorius stedim fmt sa tax paid advance unrecognized unrealized sartorius stedim financière sa gain member company report income tax deferred tax recognized integration tax regime parent balance sheet corporation benefit tax relief related consolidating gain loss temporary difference taxable income member company expense follows net impact according consolidation rule french tax integration regime tax relief income k amount income tax fiscal settled sartorius stedim biotech sa tax integration regime k contribution future tax position asset transfer dec increase solidarity contribution net movement currency translation difference employee profit sharing depreciation customer inventory total increase decrease solidarity contribution net movement currency translation difference employee profit sharing depreciation customer inventory total decrease future tax position increase solidarity contribution net movement currency translation difference employee profit sharing depreciation customer inventory total increase decrease solidarity contribution net movement currency translation difference employee profit sharing depreciation customer inventory total decrease future tax position finacial statement note annual financial statement operating income thousand sale revenue operating segment operating segment non comparable regarding contribution asset biopharm total sale revenue geographical region geographical region non comparable regarding contribution asset france export eu country north american continent total sale revenue corresponds reblling rent th entity sartorius stedim fmt sa following contribution asset transfer exceptional income expense thousand dec dec exceptional income operation capital transaction release provision transfer charge total exceptional income exceptional expense operation capital transaction addition amortization depreciation provision total exceptional expense exceptional income expense amortization depreciation charge comprised recognized non accelerated depreciation amortization current asset amortized prorated capitalized cost associated acquisition basis year stedim sartorius june expense charged share premium treated deduction calculation company tax liability finacial statement note annual financial statement breakdown income tax thousand dec dec profit income tax profit profit income tax tax charge tax tax charge profit tax gross taxable income exceptional income expense employee profitsharing contribution rd tax credit french tax integration relief net taxable income workforce analysis workforce december men woman total men woman total executive employee total following contribution asset transfer sartorius stedim biotech sa sartorius stedim fmt sa complete autonomous branch activity sartorius stedim biotech sa salaried people information director remuneration offbalance sheet commitment thousand remuneration paid member board director director meeting attendance fee dec dec amounted k fee related type commitment comment fiscal year paid commitment given retirement commitment meeting attendance fee paid sartorius guarantee bilateral stedim biotech sa general management credit line company fiscal guarantee currency hedging contract commitment part executive board remuneration renting leasing recharged sartorius stedim biotech sa commitment received contractual loan capacity credit institution frame contribution asset transfer totality salaried people transferred entity sartorius stedim fmt sa st october therefore pension commitment transferred entity reporting year sartorius stedim biotech sa concluded new year syndicated loan agreement total amount million loan booked sartorius stedim biotech gmbh finacial statement note annual financial statement financial statement agreement sartorius commitment given concern company stedim biotech required comply key sartorius stedim biotech gmbh financial ratio covenant detail please refer note section g consolidated commitment connection lease statement page summarized following table year year year leasing k k k total buyback value tangible asset building improvments total payment cumulatives depreciation cumulative leasing historical value year payment year depreciation tangible asset building improvments total information related party share buyback program thousand agm held april authorized affiliate company owned sartorius stedim company sartorius stedim biotech sa introduce biotech sa sartorius stedim fmt sa share buyback program maximum duration sartorius stedim bioprocess sarl sartorius stedim eighteen month october aseptics sa sartorius stedim biotech gmbh company sartorius stedim biotech sa consolidated financial statement sartorius ag weender landstrasse goettingen germany following find table main amount related party item dec dec investment trade receivables receivables trade payable liability income investment financial income finance expense finacial statement note annual financial statement following find table subsidiary shareholding reserve share premium retained loan change sale earnings outstand exvat ing deposit share appro owner book value advance financial dividend dec capital priation ship share held granted pledge year net profit received gross net sartorius stedim biotech gmbh euro sartorius stedim fmt sa euro sartorius stedim bioprocess sarl dinar euro sartorius icr ruble euro sartorius stedim aseptics sa euro reserve share premium retained loan sale earnings outstand change exvat ing deposit share appro owner book value advance financial dividend dec capital priation ship share held granted pledge year net profit received gross net sartorius stedim biotech gmbh euro sartorius stedim bioprocess sarl dinar euro sartorius icr ruble euro sartorius stedim aseptics sa euro finacial statement note statutory auditor report financial statement statutory auditor report financial statement free translation english report issued french note financial statement set provided solely convenience englishspeaking rule accounting method relative user report read conjunction valuation investment treasury share within construed accordance french law professional scope assessment rule auditing standard applicable france accounting principle company verified appropriateness accounting year ended december method specified information provided note financial statement made sure shareholder correct application compliance assignment entrusted u assessment made part audit annual general meeting hereby report financial statement taken whole year ended december therefore contributed opinion formed expressed first part report audit accompanying financial statement sartorius stedim biotech iii specific verification information justification assessment specific verification information required law also performed accordance professional standard applicable france annual financial statement approved specific verification required french law board director role express opinion financial statement based matter report fair audit presentation consistency financial statement information given opinion financial statement management report board director document addressed shareholder conducted audit accordance respect financial position financial professional standard applicable france statement standard require plan perform audit obtain reasonable assurance whether concerning information given accordance financial statement free material misstatement requirement article l audit involves performing procedure using french commercial code code de commerce relating sampling technique method selection remuneration benefit received obtain audit evidence amount director commitment made disclosure financial statement audit also favor verified consistency includes evaluating appropriateness accounting financial statement underlying policy used reasonableness accounting information used prepare financial statement estimate made well overall presentation applicable information obtained financial statement believe audit company company controlling evidence obtained sufficient company controlled based work appropriate provide basis audit opinion attest accuracy fair presentation information opinion financial statement give true fair view asset liability financial accordance french law verified position company december required information concerning identity result operation year ended principal shareholder holder voting accordance french accounting principle right properly disclosed management report ii justification assessment marseille february accordance requirement article l french commercial code code de commerce ernst young audit deloitte associés relating justification assessment xavier senent christophe perrau bring attention following matter supplementary information supplementary information information legal nature information legal nature general information issuer corporate purpose france abroad company purpose corporate name manufacture sell distribute equipment used biopharmaceutical area generally corporate name company carry property financial security sartorius stedim biotech sa transaction relate directly indirectly operation likely assist legal deed document issued com completion pany always preceded followed word société anonyme abbreviation sa trade commercial register ape code statement share capital heading article company bylaw company registered registre du commerce et de sociétés de marseille number rcs b economic activity code registered office ape z holding company activity registered office aubagne france zi le paluds avenue de jouques phone number inspection legal document registered office company office may transferred another location reference document may viewed département french county state registered office company website adjacent county state simple decision website amf validity board director subject ratification next present reference document bylaw annual general shareholder meeting anywhere statutory auditor report financial else france decision taken extraordinary statement last three fiscal year although general shareholder meeting report mail document historical financial information company board director decides transfer subsidiary last three fiscal year evaluation registered office authorized revise bylaw declaration made expert result heading article company document statutory statutory bylaw document found registered office legal form applicable law financial year public limited liability company joint stock company financial year also referred fiscal year société anonyme subject french legislation cover period twelve month beginning particularly french commercial code january ending december year date incorporation duration specific clause company bylaw company incorporated september société anonyme company duration form share year effective upon registration french trade commercial register registre du commerce share may nominative bearer form according et de sociétés unless subject dissolution shareholder choice share entitled extension provided present company bylaw recorded account accordance heading article french law supplementary information information legal nature appropriation profit agenda income statement summarizes income heading point excerpt article bylaw expense reporting year discloses difference deduction amortization depreciation notice letter call shall indicate provision profit said reporting year least indication required law particularly must deducted annual profit reduced agenda company electronic address written appropriate prior loss set legal reserve question shareholder may sent eventually deduction cease obligatory legal mention obligation collect opinion reserve amount one tenth share capital prior approval mass security share obligatory deduction resume whatever reason holder giving access share capital legal reserve fall one tenth distributable profit comprises profit reporting meeting may deliberate matter year less prior loss amount transferred reserve placed agenda may however remove one pursuant french law company bylaw director time increased profit brought forward profit distributed among shareholder proportion one shareholder representing percentage number share one hold annual general share capital required law may shareholder meeting may decide distribute amount condition time limit set forth law require taken reserve available expressly indicating inclusion agenda draft resolution reserve transfer made however dividend disbursed way priority annual accordance article r r profit reporting year except reduction commercial code request made capital distribution may made shareholder shareholder register draft resolution equity fall would consequently fall agenda written question sent amount capital together headquarters registered letter recorded reserve french law company bylaw delivery beginning publication meeting permit distribute revaluation surplus announcement day general distributable may corporated full part meeting delay day beginning company capital however transferring publication meeting announcement amount reserve pursuant french law one published day general annual general shareholder meeting may transfer meeting date reception request amount considers necessary available reserve company taken account ordinary extraordinary reserve carry forward request new item agenda must motivated request register draft resolution shareholder meeting provided text draft resolution may short explanation reason request convocation subject justification possession representation required share capital accordance regulatory rule annual ordinary general shareholder meeting convened take decision result moreover accordance article l revision bylaw extraordinary general paragraph labor code request draft shareholder meeting called decide resolution made work council added authorize direct indirect revision bylaw special agenda sent next day following meeting bring together holder specific class publication meeting announcement share consider revision right class share decision made general meeting binding heading point excerpt article bylaw shareholder even absent dissenting legally incapable incapacitated heading article meeting unable make valid bylaw general meeting convened decision due lack required quorum board director default independent auditor second meeting appropriate second person thus empowered general meeting held meeting adjourned called least ten day registered office place stated advance form first meeting notice convocation heading excerpt article heading excerpt article bylaw bylaw form timescale notice convocation governed french law supplementary information information legal nature admission meeting power heading point legal document relative legal information excerpt article bylaw shareholder made available registered office company every shareholder right attend general meeting participate discussion provision applicable administration person proxy regardless number share management company held simple proof identity ownership share right participate general meeting board director subject condition share must recorded name shareholder subject legal exemption company shareholder appointed broker either directed board director composed nominative share account held company minimum three member maximum bearer share account held authorized eighteen broker zero hour paris time third working day prior meeting recording registration duration company existence share bearer share account held director shall appointed renewed office authorized broker must confirmed share ordinary general meeting however case certificate provided broker share merger director may appointed extra certificate must attached postal voting form ordinary general meeting deciding transaction proxy form application admission pa issued name shareholder director must entire term office behalf shareholder represented least one share appointed broker certificate must also supplied shareholder wish attend general director term office three year meeting person received admission pa zero hour paris time third director duty shall cease end ordinary working day prior meeting general meeting deciding account financial year elapsed held year term shareholder may represented another office director concerned expires shareholder spouse partner signed civil partnership furthermore director may renewed office may may represented moral removed office time ordinary physical person choice accordance general meeting article l commercial code aim representative must present person may appointed director valid proof proxy reached age appointment would result one third member board legal representative shareholder director exceeding age proportion legally incapable incapacitated individual exceeded oldest director shall automatically representing corporate shareholder take part deemed resigned end ordinary meeting whether shareholder general meeting approving account financial year exceeded shareholder may also postal voting using registration form sent company according director may individual legal entity law regulation acceptable director legal entity required upon registration must received company day appointment appoint permanent date meeting representative subject condition obligation incurs liability case remote voting using electronic vote though personally director without prejudice proxy vote given electronic signature vote several liability legal entity represented made according condition current regulation legal entity director terminates mandate given permanent representative shall promptly notify company registered letter supplementary information information legal nature decision well identity new chairman represents board director permanent representative applies organizes directs work report event death resignation permanent general meeting ensures proper operation representative company decisionmaking body ensures particular director one director seat become vacant position fulfill duty two general meeting due death resignation board director may proceed case absence impediment affecting make appointment interim basis fill chairman board director appoints acting seat board appointment must made chairman meeting within three month vacancy number director fallen minimum board director appoints secretary article association without falling may chosen either among director statutory minimum outside secretary shall replaced simple decision board interim appointment made manner board subject ratification next ordinary meeting decision board general meeting failing ratification decision taken act accomplished shall nonetheless board director meet upon call remain valid chairman often required interest company however director representing least one number director fall third member board director may statutory minimum director remaining office precisely indicating meeting agenda call required immediately call ordinary meeting board met within last two month fill vacant seat board ceo chairing board director may director appointed replacement another shall request chairman call board meeting remain office remaining term office specified agenda predecessor meeting shall take place registered director individual cannot concomitantly office location indicated notice hold five seat board director call call meeting indicating agenda supervisory board sociétés anonymes sent least day beforehand letter registered office metropolitan france subject telegram telex fax call may verbal exception provided law meeting may held immediately director agreement company employee may appointed director unless employment agreement corresponds board director validly deliberate effective employment shall lose benefit least one half director required employment agreement number director present represented bound company employment agreement may exceed one third director office board decision taken majority member present represented organization management board director acting chairman casting vote board director elect chairman attendance sheet shall held signed among member individual director participating board meeting determines remuneration set duration chairman term office may exceed internal regulation established board office director director may provide director participating board meeting videoconference accordance person may appointed chairman applicable regulation deemed present board director age purpose calculating quorum majority chairman office exceeds age shall deemed automatically resigned supplementary information information legal nature provision shall apply adoption general management following decision mode operation appointment remuneration removal chairman ceo vice ceo accordance article l commercial code company general closing annual account consolidated account management ensured responsibility preparation management report report either chairman board director management group individual appointed board director title ceo board director deliberation recorded minute held accordance applicable law choice two mode operation minute signed acting chairman general management made board one two director director board decision concerning choice mode operation general management taken copy excerpt minute board majority vote director present director deliberation shall validly certified represented shareholder third party chairman ceo informed choice made board director condition set forth applicable power board director regulation board director determines company board director may modify option chosen business guideline ensures time implemented subject power expressly granted law shareholder meeting within limit change mode operation general corporate object deal matter management shall entail modification relating proper running company article association deliberation governs affair company general management dealing third party company bound even act board director depending mode exercise chosen outside corporate purpose unless prove board director chairman ceo shall ensure third party knew act ultra vires responsibility general management could reasonably unaware thereof company view circumstance specified mere publication article association ceo appointed board director suffice establish proof thereof set duration term office determines remuneration applicable restriction board director shall carry control power verification deems appropriate performance duty ceo must director shall receive information necessary age age limit exceeded performance duty may obtain course term office ceo shall document considers useful general deemed automatically resigned new management ceo shall appointed board director may give delegation ceo may removed office time authority representative choice within board director removal ceo limit authority law also chairman may give rise damage decided article association without valid cause board may decide creation review power ceo committee charge studying issue board chairman submits ceo vested broadest power act circumstance name company ceo shall exercise power within limit supplementary information information legal nature corporate object subject power expressly event postal voting form received granted law shareholder meeting company prior meeting board director considered calculating quorum condition timeframe set decree ceo represents company dealing third party company bound even act right vote conferred share proportional ceo outside corporate object capital represent equal par value unless prove third party knew every share capital income right carry right act ultra vires could reasonably one vote unaware thereof view circumstance specified mere publication article event share pledged voting association suffice establish proof thereof right exercised holder security issuing company may validly vote share vice ceo subscribed acquired taken pledge share taken account calculate upon motion ceo whether position quorum filled chairman board director another person board director may name one voting take place vote cast show individual responsibility assisting hand sitting standing roll ceo title vice ceo call decided officer meeting maximum number vice ceo may exceed information voting right five limit bylaw voting right agreement ceo board director event conversion bearer form converted shall determine scope extent share immediately forfeit double voting right power granted vice ceo set event capital increase incorporation remuneration reserve profit share premium double voting right applies new share issued allocated free regard third party vice ceo vice ceo charge shareholder basis existing share power ceo already carry right heading article company bylaw revision bylaw upon cessation duty case unanimously passed general shareholder impediment affecting ceo vice ceo shall meeting extraordinary session august retain unless otherwise decided board may cancelled general shareholder director office authority meeting convened extraordinary session appointment new ceo ratification special meeting beneficiary shareholder ceo may removed office time board director removal ceo december also chairman may give rise damage decided share double voting right total without valid cause share thus total voting right deduction buyback value condition exercise voting right treasury share repurchased fiscal majority quorum heading article bylaw total voting right annual extraordinary general meeting excerpt bylaw heading article quorum calculated basis share comprising share capital special meeting annual general shareholder meeting held basis share class concerned least year within six month year end net share entitled voting right virtue consider financial statement year subject law extension timeframe legal decision annual general shareholder meeting may double voting right conferred holder validly deliberate upon first convocation registered share fully paid shareholder present represented voting post registered name holder hold least one quarter share right least four year vote quorum required upon second supplementary information information legal nature convocation meeting decides basis company acquisition share majority vote held shareholder present represented including shareholder voting post element share buyback program implemented accordance provision article l crossing legal threshold et seq french commercial code modified ordinance issued january shareholder whose shareholding cross legal threshold defined french law either upwards agm april granted authorization downwards must declare said crossing notification board director maximum period autorité de marchés financier pursuant month accordance provision article law force bylaw company l seq provision provide additional threshold declaration european regulation december company buy treasury share identification shareholder handle secondary market liquidity share company said handling shall within legal regulatory framework investment service provider acting company authorized seek identity bearer scope liquidity agreement compliant shareholder deontology charter approved autorité de marchés financier payment dividend ii deliver share case exercise right attached security giving access annual general shareholder meeting mean immediately certain future date power give every shareholder part capital company refund conversion dividend payable option receiving dividend exchange exercise warrant way share provided french law cash well perform hedging transaction related issuing security according regulation term payment dividend cash determined competent authority set general meeting default board time board director person acting director cash dividend must paid within pursuant delegation authority board maximum nine month end director deems appropriate reporting year unless timeframe extended legal authorization however profit may iii allocate repurchased share bought distributed interim dividend prior company officer employee approval annual financial statement company andor company group according balance sheet prepared end applicable law regulation especially within financial year certified independent scope participation profit auditor discloses company realized company expansion stockoption plan profit since close previous financial year employee stock ownership program employee recognition necessary amortization saving plan capital forming benefit depreciation provision well deduction free granting share well carry relevant prior loss amount hedging operation related operation transferred reserve required french law according regulation determined competent company bylaw interim dividend may authority time board director exceed profit thus defined reimbursement person acting pursuant delegation dividend may required shareholder unless authority board director deems appropriate distribution made violation legal provision company determines iv retain company share beneficiary aware illegality purchased order return exchange distribution time occurred could ignore payment within scope potential external nature dividend occurs project provided maximum number share share reimbursement timebarred three may purchased end shall exceed year payment dividend dividend five percent total number share collected within five year payment constituting share capital company timebarred supplementary information information legal nature v cancel repurchased share liquidity contract decrease company capital liquidity contract concluded vi pursue objective subsequently sartorius stedim biotech sa stockbroker permitted applicable law regulation gilbert dupont following asset appeared market practice subsequently recognized liquidity account december autorités de marchés financier provided case company would inform shareholder number share press release liquidity account cash balance financial year company information following asset appeared purchased share total price liquidity account date notification ie average price contract implementation issued total amount negotiation fee excluding vat amounted k number share liquidity account cash balance owned share split following objective return share exchange payment within major contract scope potential external project several service agreement entered deliver share case exercise entity division sartorius group right attached security giving access sartorius stedim biotech group order enable mean immediately certain future date entity division benefit certain capital company general administrative service term share bought back company among service agreement service agreement financial year highest volume importance place sartorius stedim biotech gmbh sartorius december operation corporate administration gmbh subsidiary company directly controlled share sartorius ag sartorius corporate administration gmbh representing share capital allocated provides general administrative service sartorius purpose use exchange payment stedim biotech entity sartorius event external expansion operation group service include among others accounting share transferring share right related treasury management payroll accounting human financial instrument share exercised resource system legal service sartorius corporate administration gmbh invoice service board director decided propose basis internal external cost incurred plus resolution april ordinary annual margin service invoiced sartorius shareholder meeting order modify corporate administration gmbh sartorius stedim allocation treasury share knowing biotech gmbh totaled million maximum purchase price paid company share shall exceed fortyfive euro per apart abovementioned service agreement share specified informative purpose contract material obligation share constitute share capital commitment concluded outside company maximum sum allocated ordinary course company business share buyback plan amount seventysix million member sartorius stedim biotech group party four hundred seventyfour thousand seven hundred ten euro strategy sale marketing organization within sartorius stedim biotech group towards customer create valuable longterm relationship therefore example key account management endeavor conclude longterm framework contract customer total solution provider sartorius stedim biotech strives use contract cover entire product portfolio sartorius stedim biotech fit validated process customer supplementary information information legal nature registered trademark trademark application international registration name eu germany france country designated usa australia brazil mexico uk canada application filed sartorius different stedim au ch kr ru sg class biotech tr vn reg progress reg progress bx ch de e biostat fr pt hydrosart maxicaps midicaps __________ minisart sartocheck sartocon virosart bx ch de dz eg e fr hu kp li mc pt ro r sartoflow ru sd vn sartopore de bx ch ___________________ flexboy jp flexel palletank raft evam stedim jp nutribag nutrikit nutrimix nutripoche biosafe de dk gb ch biosteam fluxbulle apart trademark mentioned sartorius stedim biotech group owner applicant different trademark various country date indicated daymonthyear supplementary information information legal nature registered trademark trademark application name japan denmark finland ireland malaysia norway sweden china switzerland india taiwan sartorius trademark trademark trademark stedim trademark trademark trademark biotech trademark application application application __________ biostat hydrosart maxicaps midicaps minisart sartocheck sartocon virosart sartoflow sartopore flexboy flexel palletank raft evam stedim nutribag nutrikit nutrimix nutripoche biosafe biosteam fluxbulle apart trademark mentioned sartorius stedim biotech group owner applicant different trademark various country date indicated daymonthyear supplementary information special report statutory auditor related party agreement commitment special report statutory auditor related party agreement commitment free translation english report issued french provided solely convenience english speaking user report read conjunction construed french law professional standard applicable france year ended december shareholder capacity statutory auditor company agreement commitment submitted hereby report certain related party agreement approval general meeting commitment shareholder required inform basis hereby inform advised information provided u term agreement commitment authorized condition agreement commitment course year submitted general indicated u may identified meeting shareholder approval accordance performance engagement required article l french commercial code comment whether beneficial code de commerce appropriate ascertain existence agreement commitment responsibility accordance article r french agreement commitment already approved commercial code code de commerce evaluate general meeting shareholder benefit resulting agreement commitment prior approval hereby inform advised agreement commitment already approved addition required applicable general meeting shareholder whose inform accordance article r implementation continued year french commercial code code de commerce concerning implementation year agreement commitment already approved general meeting shareholder marseille february performed procedure considered ernst young deloitte associés necessary comply professional guidance issued national auditing body compagnie nationale xavier senent christophe perrau de commissaires aux comptes relating type engagement procedure consisted verifying information provided u consistent documentation extracted supplementary information resolution submitted annual combined shareholder meeting april resolution submitted annual combined shareholder meeting april resolution submitted annual total amount dividend disbursed ordinary shareholder meeting shareholder balance resulting disbursement first resolution remaining amount annual shareholder meeting asm carried forward next year considered report board director general report independent auditor therefore considering company hold special report chairman pursuant article treasury share net dividend paid l french commercial code approves every share par value financial statement year ended december disclosed net profit asm acknowledges informed presented transaction new tax regulation dividend according reflected financial statement summarized finance law abolished right choose report withholding tax submitting dividend distribution progressive scale asm considered report tax income application independent auditor consolidated financial allowance retained without modification statement said reporting year approves accordance article french financial statement year ended december general code disclose net profit thousand transaction included therein summarized dividend paid april group management report amount distributed january result asm grant full unreserved eligible tax rebate follows discharge director execution management duty said reporting year income eligible tax rebate income asm also approves overall amount year ended dividend distributed excess amortization amortization déc deductible profit subject corporate income déc tax well corresponding tax déc second resolution third resolution asm approves appropriation net profit asm considered special report follows independent auditor agreement subject article l following french legal reserve commercial code approves conclusion said report agreement contained therein balance resulting deduction legal reserve following added balance yearearlier profit carried forward would yield distributable profit supplementary information resolution submitted annual combined shareholder meeting april fourth resolution resolution submitted annual extraordinary shareholder meeting asm approve amount director fee allocated set aggregate amount director fee paid board director ninth resolution shareholder fulfilled quorum majority requirement pertaining extraordinary fifth resolution general shareholder meeting considered board director report decide amend article shareholder meeting complying company purpose title bylaw since recommendation afepmedef code updated doesnt exercise operating activity following june deliberating accordance quorum complete realization partial asset contribution majority requirement ordinary shareholder related transfer activity management meeting give favorable opinion element fluid benefit subsidiary sartorius stedim compensation due granted financial fmt follow year joachim kreuzburg chairman chief executive officer described thousand company purpose france abroad purchase develop administrate manage sixth resolution portfolio equity security security voting right social right company regardless shareholder meeting complying activity mean including way recommendation afepmedef code updated setting new company contribution kind june deliberating accordance quorum type social right subscription right majority requirement ordinary shareholder merger purchase social right meeting give favorable opinion element incorporation company compensation due granted financial year reinhard vogt executive vice president manage conduct coordinate activity described thousand subsidiary affiliate applicable provide said company service administrative financial accounting legal seventh resolution nature opinion advise order study research necessary shareholder meeting complying development growth recommendation afepmedef code updated june deliberating accordance quorum generally financial commercial majority requirement ordinary shareholder industrial personal real property operation meeting give favorable opinion element linked directly indirectly abovementioned compensation due granted financial corporate purpose complementary year volker niebel executive vice president related similar purpose may promote described thousand development accomplishment thereof eighth resolution shareholder meeting complying recommendation afepmedef code updated june deliberating accordance quorum majority requirement ordinary shareholder meeting give favorable opinion element compensation due granted financial year oscarwerner reif executive vice president described thousand supplementary information resolution submitted annual combined shareholder meeting april tenth resolution voting right shareholder legal entity company controlling within meaning shareholder fulfilled quorum article l commercial code requires majority requirement pertaining extraordinary prior authorisation board director general shareholder meeting considered board director report considering applies agreement one opportunity amending article title iii person listed indirect interest bylaw decide amend said article follow agreement concluded company article title iii bylaw undertaking also subject board director prior authorisation ceo one vice ceo internal regulation established board one director company owner director may provide director participating unlimited liability partner manager director member board meeting videoconference teleconference supervisory board generally corporate others mean telecommunication allowing officer undertaking identification participant ensuring effective participation accordance agreement must authorised approved applicable regulation deemed present condition set forth article l purpose calculating quorum majority commercial code provision shall apply adoption following decision agreement involving daytoday transaction concluded arm length shall subject appointment remuneration removal authorisation approval procedure set forth chairman ceo vice ceo article l et seq commercial code closing annual account consolidated account preparation management report report twelfth resolution management group shareholder fulfilled quorum majority rest article remains unchanged requirement pertaining ordinary general shareholder meeting considered board director report accordance provision article l eleventh resolution et seq article l french commercial code shareholder fulfilled quorum majority requirement pertaining extraordinary decide increase share capital company general shareholder meeting considered maximum nominal amount eur six million six board director report considering hundred forty six thousand four hundred ninety nine opportunity amending article title iii thirty four cent bylaw decide amend said article follow specified maximum nominal amount calculated based number share existing date article title iii bylaw meeting increasing nominal value existing share currently amounting eur sixty one cent director legal entity ceo eur one vice ceo prohibited contracting form borrowing company obtaining decide increase share capital current account overdraft facility company carried capitalization endorsement guarantee commitment available sum item issue premium third party prohibition also applies indicated company annual account permanent representative director legal fiscal year preceding date decision entity spouse ascendant descendant board director complete share capital person listed well intermediary increase agreement concluded directly indirectly authorize board director implement via intermediary company decision increase share capital consequently ceo one vice ceo one director one determine definitive nominal amount share shareholder holding capital increase decided shareholder pursuant supplementary information resolution submitted annual combined shareholder meeting april resolution based number share existing thirteenth resolution date decision board director complete share capital increase authorization granted board director reduce share capital cancellation shareholder grant board director share purchased share buyback program right subdelegate accordance applicable law regulation power shareholder fulfilled quorum implement delegation power particular majority requirement pertaining extraordinary general shareholder meeting considered determine date completion share capi board director report statutory auditor tal decide date increase special report accordance provision nominal value existing share take article l et seq article l effect french commercial code make adjustment take account impact transaction involving share capital authorize board director cancel one company set term enabling several time sole initiative portion necessary right holder security giving share purchased company share access share capital company buyback program limit ten per cent preserved company share capital twentyfour discretion charge cost capital month period provided ten per cent increase premium arising thereon limit applied company share capital deduct premium sum necessary necessary adjusted take increase legal reserve account transaction affecting share capital duly record completion capital increase decid company occur subsequently shareholder ed shareholder pursuant resolution meeting definitive nominal amount share capi tal increase make necessary amendment authorize board director reduce share article association company capital company accordingly complete necessary formality provide decla ration disclosure authority particu shareholder grant board director larly autorité de marchés financier right subdelegate accordance generally take appropriate measure applicable law regulation power implement authorization particular delegation power granted period five year date shareholder meeting establish definitive amount capital reduction determine term condition reduction duly record reduction charge difference purchase price cancelled share nominal value available premium reserve amend article association company accordingly complete necessary formality provide declaration disclosure authority particularly autorité de marchés financier generally take appropriate measure authorization granted period twentysix month date shareholder meeting supplementary information resolution submitted annual combined shareholder meeting april fourteenth resolution set following limit amount issuance may carried pursuant delegation authority granted board delegation authority director issue share andor security giving access share capital company andor security nominal amount capital increase giving right allotment debt instrument capital increase may carried immediately preferential subscription right future pursuant delegation shareholder authority shall exceed maximum amount two million euro equivalent value shareholder fulfilled quorum amount date issuance decision majority requirement pertaining extraordinary including nominal value share general shareholder meeting considered issued applicable pursuant adjustment board director report statutory auditor made order protect right holder special report noted share capital security giving access company share capital fully paidup accordance accordance applicable law regulation provision article l trough l well contractual provision specified l trough l l limit nominal amount capital l french commercial code increase without preferential subscription right shareholder set th th th delegate board director right th th th resolution submitted subdelegate accordance applicable law shareholder meeting shall deducted regulation authority proceed one overall limit several time france abroad proportion time considers appropriate euro b nominal value debt instrument currency monetary unit established may issued pursuant delegation reference basket currency preferential authority shall exceed maximum amount subscription right shareholder maintained two million euro equivalent value issuance share preference share amount date issuance decision andor security kind whatsoever specified amount include security giving right issuance abovepar reimbursement premium preference share giving access share capital provided ii limit issuance debt company new existing share andor ii instrument set th th th th th th issuance security giving right allotment resolution submitted shareholder meeting debt instrument valuable consideration free shall deducted overall limit consideration governed article l et seq french commercial code specified shareholder share security referred ii may subscribed either cash offset resolve shareholder company debt company preferential right subscribe issuance issuance share andor security board delegate board director right director may decide pursuant delegation subdelegate accordance applicable law authority irreducible basis proportion regulation authority proceed one number share owned several time france abroad proportion time considers appropriate euro note board director may grant currency monetary unit established shareholder additional preferential right reference basket currency preferential introducing reducible subscription right exercisable subscription right shareholder maintained proportion shareholder existing preferential issuance security giving access share right within limit request capital company company hold directly indirectly half share note delegation authority automatically capital andor ii issuance security giving entail benefit holder security access share capital company may issued pursuant delegation directly indirectly hold half authority express waiver shareholder company share capital subject authorization preferential subscription right respect competent body company referred share security may give access ii immediately future supplementary information resolution submitted annual combined shareholder meeting april note pursuant article l subordination accordance provision french commercial code irreducible article l french commercial code set applicable reducible subscription absorb interest rate interest rate may fixed entirety issuance share variable zerocoupon indexed specify security giving access share capital circumstance compulsory optional suspension company board director may use cancellation interest payment stipulate condition provided law order term fixed perpetual possibility shall determine option listed reduction increase nominal value set term issuance including granting guarantee security interest limit capital increase amount amortization including possibility redemption subscription provided said amount equal delivery company asset necessary least three quarter amount issuance security may accompanied warrant entitling decided upon holder allotment acquisition subscription bond debt instrument freely allocate unsubscribed share defined market authority example due security giving access share capital redemption remuneration term company right indexation option right amend term share andor offer part unsubscribed share security question term security giving access share capital compliance applicable formality company public french international market abroad determine mean payment share andor security giving access share resolve issuance warrant giving entitlement capital company issued immediately subscribe company share may also future made way free allocation owner existing share stipulated board set necessary term exercise director may decide fractional allotment right right right conversion exchange neither negotiable transferable redemption case may including delivery corresponding security sold company asset share security already issued company attached acknowledge board director shall report share andor security giving access share use made delegation capital company issued immediately authority next ordinary shareholder meeting future particular period accordance applicable law regulation may retrospective dividend payable new share well term shareholder grant board director condition completion share right subdelegate accordance capital increase applicable law regulation power implement delegation authority set term company particular necessary time fixed period right purchase exchange stock exchange decide increase share capital company security giving access share capital determine nature share andor company issued issued immediately security issued future purpose canceling security taking account applicable decide amount share capital increase legal provision issuance price share andor security issued applicable amount issuance determine condition accordance premium applicable law allotment right holder security giving access share may determine date term capital temporarily suspended increase characteristic share andor security issued addition case discretion charge cost capital bond debt instrument determine whether increase premium arising thereon subordinated level supplementary information resolution submitted annual combined shareholder meeting april deduct premium sum necessary fifteenth resolution increase legal reserve delegation authority granted board determine make adjustment take account director issue share andor security giving access impact transaction involving share share capital company andor security capital company particular change giving right allotment debt instrument nominal value share increase share capital without preferential subscription right incorporation reserve free allocation shareholder public offering share stock split reverse stock split distribution dividend reserve premium shareholder fulfilled quorum asset redemption capital majority requirement pertaining extraordinary transaction affecting shareholder equity general shareholder meeting considered share capital set term enabling board director report statutory auditor necessary right holder security giving special report noted share capital access share capital company fully paidup accordance preserved provision article l trough l l trough l l trough duly record completion capital increase l french commercial code carried pursuant delegation authority make necessary amendment article delegate board director right association company subdelegate accordance applicable law regulation authority proceed generally enter agreement particular public offering one several time france ensure completion proposed issue take abroad proportion time considers measure accomplish formality required appropriate euro currency issuance listing financial administration monetary unit established reference basket share andor security issued delegation currency issuance share authority exercise right attached preference share andor security kind thereto whatsoever security giving right issuance preference share giving access delegation authority granted period share capital company new existing twentysix month date share andor ii issuance security giving shareholder meeting right allotment debt instrument valuable consideration free consideration governed article l et seq french commercial code specified share security referred ii may subscribed either cash offset debt company delegate board director right subdelegate accordance applicable law regulation authority proceed public offering one several time france abroad proportion time considers appropriate euro currency monetary unit established reference basket currency issuance share andor security giving access share capital company following issuance company company hold directly indirectly half share capital company directly indirectly hold half company share capital security giving access share capital company delegation authority automatically entail express waiver shareholder preferential subscription right supplementary information resolution submitted annual combined shareholder meeting april respect share andor security giving resolve waive shareholder preferential access share capital company subscription right share andor security security may give access giving access share capital company may issued pursuant delegation delegate board director right authority specified board director subdelegate accordance applicable law may grant shareholder priority subscription period regulation authority proceed respect part issuance share public offering one several time france andor security giving access share capital abroad proportion time considers company period term appropriate euro currency shall determine accordance provision monetary unit established reference basket article l french commercial code currency issuance security giving access priority subscription period shall give rise share capital company creation negotiable right shall exercised company hold directly indirectly half proportion number share owned share capital andor ii issuance security shareholder may exercised board giving access share capital company director considers appropriate reducible directly indirectly hold half irreducible basis specified share andor company share capital subject security subscribed said manner authorization competent body subject public offering france abroad company referred ii public offering share andor security set following limit amount decided pursuant delegation authority may issuance may carried pursuant carried one offering issued delegation authority simultaneously private placement set forth article l ii french monetary nominal amount capital increase financial code decided pursuant delegation capital increase may carried immediately authority th resolution submitted future pursuant delegation shareholder meeting authority shall exceed maximum amount two million euro equivalent value shareholder amount date issuance decision including nominal value share note delegation authority automatically issued applicable pursuant adjustment entail benefit holder security made order protect right holder may issued pursuant delegation security giving access company share capital authority express waiver shareholder accordance applicable law regulation preferential subscription right respect well contractual provision specified share security may give access nominal amount capital increase carried immediately future pursuant delegation authority shall deducted overall limit set paragraph note pursuant article l th resolution submitted shareholder french commercial code irreducible meeting applicable reducible subscription absorb entirety issuance share b nominal value debt instrument security giving access share capital may issued pursuant delegation company board director may use authority shall exceed maximum amount condition provided law order two million euro equivalent value shall determine option listed amount date issuance decision specified amount include abovepar reimbursement premium limit capital increase amount provided ii nominal amount debt subscription provided said amount instrument shall deducted overall limit equal least three quarter amount set paragraph b th resolution submitted issuance decided upon shareholder meeting freely allocate unsubscribed share security supplementary information resolution submitted annual combined shareholder meeting april note pursuant article l subscription bond debt instrument french commercial code defined market authority example due redemption remuneration term issuance price share issued right indexation option right shall least equal minimum set forth amend term share andor applicable law regulation date security question term issuance decision compliance applicable formality issuance price security giving determine mean payment share access share capital company andor security giving access share issued share shall amount capital company issued immediately collected company immediately future increased applicable amount could collected later company set necessary term exercise shall share issued consequently right right conversion exchange issue security least equal redemption case may including delivery amount set forth paragraph company asset share security already issued company attached acknowledge board director shall report share andor security giving access share use made delegation capital company issued immediately authority next ordinary shareholder meeting future particular period accordance applicable law regulation may retrospective dividend payable new share well term shareholder grant board director condition completion share right subdelegate accordance capital increase applicable law regulation power implement delegation authority set term company particular necessary time fixed period right purchase exchange stock exchange decide increase share capital company security giving access share capital determine nature share andor company issued issued immediately security issued future purpose canceling security taking account applicable decide amount capital increase legal provision issuance price share andor security issued applicable amount issuance determine condition accordance premium applicable law allotment right holder security giving access share may determine date term capital temporarily suspended increase characteristic share andor security issued addition case discretion charge cost capital bond debt instrument determine whether increase premium arising thereon subordinated level deduct premium sum necessary subordination accordance provision increase legal reserve article l french commercial code set interest rate interest rate may fixed determine make adjustment take account variable zerocoupon indexed specify impact transaction involving share circumstance compulsory optional suspension capital company particular change cancellation interest payment stipulate nominal value share increase share capital term fixed perpetual possibility incorporation reserve free allocation reduction increase nominal value set share stock split reverse stock split distribution term issuance including granting dividend reserve premium guarantee security interest asset redemption capital amortization including possibility redemption transaction affecting shareholder equity delivery company asset necessary share capital set term enabling security may accompanied warrant entitling necessary right holder security giving holder allotment acquisition supplementary information resolution submitted annual combined shareholder meeting april access share capital company sixteenth resolution preserved delegation authority granted board duly record completion capital increase director issue share andor security giving access carried pursuant delegation authority share capital company andor security make necessary amendment article giving right allotment debt instrument association company without preferential subscription right shareholder private placement set forth generally enter agreement particular article l ii french monetary ensure completion proposed issue take financial code measure accomplish formality required issuance listing financial administration shareholder fulfilled quorum share andor security issued delegation majority requirement pertaining extraordinary authority exercise right attached general shareholder meeting considered thereto board director report statutory auditor special report noted share delegation authority granted period capital fully paidup accordance twentysix month date provision article l l shareholder meeting l l l l french commercial code article l ii french commercial code delegate board director right subdelegate accordance applicable law regulation authority proceed private placement set forth article l ii french monetary financial code one several time france abroad proportion time considers appropriate condition limit set forth applicable law regulation euro currency monetary unit established reference basket currency issuance share preference share andor security kind whatsoever security giving right issuance preference share giving access share capital company new existing share andor ii issuance security giving right allotment debt instrument valuable consideration free consideration governed article l et seq french commercial code specified share security referred ii may subscribed either cash offset debt company delegate board director right subdelegate accordance applicable law regulation authority proceed private placement set forth article l ii french monetary financial code one several time france abroad proportion time considers appropriate condition limit set forth applicable law regulation euro currency monetary unit established reference basket currency issuance share andor security supplementary information resolution submitted annual combined shareholder meeting april giving access share capital company b nominal value debt instrument following issuance company may issued pursuant delegation company hold directly indirectly half authority shall exceed maximum amount two share capital company directly million euro equivalent value indirectly hold half company share amount date issuance decision capital security giving access share capital specified limit mutual limit company delegation authority set paragraph b th resolution automatically entail express waiver amount include abovepar shareholder preferential subscription right reimbursement premium provided respect share security giving access ii nominal amount debt instrument shall share capital company deducted overall limit set paragraph security may give access b th resolution submitted shareholder meeting delegate board director right subdelegate accordance applicable law resolve waive shareholder preferential regulation authority proceed subscription right share andor security private placement set forth article l ii giving access share capital company french monetary financial code one may issued pursuant delegation several time france abroad proportion authority time considers appropriate condition limit set forth applicable law private placement set forth article l regulation euro currency ii french monetary financial code monetary unit established reference basket share andor security decided pursuant currency issuance security giving access delegation authority may carried one share capital company offering issued simultaneously public company hold directly indirectly half offering decided pursuant delegation share capital andor ii issuance security authority th resolution submitted giving access share capital company shareholder meeting directly indirectly hold half company share capital subject shareholder authorization competent body company referred ii note delegation authority automatically entail benefit holder security set following limit amount may issued pursuant delegation issuance may carried pursuant authority express waiver shareholder delegation authority preferential subscription right respect share security may give access nominal amount capital increase immediately future capital increase may carried immediately future pursuant delegation note pursuant article l authority shall exceed maximum amount two french commercial code irreducible million euro equivalent value applicable reducible subscription absorb amount date issuance decision entirety issuance share including nominal value share security giving access share capital issued applicable pursuant adjustment company board director may use made order protect right holder condition provided law order security giving access company share capital shall determine option listed accordance applicable law regulation well contractual provision specified limit mutual limit set paragraph limit capital increase amount th resolution nominal subscription provided said amount amount capital increase carried pursuant equal least three quarter amount delegation authority shall deducted issuance decided upon overall limit set paragraph th resolution submitted shareholder meeting freely allocate unsubscribed share security supplementary information resolution submitted annual combined shareholder meeting april note pursuant article l subscription bond debt instrument french commercial code defined market authority example due redemption remuneration term issuance price share issued right indexation option right shall least equal minimum set forth amend term share andor applicable law regulation date security question term issuance decision compliance applicable formality issuance price security giving determine mean payment share access share capital company andor security giving access share issued share shall amount capital company issued immediately collected company immediately future increased applicable amount could collected later company set necessary term exercise shall share issued consequently right right conversion exchange issue security least equal redemption case may including delivery amount set forth paragraph company asset share security already issued company attached acknowledge board director shall report share andor security giving access share use made delegation capital company issued immediately authority next ordinary shareholder meeting future particular period accordance applicable law regulation may retrospective dividend payable new share well term shareholder grant board director condition completion share right subdelegate accordance capital increase applicable law regulation power implement delegation authority set term company particular necessary time fixed period right purchase exchange stock exchange decide increase share capital company security giving access share capital determine nature share andor company issued issued immediately security issued future purpose canceling security taking account applicable decide amount capital increase legal provision issuance price share andor security issued applicable amount issuance determine condition accordance premium applicable law allotment right holder security giving access share may determine date term capital temporarily suspended increase characteristic share andor security issued addition case discretion charge cost capital bond debt instrument determine whether increase premium arising thereon subordinated level deduct premium sum necessary subordination accordance provision increase legal reserve article l french commercial code set interest rate interest rate may fixed determine make adjustment take account variable zerocoupon indexed specify impact transaction involving share circumstance compulsory optional suspension capital company particular change cancellation interest payment stipulate nominal value share increase share capital term fixed perpetual possibility incorporation reserve free allocation share reduction increase nominal value set stock split reverse stock split distribution term issuance including granting dividend reserve premium asset guarantee security interest redemption capital transaction amortization including possibility redemption affecting shareholder equity share capital delivery company asset necessary set term enabling necessary security may accompanied warrant entitling right holder security giving access holder allotment acquisition share capital company preserved supplementary information resolution submitted annual combined shareholder meeting april duly record completion capital increase seventeenth resolution carried pursuant delegation authority make necessary amendment article authorization granted board director association company event issuance share andor security giving access share capital company generally enter agreement particular public offering private placement set forth ensure completion proposed issue take article l ii french monetary measure accomplish formality required financial code without preferential subscription issuance listing financial administration right shareholder set issuance price share andor security issued delegation condition defined shareholder authority exercise right attached meeting maximum ten per cent thereto share capital per year delegation authority granted period shareholder fulfilled quorum twentysix month date majority requirement pertaining extraordinary shareholder meeting general shareholder meeting considered board director report statutory auditor special report accordance provision article l french commercial code authorize board director right subdelegate accordance applicable law regulation issuance decided th th resolution depart pricing term set forth applicable law regulation date issuance decision ie day article r french commercial code set price share andor security giving access share capital company issued public offering private placement set forth article l ii french monetary financial code accordance following provision issuance price equal discretion board director arithmetic average closing price observed maximum period three month preceding date issuance decision b volumeweighted average price market three latest trading day preceding date issuance decision potential maximum discount twenty per cent issuance price security giving access share capital company shall amount collected company immediately increased applicable amount could collected later company shall share issued consequently issuance security least equal amount set forth paragraph supplementary information resolution submitted annual combined shareholder meeting april resolve nominal amount capital eighteenth resolution increase capital increase may carried pursuant authorization shall exceed delegation authority granted board limit ten per cent share capital director increase number share andor company based share capital date security giving access share capital issuance decision period twelve company issued event share capital month specified nominal amount increase without preferential subscription capital increase capital increase may right shareholder carried pursuant authorization deducted amount limit set forth either shareholder fulfilled quorum paragraph th resolution majority requirement pertaining extraordinary inparagraph th resolution case general shareholder meeting considered may board director report statutory auditor special report pursuant provision shareholder note board director article l r french must provide additional report duly certified commercial code statutory auditor setting definitive condition transaction providing delegate board director right assessment method tool used evaluate subdelegate accordance applicable law impact transaction situation regulation authority decide shareholder issuance carried th th resolution increase number share andor security authorization granted period twentysix giving access share capital company month date shareholder issued event share capital increase meeting without preferential subscription right shareholder price used initial issuance within limit time quantity term set forth applicable law regulation well market practice date issuance decision ie day period thirty day closing subscription limit fifteen per cent initial issuance particular view granting oversubscription option specified share andor security may issued pursuant delegation authority may subscribed either cash offset debt company resolve nominal amount capital increase capital increase may carried pursuant delegation authority deducted amount limit set forth resolution pursuant issuance decided delegation authority granted period twentysix month date shareholder meeting supplementary information resolution submitted annual combined shareholder meeting april nineteenth resolution resolve security giving access share capital company issued pursuant delegation authority granted board delegation authority may particular consist director issue share andor security giving access debt instrument combined issuance share capital company consideration debt instrument enable issuance contribution kind consisting company debt instrument intermediate security share andor security giving access share specified one hand nominal amount capital maximum ten per cent debt instrument may issued pursuant share capital outside public exchange offer initiated delegation authority shall exceed maximum company amount two million euro equivalent value amount date shareholder fulfilled quorum issuance decision hand majority requirement pertaining extraordinary limit mutual limit set paragraph b general shareholder meeting considered th resolution amount board director report statutory auditor include abovepar reimbursement premium special report accordance provision provided ii nominal amount article l et seq article l debt instrument shall deducted overall l trough l french limit set paragraph b th resolution commercial code submitted shareholder meeting delegate board director right resolve cancel preferential subscription right subdelegate accordance applicable law given shareholder company share regulation authority proceed one andor security may issued several time france abroad proportion delegation authority holder share time considers appropriate issuance andor security subject contribution kind share preference share andor refered security kind whatsoever security giving right issuance preference share note delegation authority automatically giving access share capital company entail benefit holder security new existing share based report giving access share capital company expert appraiser referred article l may issued pursuant delegation french commercial code consideration authority express waiver shareholder contribution kind consisting share andor preferential subscription right respect security giving access share capital case share security may give access immediately article l french commercial future code applicable shareholder grant board director resolve nominal amount capital right subdelegate accordance increase capital increase may carried applicable law regulation power pursuant delegation authority shall implement delegation authority exceed limit ten per cent share particular capital company specified limit mutual limit set paragraph decide increase share capital company th resolution nominal amount consideration asset transferred capital increase carried pursuant company determine nature share delegation authority shall deducted andor security issued overall limit set paragraph th resolution submitted shareholder meeting establish list share andor security transferred company approve valuation contribution kind set term issuance share andor security made consideration said contribution amount cash portion paid approve granting specific benefit reduce subject transferor consent valuation contribution consideration specific benefit supplementary information resolution submitted annual combined shareholder meeting april determine characteristic security giving access share capital company issued consideration contribution kind new existing share andor ii issuance set term right holder security giving right allotment debt security giving access company capital instrument valuable consideration free preserved consideration governed article l et seq french commercial code consideration discretion charge cost capital security tendered public exchange offer made increase premium arising thereon company france abroad accordance deduct premium sum necessary local regulation respect security increase legal reserve company whose share admitted trading regulated market referred article l duly record completion capital increase french commercial code carried pursuant delegation authority make necessary amendment article resolve nominal amount capital association company increase capital increase may carried immediately future pursuant generally enter agreement particular delegation authority shall exceed maximum ensure completion proposed issue take amount two million euro measure accomplish formality required equivalent value amount date issuance listing financial administration issuance decision including nominal value share andor security issued delegation share issued applicable pursuant authority exercise right attached adjustment made order protect right thereto holder security giving access company share capital accordance applicable law delegation authority granted period regulation well contractual provision twentysix month date specified limit mutual limit set shareholder meeting paragraph th resolution nominal amount capital increase carried pursuant delegation authority shall twentieth resolution deducted overall limit set paragraph th resolution submitted shareholder delegation authority granted board meeting director issue share andor security giving access share capital company consideration resolve security giving access share security tendered public exchange offer capital company issued pursuant initiated company without preferential delegation authority may particular consist subscription right shareholder debt instrument combined issuance debt instrument enable issuance shareholder fulfilled quorum debt instrument intermediate security majority requirement pertaining extraordinary specified one hand nominal amount general shareholder meeting considered debt instrument may issued pursuant board director report statutory auditor delegation authority shall exceed maximum special report accordance provision amount two million euro article l trough l l equivalent value amount date l l trough l issuance decision hand french commercial code limit mutual limit set paragraph b th resolution amount delegate board director right include abovepar reimbursement premium subdelegate accordance applicable law provided ii nominal amount regulation authority proceed one debt instrument shall deducted overall several time france abroad proportion limit set paragraph b th resolution time considers appropriate euro submitted shareholder meeting currency monetary unit established reference basket currency issuance share preference share andor security kind whatsoever security giving right issuance preference share supplementary information resolution submitted annual combined shareholder meeting april resolve waive preferential subscription right company particular change nominal shareholder respect share andor value share increase share capital security may issued pursuant incorporation reserve free allocation share delegation authority favor holder stock split reverse stock split distribution security mentioned dividend reserve premium asset redemption capital note delegation authority automatically transaction affecting shareholder equity entail benefit holder security capital set term enabling giving access share capital company necessary right holder security giving may issued pursuant delegation access share capital company authority express waiver shareholder preserved preferential subscription right respect share security may give access immediately duly record completion capital increase future carried pursuant delegation authority make necessary amendment article shareholder grant board director association company right subdelegate accordance applicable law regulation power generally enter agreement particular implement delegation authority ensure completion proposed issue take particular measure accomplish formality required issuance listing financial administration decide increase share capital company share andor security issued delegation consideration security mentioned authority exercise right attached determine nature share andor thereto security issued delegation authority granted period set exchange ratio applicable cash twentysix month date balance consideration paid shareholder meeting confirm number security tendered exchange determine date term condition issuance characteristic share andor security may issued pursuant delegation authority particular price date first entitlement dividend new share andor security giving access share capital company record contribution premium account shareholder shall right balance sheet liability difference issuance price new share nominal value determine condition accordance applicable law allotment right holder security giving access share may temporarily suspended discretion charge share premium expense related completion share capital increase well sum required order constitute legal reserve determine make adjustment take account impact transaction involving capital supplementary information resolution submitted annual combined shareholder meeting april twentyfirst resolution decide event share issued delegation authority granted board fractional right negotiable director increase share capital corresponding share sold proceeds capitalization reserve earnings premium sale allocated holder sum upon capitalization would right term specified law regulation permitted make adjustment take account impact shareholder fulfilled quorum transaction involving share capital majority requirement pertaining ordinary general company particular change nominal shareholder meeting considered board value share increase share capital director report statutory auditor special incorporation reserve free allocation share report accordance provision stock split reverse stock split distribution article l l dividend reserve premium l french commercial code asset redemption capital transaction affecting shareholder equity delegate board director right share capital set term enabling subdelegate accordance applicable law necessary right holder security giving regulation authority proceed one access share capital company several time france abroad proportion preserved time considers appropriate increase share capital company discretion charge cost capital incorporation share premium reserve earnings increase premium arising thereon amount may converted capital deduct premium sum necessary successively simultaneously accordance increase legal reserve applicable law article association freely allocating new share andor increasing duly record completion capital increase nominal value existing share carried pursuant delegation authority combination two procedure make necessary amendment article association company resolve nominal amount capital increase capital increase may carried generally enter agreement particular immediately future pursuant ensure completion proposed issue take delegation authority shall exceed maximum measure accomplish formality required amount two million euro issuance listing financial administration specified nominal amount limit separate share andor security issued delegation overall limit set paragraph th authority exercise right attached resolution submitted shareholder meeting thereto shareholder grant board director delegation authority granted period right subdelegate accordance twentysix month date applicable law regulation power shareholder meeting implement delegation authority particular determine amount nature sum incorporated capital set number new share issued andor amount nominal value existing share increased decide date may retrospective new share rank dividend increase nominal value existing share take effect supplementary information resolution submitted annual combined shareholder meeting april twentysecond resolution resolve issuance price share andor security giving access share capital delegation authority granted board company set accordance article director issue share andor security giving access l et seq french labor code provided share capital company reserved pursuant abovementioned article member enrolled employersponsored company discount set shall exceed twenty per cent saving plan without preferential subscription right average quoted price company share shareholder regulated market nyse euronext paris twenty trading day preceding date shareholder fulfilled quorum decision setting opening date subscription majority requirement pertaining extraordinary period shareholder expressly authorize board general shareholder meeting considered director reduce cancel aforementioned board director report statutory auditor discount considers appropriate particular special report accordance provision order take consideration international article l et seq article l accounting standard inter alia locally applicable l french commercial code legal accounting tax social provision article l et seq french labor country certain beneficiary board code director may also substitute part discount granting share andor security giving delegate board director right access share capital company pursuant subdelegate accordance applicable law provision regulation authority proceed one several time france abroad proportion authorize board director freely grant time considers appropriate issuance pursuant term delegation authority share preference share andor share security giving immediate deferred security kind whatsoever security claim share company substitute giving right issuance preference share part discount andor grant abondement giving access share capital company case may provided total benefit new existing share reserved member enrolled resulting discount andor grant employersponsored saving plan abondement may exceed applicable legal plan whose member capital increase may regulatory limit reserved equivalent term article l french labor code instituted within french shareholder grant board director foreign entity group entity falling within right subdelegate accordance scope company consolidated combined applicable law regulation power financial statement pursuant article l implement delegation authority l french labor code particular specified share security referred ii may subscribed either cash establish accordance law list offset debt company company beneficiary indicated may subscribe share security resolve nominal amount capital giving access capital thereby issued increase capital increase may carried may freely allotted share andor security giving immediately future pursuant access capital delegation authority shall exceed maximum amount two million euro decide subscription may made directly specified limit limit separate beneficiary belonging entity group saving overall limit set paragraph th plan similar plan via dedicated mutual fund resolution submitted shareholder meeting vehicle entity permitted applicable law regulation resolve waive preferential subscription right shareholder respect share andor determine condition particular regard security giving access share capital length service must met company may issued pursuant beneficiary capital increase delegation authority favor beneficiary defined set opening closing date subscription supplementary information resolution submitted annual combined shareholder meeting april set amount issuance made twentythird resolution present delegation authority particular determine issuance price date time limit asm give authority carrier term condition subscription payment original copy extract herewith asms delivery date entitlement dividend minute undertake formality may share andor security may necessary retrospective rule pro rating event oversubscription term condition issue subject applicable legal regulatory limit case issue new share charge amount required pay said share reserve profit share premium discretion charge cost capital increase premium arising thereon deduct premium sum necessary increase legal reserve duly record completion capital increase carried pursuant delegation authority make necessary amendment article association company generally enter agreement particular ensure completion proposed issue take measure accomplish formality required issuance listing financial administration share andor security issued delegation authority exercise right attached thereto delegation authority granted period twentysix month date shareholder meeting supplementary information information reference document annual financial report information reference document annual financial report declaration responsibility reference document annual financial report hereby certify taken reasonable received completion letter auditor measure effect information stating audited information contained present reference document contained reference document best knowledge accordance financial position financial statement fact make omission likely affect import read document entirety certify best knowledge historical financial information presented financial statement prepared accordance document discussed auditor report applicable accounting standard give fair found page reference view asset liability financial position document profit loss company activity included consolidation february management report page present fair review development performance business financial position company activity included consolidation well description main risk uncertainty exposed joachim kreuzburg chairman board ceo supplementary information information reference document annual financial report table reconciliation order facilitate understanding present april european document concerning presentation sartorius commission column right stedim biotech sa table left corresponding page present document heading note european regulation heading part european regulation n april page person responsible person responsible information certification person responsible registering document independent auditor name address independent auditor issuer selected financial information presentation selected historical financial information every year period covered financial information risk factor information issuer history development company corporate name commercial name issuer place registration number issuer date establishment life issuer registered office legal form issuer legislation governing operation country origin address investment principal investment including amount carried overview operation principal operation principal market dependence patent license contract competition organigram organizational chart description group list subsidiary property plant equipment significant existing planned property plant equipment environmental issue analysis financial situation result financial position operating profit cash position capital issuer capital short longterm cash flow borrowing condition financial structure expected source financing research development patent license information trend profit forecast estimate applicable governing management supervisory executive body composition governing management body nature family link amongst person conviction fraud within last five year least bankruptcy sequestration liquidation member governing body indictment andor official public sanction member governing body conflict interest level governing management body remuneration benefit remuneration paid benefit kind pension retirement benefit supplementary information information reference document annual financial report heading part european regulation n april page operation governing management body expiration date current mandate term office service agreement member audit remuneration committee issuer corporate governance employee workforce end period covered historical financial information shareholding capital employee shareholding capital principal shareholder crossing threshold double voting right control business transaction related party financial information issuer asset financial situation profit historical financial information result last five year consolidated financial result statement profit loss consolidated financial statement statement financial position statement profit loss statement cash flow statement change equity note consolidated financial statement verification annual historical information independent auditor report last financial information dividend distribution policy legal arbitration procedure significant change financial commercial situation additional information share capital amount issued capital number share authorized number share issued fully paid number share issued fully paid par value per share reconciliation number share outstanding beginning end year share representing capital applicable number book value face value share held behalf issuer subsidiary issuer amount convertible security exchangeable security security warrant applicable information term acquisition right obligation authorized unissued capital undertaking increase capital applicable information capital member group option agreed conditionally unconditionally put option applicable history share capital period covered historical financial information memorandum article association object purpose issuer member administrative management supervisory body right preference restriction attaching class existing share action required change right shareholder applicable condition governing manner annual general meeting extraordinary general meeting shareholder called including condition admission provision issuer article association statute charter bylaw would effect delaying deferring preventing change control issuer applicable provision article association statute charter bylaw governing ownership threshold shareholder ownership must disclosed condition imposed memorandum article association statute charter bylaw governing change capital condition stringent required law applicable major contract information provided third party declaration expert declaration interest applicable document accessible public information shareholding supplementary information glossary glossary industrial productspecific term bioreactor freezethaw technology englishspeaking country bioreactor used vessel technology used controlled freezing thawing cultivating animal human cell culture medium non biological liquid liquid biologics englishspeaking country term also used synonymously fermentor system microorganism membrane chromatography bacteria yeast fungi multiply case vessel selective separation mixture substance adsorption used obtain cell part one metabolite specifically modified membrane membrane adsorbers flowing system capsule readytouse filter unit consisting filter housing hose membrane filter connector incorporated filter cartridge connection thin film foil made polymer porous structure piping film used filtration application crossflow monoclonal antibody term taken filtration technology instead directly flowing synthetic antibody increasingly used medical filter static filtration liquid flow perpendicularly diagnosis treatment filter surface prevents filter blockage resulting longer inservice life filter purification important step downstream processing disposable product single use cf singleuse product recombinant protein protein manufactured using genetically modified organism example downstream processing include pharmaceutical protein insulin vaccine collective term various step follow fermentation cell cultivation production biopharmaceuticals example scaleup separation purification concentration transfer scale increase size term used denote progression process increase range lab fda food drug administration scale pilot scale process scale retaining u governmental agency responsible monitoring technology material construction geometry throughout food biotechnological medical veterinary pharmaceutical product singleuse product see disposable fermentation technical process used produce transform intra sterile filter sterilizinggrade filter extracellular substance help microorganism membrane filter whose pore size usually μm smaller product processspecific validation test required fluid management technology confirm whether filter type selected delivers sterile filtrate technology system use handling sensitive biological liquid example transportation storage medium sterility test sterility testing test verify sample contains living viable substance validation systematic checking essential step facility research development production including testing pharmaceutical ensure product manufactured made reliably reproducibly desired quality supplementary information glossary business economic term amortization ifrs international financial reporting standard amortization relates exclusively potential reduction internationally recognized accounting principle value goodwill allocation purchase price intangible asset acquired carried accordance ifrs investment rate ratio capital expenditure sale revenue cash flow short longterm management liquid fund cash pro forma balance inflow outflow fund pro forma presentation used annual report mean figure include business generated stedim consolidated derivative financial instrument first time june full previous year instrument hedging risk change market business generated sartorius stedim plastic gmbh consolidated price foreign currency january full fiscal year preceding year ebit supply chain management earnings interest tax setup coordinated control integrated flow material information finance supply chain entire value ebit margin added process ratio ebit see ebit sale revenue tecdax ebita german stock index transaction service provider earnings interest tax amortization related marketplace organizer deutsche börse ag business combination amortization item refers amortization confirmed connection purchase price treasury allocation ppa intangible asset acquired specified short mediumterm liquidity management ifrs standard underlying ebita adjusted onetime item ebita margin ebita see ebita adjusted extraordinary item ratio ebita see ebita sale extraordinary item amounted million previous year million essentially cover onetime expense strategic ebitda group project integration acquisition related item earnings interest tax depreciation amortization underlying ebita margin ebitda margin ratio operating ebita see underlying ebita sale revenue ratio ebitda see ebitda sale revenue underlying ebitda fixed asset ebitda see ebitda adjusted extraordinary item sum intangible asset property plant equipment extraordinary item amounted million previous year financial asset million essentially cover onetime expense strategic group project integration acquisition related item free float share public company freely available underlying ebitda margin investing public ratio operating ebitda see underlying ebitda sale revenue goodwill underlying consolidated net profit represents difference price paid company profit figure yielded adjustment extraordinary business net asset goodwill form intangible asset item amortization business combination refers exclusively purchase price allocation ppa intangible ia international accounting standard asset acquired according revised ifrs internationally recognized accounting principle supplementary information adresses adresses europe france austria ireland sartorius stedim biotech sa sartorius stedim austria gmbh sartorius stedim ireland ltd zone industrielle le paluds franzosengraben unit business centre avenue de jouques c vienna stadium business park aubagne cedex phone ballycoolin road phone fax dublin fax separationaustriasartoriuscom phone infosartoriusstedimcom fax belgium infoirelandsartoriusstedimcom sartorius stedim france sa zone industrielle le paluds sartorius stedim belgium nv italy avenue de jouques c leuvensesteenweg b aubagne cedex vilvoorde sartorius stedim italy spa phone phone via dellantella fax fax antella bagno ripoli florence infobiotechfrancesartoriusstedimcom lindreymensartoriuscom phone fax sartorius stedim aseptics sa denmark infoitalysartoriuscom zone industrielle de saux rue ampère lourdes sartorius stedim nordic netherlands phone lyskaer fax herlev sartorius stedim nl infosartoriusstedimcom phone westblaak fax kg rotterdamm germany infodksartoriusstedimcom phone fax sartorius stedim biotech gmbh hungary officenlsartoriuscom augustspindlerstr goettingen sartorius stedim hungária kft poland phone kagyló u fax budakeszi sartorius stedim poland sp zoo infosartoriusstedimcom phone ul wrzesinska fax kostrzyn sartorius stedim plastic gmbh ssbsartoriushu phone karlarnoldstr fax goettingen biuroplsartoriuscom phone fax portugal infosartoriusstedimcom sartorius stedim spain sa sartorius stedim system gmbh cisabel colbrand oficina robertboschstraße polígono industrial de fuencarral guxhagen madrid phone phone fax fax infosartoriusstedimcom biotech_spainsartoriusstedimcom supplementary information adresses africa russia uk tunisia sartorius icr ooo saintpetersburg sartorius stedim uk ltd sartorius stedim bioprocess sarl rasstannaya str building letter longmead business centre km route de zaghouan st petersburg blenheim road mhamdia bourbiâa phone epsom surrey kt qq bp ben arous fax phone phone russiasartoriuscom fax fax uksartoriussartoriusstedimcom infosartoriusstedimcom spain sartorius stedim lab ltd sartorius stedim biotech sarl sartorius stedim spain sa unit km route de zaghouan cisabel colbrand oficina stonedale road mhamdia bourbiâa polígono industrial de fuencarral stonehouse gloucestershire gl rq bp ben arous madrid phone phone phone fax fax fax alanjohnsonsartoriusstedimcom infosartoriusstedimcom biotech_spainsartoriusstedimcom tab biosystems sartorius stedim integrated service sarl switzerland york way km route de zaghouan royston herfordshire sg wy mhamdia bourbiâa sartorius stedim switzerland ag phone bp ben arous ringstrasse fax phone tagelswangen infotapbiosystemscom fax phone infosartoriusstedimcom fax biotechswitzerlandsartoriusstedimcom supplementary information adresses north america latin america asia pacific usa argentina china sartorius stedim north america inc sartorius argentina sa sartorius stedim biotech beijing co ltd orville drive int avalos yu road tianzhu airport bohemia new york becs munro industrial park zone b phone buenos aire shun yi district beijing fax phone phone infosartoriusstedimcom fax fax sartoriussartoriuscomar enquirycnsartoriusstedimcom tap biosystems montchanin road brazil india greenville de phone sartorius brasil ltda sartorius stedim india pvt ltd fax avenida senador vergueiro jakkasandra infotapbiosystemscom são bernardo campo kunigal road cep sp nelamangala bangalore puerto rico phone phone fax fax sartorius stedim filter inc sartoriussartoriuscombr biotechindiasartoriuscom carretera int barriada arturo lluveras mexico japan po box yauco puerto rico sartorius de méxico sa de cv sartorius stedim japan kk phone circuito circunvalación poniente th floor daiwa shinagawa north bldg fax ciudad satélite kitashinagawa shinagawaku marcoslopezsartoriuscom naucalpan estado de méxico tokyo phone phone fax fax sartoriussartomexcommx infosartoriuscojp malaysia sartorius stedim malaysia sdn bhd lot l e b enterprise technology park malaysia bukit jalil kuala lumpur phone fax ehtansartoriuscommy supplementary information adresses singapore australia sartorius stedim singapore pte ltd sartorius stedim australia pty ltd science park road unit rodeo drive capricorn dandenong south melbourne singapore science park ii victoria singapore phone phone fax fax infoaustraliasartoriusstedimcom chooleepangsartoriusstedimcom south korea sartorius korea biotech co ltd th floor solid space pangyoyeokro bundanggu seongnamsi gyeonggido phone fax infosartoriuscokr vietnam sartorius representative office unit c th floor tower big building pham hung street dinh tu liem hanoi phone fax sartoriusvnhnvnnvn address visit website internet wwwsartoriuscom supplementary information product highlight bioprocess solution sartorius stedim biotech concentrate bioprocess business pharmaceutical customer broad product portfolio company help biotech medication vaccine manufactured safely efficiently key mission optimize pharmaceutical manufacturing process primarily increasing usage singleuse product solution sartorius stedim biotech global leader filtration fermentation cell cultivation membrane chromatography fluid management biostat cultibag str cell culture medium sartopore platinum sartocheck plus bag tester singleuse bioreactor system nutrient solution buffer new highly efficient filter test system checking cell culture process use production generation sterile filtration integrity singleuse bag scalable l active biopharmaceutical biopharmaceutical medium ingredient supplementary information product highlight local presence worldwide royston uk dublin ireland stonehouse uk epsom uk vilvoorde belgium rotterdam netherlands aubagne france lourdes france madrid spain bohemia ny usa wilmington nc usa mexico city mexico yauco puerto rico são paulo brazil buenos aire argentina sale production production sale herlev denmark goettingen germany poznan poland guxhagen germany vienna austria budapest hungary tagelswangen switzerland florence italy beijing china seoul south korea tokyo japan hanoi vietnam mohamdia tunisia bangalore india kuala lumpur malaysia singapore singapore melbourne australia financial schedule analyst conference sfaf paris france march annual general shareholder meeting aubagne france april payment dividends april publication firstquarter figure april publication firsthalf figure july publication ninemonth figure october publication preliminary figure fiscal january annual general shareholder meeting aubagne france april publication firstquarter figure april subject appro val annual general shareholder meeting contact petra kirchhoff andreas theisen vice president director corporate communication ir investor relation phone phone petrakirchhoffsartoriuscom andreastheisensartoriuscom publication published financial reporting system firesys sartorius stedim biotech sa michael konrad gmbh corporate communication frankfurt main germany c aubagne cedex france photography peter ginter lohmar germany editorial deadline february published february translation original frenchlanguage document de référence sartorius stedim biotech sa zone industrielle le paluds avenue de jouques c aubagne cedex france phone fax infosartoriusstedimcom wwwsartoriusstedimcom sartorius stedim biotech sa printed germany publication oge order